Evaluation of Antioxidant, Anticancer and Immunomodulatory Activities of Wild Carrot (Daucus carota ssp. carota) Oil and its Fractions. by Shebaby, Wassim Nasri.
UNIVERSITY OF
SURREY
Evaluation of antioxidant, anticancer and 
immunomodulatory activities of wild carrot 
(Daucus carota ssp. carota) oil and its fractions.
By
Wassim Nasri She baby
Submitted for the Degree of Doctor of Philosophy 
Faculty of Health and Medical Sciences
University of Surrey
October 2014
ProQuest Number: 27727049
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 27727049
Published by ProQuest LLC (2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
DEDICATION
To the spirit of my late father 
who would be proud of me 
as I  am grateful to his memory
ACKNOWLEDGEMENT
I am greatly indebted to my principal supervisor Dr. Kikki Bodman-Smith for her 
kindness, valuable suggestions, constant encouragement and dedicated assistance. I 
would also extend my deepest gratitude and appreciation to my collaborative 
supervisor Dr. Costantine Daher for his continuous support, patience and daily 
follow-up. Without him I would not have accomplished my thesis.
My appreciation also goes to Dr. Mohamad Mroueh for his inspiring guidance and 
full commitment to my research work. I should never forget the sincerity and helpful 
supervision of Dr. Mirvat El-Sibai whose contribution for this work has been 
indispensable. My deepest regards are also directed towards both Dr. Marc Karam 
for his moral support and suggestions and Dr. Robin Taleb for his technical guidance 
in chromatography. Special thanks should also be directed to Mr. Jean Karam, the 
animal-housekeeper.
As for the ones who have always been with me, I address my warmest regards to my 
family, namely my beloved wife Doris and lovely children Marc and Mario for their 
never ending support, endurance and understanding.
Last but not least, I mostly acknowledge the essential patronage of my dearest and 
compassionate sister Lana and her precious family, who immensely provided me 
with the needed caring to fulfill my dream. Of course, my wonderful mother Afaf, 
my considered sisters Rina, Ghada, and their families for their prayers, reassurance 
and affection. As Saint Paul has said, “and the greatest of these is love.”
3
ABSTRACT
Daucus carota L.ssp.carota, also known as wild carrot, has been used in traditional medicine 
in Lebanon to treat several diseases including cancer. The aim of the present study was to 
characterize the chemical constituents of D. carota oil extract (DCOE) and evaluate its anticancer 
activity. DCOE was chromatographed on silica gel column and four fractions were obtained. GC- 
MS and HPLC analysis of DCOE and fractions showed the presence of several sesquiterpenes and 
phenolic compounds. A major finding was the identification of 2-himachalene-6-ol, a sesquiterpene 
reported for the first time from wild carrot plant species. In vitro antioxidant activity of DCOE and 
its fractions was demonstrated and correlated to the phenolic and flavonoid contents. In vivo 
antioxidant and hepatoprotective activities of DCOE fractions was also observed in CCL-induced 
hepatotoxicity in mice.
The anticancer effects of DCOE and its fractions were evaluated against several human cancer 
cell lines and found to exhibit dose dependent anti-proliferative activities, with FI and F2 
demonstrating the highest cytotoxicity. The inhibition of cell growth by FI or F2 fractions was 
mainly due to cell cycle arrest and apoptotic cell death as assessed by flow cytometry analysis and 
western blot analysis of several pro-apoptotic and anti-apoptotic proteins. Additionally, the 
induction of apoptosis was mediated through the inhibition of both MAPK/Erk and PI3K/Akt 
pathways in human colon cancer cells (HT-29) and only through MAPK/Erk pathway in human 
breast cancer cells (MDA-MB-231).
The antitumour promoting effect of F2 was illustrated by significant decrease in tumour 
incidence, yield and volume in DMBAVTPA- induced mouse skin carcinogenesis. Also, DCOE and 
fractions exhibited in vivo immunomodulatory effects through enhancing the release of 
immunomediators.
4
In conclusion, the present study confirms the anticancer activity of wild carrot which can be 
considered as a potential remedy against various types of cancer with limited toxicity.
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CHAPTER 1: GENERAL INTRODUCTION
1.1 Medicinal plants and natural products
Since earliest times, humans have been exploring their environment for plants as a source of 
food and health. Of approximately 300,000 species of higher plants, about 40,000 to 70,000 have 
been documented as medicinal plants (McChesney et ah, 2007). Many reports have been published 
describing the potential use of plants against several diseases including cancer (Altmann and 
Gertsch, 2007; Bhanot et al., 2011). Today, roughly three quarters of the world’s population relies 
upon medicinal plants for its primary pharmaceutical care (WHO, 2002). There are two major 
groups of metabolites that exist in plants: primary metabolites which are directly involved in cell 
growth and survival, and secondary metabolites which have no known primary function in plants 
except a possible role in the defence against predators and pathogens such as virus and bacteria 
(Van Wyk and Wink, 2004). However, plant secondary metabolites such as terpenes, phenolics and 
alkaloids were also shown to possess promising antioxidant and anticancer properties (Aggarwal 
and Shishodia, 2006; Silva et al., 2011)
1.1.1 Terpenes
Terpenes are a large and diverse class of organic compounds that are synthesized primarily by 
a wide variety of plants, insects, microoroganisms and animals. They are the major components of 
resin, and of turpentine produced from resin. Sometimes, terpenes can undergo oxidation or 
rearrangement of the carbon skeleton which results in modified compounds referred to as 
terpenoids. Terpenes and terpenoids are the major constituents of essential oils in wide variety of 
plant species. The smallest unit of terpenes is the isoprene unit which has a molecular formula
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CsHs. Accordingly, terpenes are classified by the number of isoprene units in the molecule (Croteau 
et ah, 2000; Breitmaier, 2006).
Isoprene unit
• Hemiterpenes (C5) are the smallest terpenes consisting of a single isoprene unit which is 
considered the only hemiterpene.
• Monoterpenes consist of two isoprene units with a molecular formula CioHie. Found mainly in 
essential oils of plants.Examples of monoterpenes are: limonene, Pinenes (a and 
P) and terpineol.
• Sesquiterpenes derived from three isoprene units and have the molecular formula C15H24. They 
are also present in essential oils. Examples of sesquiterpenes are: p-caryophyllene 
and humulene.
• Diterpenes are composed of four isoprene units and have the molecular formula C20H32. They 
include phytol, plant hormones Gibberellins and taxadiene a precursor of taxol.
• Sesterterpenes are rare terpenes having 25 carbons and five isoprene units. An example of a 
sesterterpene is geranylfamesol.
• Triterpenes consist of six isoprene units and have the molecular formula C30H48. They are 
abundant in resins. Members of this class include biologically active compounds such as 
betulinic acid, brusatol, and boswellic acids.
• Tetraterpenes contain eight isoprene units and have the molecular formula C40H64. Biologically 
important tetraterpenes include the acyclic lycopene, the monocyclic gamma-carotene, and the 
bicyclic alpha- and beta-carotenes.
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• Polyterpenes those containing more than eight isoprene units. An example of polyterpenes is 
natural rubber.
1.1.2 Phenolic compounds
Phenolic compounds are made up of one or more aromatic rings containing one or more 
hydroxyl groups. These compounds are the most abundant secondary metabolites in plants and 
comprise over 8000 phenolic structures. Phenolics are involved in the defense mechanisms against 
predators, parasites, pathogens and harmful ultraviolet radiation, as well as contributing to the 
colour of plants. In addition to their role in plants, phenolic compounds in our diet offer important 
health benefits and may minimize the risk of diseases such as cancer (Jung et al., 2006; God et al., 
2007). They are found in various plant foods including fruits, vegetables, cereals, olives and 
legumes. Plant phenolics are generally classified as phenolic acids, flavonoids, stilbenes, 
coumarins, tannins and lignans (Dai and Mumper, 2010)
Flavonoids are the largest group of phenolic compounds consisting of two aromatic rings connected 
by three carbons that are in an oxygenated central C-ring. Flavonoids are categorized into several 
subgroups based on their molecular structure. They include flavones, flavonols, flavanols, 
flavanones, isoflavones, and anthocyanins (Saxena et al., 2012). Flavonoids are found in all dietary 
plants such as fruits and vegetables in addition to tea and wine. The most common flavones are 
luteolin and apigenin present in legumes, parsley and thyme. Quercetin, kaempferol and myricetin 
are the predominant flavonols. These compounds are abundant in food such as onions, cherries, 
apples, broccoli, tomato, berries, tea and red wine. Catechin is a flavanol which occurs in tea and 
many fruits. Flavanone, including hesperidin and naringenin are found in citrus fruits. 
Anthocyanins such as caynidin and malvidin are abundant in berry fruits, red rice, cabbage and 
beans. Finally, daidzein, genistein and glycitein are the main isoflavones in soybean (Fresco et al., 
2006; D Archivio et al., 2007).
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Phenolic acids are the second important class of phenolic compounds and are present in a wide 
variety of plants. They are classified into two groups: derivatives of benzoic acids such as gallic 
acid, vanillic acid, and syringic acid and derivatives of cinnamic acids such as ferulic acid, caffeic 
acid,/>coumaric acid, and chlorogenic acid (D Archivio et ah, 2007; Huang et ah, 2009).
Tannins are another major group of polyphenolic compounds and are subdivided into two classes: 
hydrolysable tannins and non-hydrolysable tannins which are the condensed form. They are 
complex polyphenols that can be decomposed to sugars and phenolic acids by both enzymatic and 
non-enzymatic hydrolytic pathways. Tannins occur in unripe fruits, food flavourings and red wine. 
Stilbenes are phenolic compounds with two aromatic rings linked by an ethene bridge (Ree, 2001). 
Resveratrol is an important member of this group and it is the major phenolic compound in red 
wine (Fresco et ah, 2006).
1.1.3 Alkaloids
Alkaloids are natural compounds containing nitrogen in addition to carbon, hydrogen and 
oxygen. These phytochemicals are derived from wide variety of organisms such as bacteria and 
plants. Alkaloids are divided into several groups including true alkaloids, protoalkaloids, 
polyamine alkaloids, and pseudalkaloids (Cordell, 1981). An abundant number of alkaloids are still 
in medicinal practices such as codeine and morphine that are used as analgesics. Other examples 
that act as antitumour agents include vinblastine and vincristine (Pelletier, 1996).
1.2 The Daucus carota plant
1.2.1 An introduction to the family Umbelliferae and genus Daucus
The Apiaceae or Umbelliferae, commonly known as carrot or parsley family, consists mostly 
of aromatic plants with hollow stems. It is one of the largest families of flowering plants and
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contains 434 genera with more than 3,700 species. Included in this family are well-known plants 
such as caraway, fennel, carrot, celery, parsley, cumin, Queen Anne’s lace (wild carrot), cicely and 
coriander. Some members of this family are important source of food such as Daucus carota 
(Carrot) and Apium graveolens (Celery). Others are rich in aromatic compounds and often used as 
spices such as pteroselinum hortense (Parsley), Carum carvi (Caraway).The Daucus genus has 
about 25 species of which the best known is the cultivated carrot. Members of this genus include 
more than 80% of the herbaceous plants. The members of this genus differ in the form of the leaves. 
They are annual plants or mostly biennial plants and characterized by the formation of umbel 
flowers. The petals of the flower are white, reddish, pinkish or yellowish (Saenz Lain, 1980).
1.2.2 The Daucus carota L., species
Daucus carota L., is a polymorphic species that consists of eleven interrelated subspecies. 
Daucus carota L. ssp. Sativus is a major vegetable cultivated worldwide and its enlarged taproot 
is eaten as a raw vegetable or cooked. In contrast, other forms of Daucus carota include the 
subspecies maritimus, halophilus, gummifer, maximus, and carota (wild carrot) have small roots 
with unpleasant taste. These subspecies grow wild in different world locations (Castroviejo, 2003).
1.2.3 General background of the plant
Daucus carota (Linnaeus) ssp. carota, known as wild carrot, is a member of the family 
Umbelliferae (Apiacae). Other common names for wild carrot are Queen Anne's Lace and Bird's 
Nest (Mitich, 1996). Daucus carota is a tall, robust, biennial plant, usually growing up to 1 m tall. 
The flowering stalks are long and largely devoid of leaves, terminating in compound umbels of 
small white flowers (figure 1.1). Each compound umbel has a whorl of green bracts at its base. The 
umbels are claret-colored or pale pink before they open, then bright white and rounded when in full
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flower. Each flower produces a single seed. Initially, the colour of the seeds is light reddish purple, 
turning green and then greyish brown upon maturation. As the seeds mature, the compound umbels 
start to close and assume a shape that is more or less spheroid. There may be hundreds of flowers 
in a typical umbel. The clusters are up to 11cm wide (Hoffman, 1990).
Figure 1.1 Daucus carota ssp. Carota plant umbel (Elpel, 2000).
1.2.4 Geographic Allocation
Daucus carota is mainly found in Western Asia, Mediterranean region, Southwest Asia, 
Australia, Tropical Africa, and the American continent (Reed, 1976). It originated in Afghanistan 
and then spread to China in the 13-14th century to reach England in the 15th century. This plant is 
also recognized in Europe, North Africa, Jordan, Puerto Rico, Iran, and Iraq (Holm et al., 1979; 
Ross, 2005). It is found abundantly in the Lebanese regions and it is very common on roadsides 
and various fields.
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1.2.5 Phytochemical analysis of wild carrot
Several studies have been carried out on the wild carrot essential oil from different world 
locations in order to identify their components. The oil derived from different parts of the wild 
carrot grown in Poland consisted mainly of monoterpene hydrocarbons (72-84%) (Staniszewska et 
al., 2005). In another study on the essential oil obtained from Portuguese mature umbels was 
predominantly composed of oxygenated monoterpenes (68.7%) and hydrocarbon monoterpenes, 
(19.3%). The main components of the Portuguese oil were geranyl acetate (65.0%) and a-pinene 
(13.0%). The essential oil extracted from the Sardinian mature umbels was predominantly 
composed of hydrocarbon sesquiterpenes (61.6%) and phenylpropanoids (15.2%). The 
sesquiterpenes include (3-Bisabolene (51.0%) and 11 aH-himachal-4-ene-1 -p-ol (9.0%), while 
phenylpropanoids include E-methylisoeugenol (10.0%) (Maxia et al., 2009). The oil of wild carrot 
from Corsica consists chiefly of phenylpropanoids (45.8%) and monoterpene hydrocarbons 
(38.6%), accompanied by noticeable contents of sesquiterpenes (11.1%) and much smaller amounts 
of oxygenated monoterpenes. Among the phenylpropanoids, (£)-methylisoeugenol (33.0%) and 
elemicin (11.4%) were the major constituents. The monoterpene hydrocarbons were distinctly 
dominated by a-pinene (24.9%), while sabinene, myrcene and limonene were present at much 
lower amounts (3.7%, 3.5% and 2.2%, respectively). The sesquiterpene fraction consisted mainly 
of p-bisabolene (4.4%) and 11 a/f-himachal-4-en-1 p-ol (1.6%) (Gonny et al., 2004). In another 
study, oil samples from wild carrot seeds (fruits) growing in Lithuania contained mainly sabinene 
(28.2-37.5%), a-pinene (16.0-24.5%), terpinen-4-ol (4.6-7.5%), y-terpinene (2.9-6.0%) and 
limonene (2.3-4.0%) (Mockute and Nivinskiene, 2004).
25
1.2.6 Medicinal uses of wild carrot
The essential oil of wild carrot obtained from the aerial part of the plant at the end of the 
flowering stage has been reported to have antimicrobial activity against human enteropathogens 
such as Campylobacter jejuni, Campylobacter coli and Campylobacter lari. The antimicrobial 
activity was attributed to the polar fraction of the oil which contained (E)-methylisoeugenol 
(41.8%) and elemicin (33.6%) (Rossi et al., 2007). Similarly, the oil of mature umbels of wild 
carrot growing in Poland showed a considerable antibacterial effect with a m inim um inhibitory 
concentration at 3-4pL/mL (Staniszewska et al., 2005). Also, antifungal activities of oil extract 
obtained from Sardinian wild carrot showed various degrees of inhibition against several fungi 
including Candida, Dermatophyte and Aspergillus strains (Maxia et al., 2009).
Wild carrot has been reported to possess antilithic, diuretic, and carminative properties, and has 
been used traditionally to treat urinary calculus, cystitis, gout, and lithuria (Barnes, 1998; Thomas 
et al., 2001; Van Wyk and Wink, 2004). In European folk medicine, the volatile oil from wild carrot 
is used as a urinary antiseptic and anti-inflammatory remedy for cystitis and prostatitis (Hoffman, 
1990). It has been reported that dichloromethane-methanol extract of the flower of wild carrot from 
Turkey, using the DPPH method, revealed significant antioxidant activity (Yurdanur Akgul, 2009). 
A new eudesmane type sesquiterpenes compound isolated from the fruits of wild carrot was shown 
to possess cytotoxic activity against two human gastric cancer cell lines, BGC-823 and AGS 
leading to an increase in cell death (Hong-Wei Fu, 2009). Later studies conducted in our laboratory, 
showed that DCOE exhibited significant anti-tumour promoting effect against DMBA/TPA skin 
carcinogenesis model in mice (Abu Zeinab et al., 2011).
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1.3 Cancer
In most living cells, a balance is preserved between cell renewal and cell death. As body cells 
die, different types of stem cell produce new cells that differentiate to replace dead cells. When 
cells grow and divide uncontrollably, they give rise to clones of cells that can proliferate extensively 
producing a tumour, or neoplasm. A tumour is benign when it does is not invade neighbouring 
tissues. Whereas, a malignant tumour continues to proliferate and becomes progressively invasive; 
the term cancer refers specifically to a malignant tumour. Additionally, malignant tumours 
demonstrate metastasis where they are able to invade other tissues via the blood or lymphatic 
vessels (Hanahan and Weinberg, 2011). In spite of the therapeutic improvements made in 
understanding the mechanisms involved in carcinogenesis, cancer has become the primary cause 
of death in developed countries and the second in western word (Siegel et ah, 2011). Consequently, 
cancer chemotherapy has come to be a major field of research. Cancer development is mainly 
attributed to environmental factors and to a lower extent to genetics. Common environmental 
factors include diverse lifestyles, infection, radiation, and environmental pollutants (Manton et ah, 
2011).
1.3.1 Classification
Cancers are classified into several types according the origin of the tumour and these include 
(Hanahan and Weinberg, 2011):
• Carcinoma: Malignant tumours originating from epithelial cells. This group represents the 
most common cancers including colon, breast, lung and prostate cancer.
• Sarcoma: Malignancies derived from connective tissue such as bone, cartilage and nerve.
• Leukemia and lymphoma: These cells are derived from hematopoietic (blood-forming) cells.
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• Germ cell tumour: Cancers that arise from pluripotent cells. They are mainly present in the 
ovary and testicle.
• Blastoma or Elastic tumour: Cancer cells produced from immature cells or embryonic cells.
1.3.2 Carcinogenesis
Carcinogenesis is a multi-step process including initiation, promotion and progression. The 
first stage involves a reaction between the cancer-producing substance (carcinogen) and the DNA 
molecule of the cell which leads to genetic susceptibility or it may remain dormant and the 
individual may only be at risk for developing cancer at a later stage. The second stage is a slow 
process that ranges from several months to years. During this stage, a change in diet and lifestyle 
can have a protective effect so that the person may not develop cancer during his or her lifetime. 
The third and final stage involves progression and spread of the cancer where diet may be less 
effective (Hanahan and Weinberg, 2000).
1.3.3 Colorectal cancer:
Colorectal cancer is a disease derived from the epithelial cells lining the colon and it is the
result of inherited or acquired mutations (Ionov et al., 1993). The major common colon cancer cell
type is adenocarcinoma which comprises 95% of cases. Other, rarer types of colon cancer
include lymphoma and squamous cell carcinoma. Among different cancers, colon cancer is the
third leading cause of death in the United States and its prevalence is related to certain genetic and
nutritional factors (Pisani et al., 2002). It is the third most common diagnosed cancer among males
and the second among female with an incidence of 1.2 million new cases in 2008 (Jemal et al.,
2011). Furthermore, the rate of colorectal cancer is increasing with time due to a dietary patterns,
obesity and the increased prevalence of smoking (de Kok et al., 2008; Center et al., 2009a; Center
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et al., 2009b). As a result of the early screening and advancement in the field of medicine the rates 
of deaths from colorectal cancer has seen a decrease in western countries as compared to the 
developing world where the rates of death are still increasing due to the limited resources and poor 
health facilities (Chu et al., 1994; Sant et al., 2001; Mitry et al., 2002; Center et al., 2009a). Finally, 
there are several modifiable factors that can decrease the risk of colorectal cancer such as smoking, 
physical inactivity, excessive alcohol consumption and obesity (Giovannucci and Wu, 2006; Boyle 
and Levin, 2008; Aleksandrova et al., 2013).
1.3.4 Breast Cancer
Breast cancer originates mainly from cells of the inner lining of milk ducts or the lobules that 
provide the lobules with milk (Sariego, 2010). Cancer that is produced from ducts are called ductal 
carcinoma, whereas those derived from lobules are called lobular carcinoma. Risk factors 
associated with breast cancer involve hereditary (Bennett et al., 1999), hormonal (Henderson and 
Feigelson, 2000) and environmental factors (Lichtenstein et al., 2000). Previous reports indicated 
that inherited or acquired mutations occurring in p53, BRCA1, and BRCA2 genes are associated 
with breast cancer (Dunning et al., 1999) and can interfere in the mechanisms of DNA repair (Patel 
et al., 1998). Other types of mutations that are also linked to breast cancer involve the exposure of 
cells to estrogen (Cavalieri et al., 2006). Breast cancer is the most common cancer in females 
ranging from 40-55 years old, and is the leading cause of death in women globally. In addition, it 
is the most diagnosed cancer among females accounting for 23 % of the total new cancer cases and 
14 % of the total cancer deaths (Jemal et al., 2011). On the other hand, of the several factors that 
play a role in the variation of the global incidence rates are the availability of early detection tools, 
as well as the differences between hormonal and reproductive factors (Mackay et al., 2006; Jemal 
et al., 2010). Reproductive factors that increase the risk of breast cancer include the use of oral
contraceptives, hormonal replacement therapy, nulliparity, and an elongated menstrual history 
(Mackay et al., 2006). As a result of the early detection of breast cancer through mammography 
and the advancement in treatment, the rates of death have significantly decreased in North America 
and several European countries compared to the developing countries that are experiencing an 
increase in mortality rate (Althuis et al., 2005; Colditz et al., 2005; Autier et al., 2010; Jemal et al., 
2010). Finally, the best available approaches to decrease the risk of breast cancer are minimizing 
alcohol intake, maintaining a healthy body weight, and increasing physical activity (Kushi et al., 
2006).
1.3.5 Skin Cancer
Skin cancer is one of the most common type of cancer worldwide. There are three main types 
of skin cancer: melanoma, Basal cell carcinoma (BCC), and squamous cell carcinoma (SCC). Basal 
cell carcinoma is the most common but the least lethal cancer. It is a malignant epithelial cell 
tumour that begins first as a small papule (a small, circumscribed, solid elevation of the skin) and 
then enlarges peripherally to develop into a crater that erodes, crusts, and bleeds (Rigel et al., 2006). 
The second most common type of skin cancer is squamous cell cancer which originates from the 
squamous cells in the middle layer of the epidermis. SCC is a malignant tumour which may occur 
in many different organs, including the skin, lips, mouth, esophagus, lungs, vagina, and cervix 
(Lane and Comae, 1999). Basal cell carcinoma and SCC are usually present in skin areas that are 
highly exposed to sunlight, mainly the head and neck regions (Preston and Stem, 1992; Diepgen 
and Mahler, 2002). Their occurrence is positively correlated to the quantity of ultraviolet radiation 
received and inversely proportional to the6 ‘degree of skin pigmentation in the population. ’ ’ (Suarez 
et al., 2007). Melanoma is the least common, but the most aggressive type of skin cancer and it is 
responsible for the majority of skin cancer mortalities. The malignant melanoma is derived from 
uncontrolled proliferation of the pigment producing cells known as melanocytes. Several studies
suggest that over exposure to sunlight is the major risk factor for the development of melanoma 
(Kricker et ah, 1994; Westerdahl et ah, 1994; Epstein et ah, 1999).
1.3.5.1 Skin Carcinogenesis in mice
Skin carcinogenesis is divided into three main distinct chronological stages. The first stage is 
initiation and is considered to be an irreversible mutational change which can be accomplished by 
the single topical application of a sub-carcinogenic dose of a skin carcinogen such as 7,12- 
dimethylbenz(a)anthracene (DMBA), a chemical belonging to the family of polycyclic aromatic 
hydrocarbons (Braithwaite et ah, 1998). DMBA has the ability to induce the carcinogenesis 
process in cells yet doesn’t lead to the development of visible tumours if applied alone (DiGiovanni, 
1992).
The second stage is promotion which involves the clonal expansion of initiated cells to form 
visible non-malignant lesions called “papillomas”. A well-established promoting agent is croton 
oil with the active ingredient 12-O-tetradecanoayl phorobol-13-acetate (TPA). This process 
involves a stimulating action on the initiated cells allowing them to expand and divide. Unlike the 
initiating agents, TPA doesn’t require any metabolic activation or any DNA binding for its effect; 
instead it acts by binding to the membrane associated cellular receptors (Lawley, 1987; 
DiGiovanni, 1992).
The third stage is progression, where additional genetic instability in papillomas occurs, 
leading to invasive squamous cell carcinoma. This stage involves 3 major steps. First, the sequential 
trisomy of the chromosomes 6 and 7; second, amplification of the mutation Ha-ras- allele, and at 
last recessive mutation in the tumour suppressor gene p53 (DiGiovanni, 1992).
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1.4 Plant derived anticancer agents
Natural products are considered an important source of anticancer agents and are derived from 
different types of organisms such as plants, animals, microorganisms, marine organisms, and 
dietary sources. Numerous plant derived compounds, exhibit anticancer activity against several 
types of cancers (Altmann and Gertsch, 2007). The first discovery of anticancer compounds was 
early in 1950s by the isolation and development of vinca alkaloids such as vinblastine and 
vincristine. These drugs were used for the treatment of several types of leukemia (DeVita et al., 
1970). In general, phytochemicals mainly alkaloids, phenols, and terpenes demonstrate their anti­
tumour effect through various mechanisms including powerful antioxidants, inhibition of cell 
proliferation and induction of apoptosis (Reddy et al., 2003; Bhanot et al., 2011).
1.4.1 Anticancer activities of alkaloids
Plant alkaloids constitute a major chemotherapeutic medication for the treatment of cancer. 
The vinca alkaloids, vinblastine (VLB) and vincristine (VCR), were the earliest plant-derived anti­
cancer agents discovered and developed in the 1950s.They were first isolated from the Madagascar 
periwinkle, Catharanthusroseus, which was used in traditional medicine by various cultures for 
the treatment of diabetes (Gueritte and Fahy, 2005). These compounds bind specifically to tubulin, 
and prevent their assembly into microtubules (Noble, 1990). Later investigations led to the 
development of two semi-synthetic analogs, vinorelbine (VRLB) and vindesine (VDS) from the 
modification of VLB and VCR (Ding et al., 2005) and are currently used for the treatment of 
different types of cancer (Newman et al., 2003; Cragg and Newman, 2005). The taxanes, another 
group of alkaloids, include paclitaxel and docetaxel have shown anitumour activities against 
several tumour types (Wani et al., 1971). Two semi-synthetic drugs etoposide and teniposide
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derived from the natural product, ‘ epipodophyllotoxin’ an isomer of podophyllotoxin were found 
to be extremely active against several cancers (Harvey, 1999; Mans et ah, 2000; Cragg and 
Newman, 2005). These agents induce cell cycle arrest and inhibit the replication of DNA. 
Furthermore, the ‘combretastatins’ are colchicine related alkaloids produced from Combretum 
caffrum, exhibit potent anti-angiogenic activity resulting in tumour necrosis (Cragg and Newman, 
2005).
1.4.2 Anticancer activities of phenolic compounds
In addition to their antioxidant capacity and anticancer potential, phenolic compounds exhibit 
a wide variety of biological functions which are mainly related to modulation of carcinogenesis. A 
large number of epidemiological studies revealed that increased consumption of vegetables, fruits 
and legumes rich in phenolic compounds and flavonoids are associated with a significant decrease 
in cancer incidence (Batra and Sharma, 2013). Numerous in vitro and in vivo models have been 
used to determine the anticancer activity of these phytochemicals. For example, several 
polyphenols isolated from plant foods including quercetin, kaempferol, anthocyanins, coumaric 
acid and ellagic acid were shown to inhibit growth of many human cancer cell lines (Llorach et al., 
2003; Seeram et al., 2006). Similar antiproliferative activities against several cancer cell lines have 
been reported with wine extract rich in polyphenols (resveratrol, catechin, and quercetin) 
(Damianaki et al., 2000; Kampa et al., 2000) and tea extract composed of other polyphenols 
(epicatechin, epigallocatechin, epicatechin-3-gallate, and epigallocatechin-gallate) (Zhang et al., 
1999; Weisburg et al., 2004; Nichenametla et al., 2006). Furthemore, other phenolic extracts 
derived from olives, citrus, and curcumin from spice turmeric strongly inhibited various types of 
cancer cell lines including breast, lung, leukemia, and prostate (Manthey et al., 2001; Sarkar and 
Li, 2002). Numerous in vivo studies have been also conducted to evaluate the antitumour efficiency
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of phenolic extracts derived from plant foods. The animal models commonly exploited include 
chemically or genetically induced tumours as well as xenograft models. As an example, 
anthocyanin-rich extract from berry and grapes significantly inhibited tumourigenesis in rats and 
mice models (Ding et al., 2006; Lala et al., 2006). Tea extracts and its polyphenols such as 
epigallocatechin-gallate (EGCG) and the aflavin have also been shown to possess tumour 
preventive effects in various animal models (Huang et al., 1997; Chung et al., 1998; Yang et al., 
2002; Lambert and Yang, 2003).
1.4.3 Anticancer activities of terpenes
Terpenes are referred to as terpenoids when containing oxygen. These phytochemicals 
demonstrate various biological properties including anticancer, antifungal, antimicrobial, anti­
inflammatory, and antiviral activities (Dzubak et al., 2006; Salminen et al., 2008). For instance, the 
monoterpene limonene, an important constituent of essential oils of citrus fruits and other herbs, 
exhibits antitumour activity and prevents the development and progression of cancer (Crowell, 
1999; Kris-Etherton et al., 2002). Similar effects have been obtained from other monoterpenes such 
as carvone and perillyl alcohol (Mills et al., 1995; Crowell, 1999).
A second well known group of terpenes is sequiterpenes which also demonstrate various 
biological activities. Previous studies indicated that (3-elemene, a natural sesquiterpenene, exhibits 
wide anticancer activity against many cancer cell lines including breast, cervical, ovarian, 
leukemic, brain, lungs and colon carcinoma cells. (Yuan et al., 1999; Zou et al., 2001; Li et al., 
2005; Wang et al., 2005; Tao et al., 2006; Yao et al., 2008). Other sesquiterpenes such as 
furanodiene (Sun et al., 2009), curcumol (Xu et al., 2005), gemacrone (Zhong et al., 2011), widdrol 
(Kwon et al., 2010), p-caryophyllene (Amiel et al., 2012), p-eudesmol (Ma et al., 2008) and a-
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bisabolol (Cavalieri et al., 2004) have been reported to inhibit cell proliferation and induce 
apoptosis in several human cancer cells.
Diterpenes, another major group of terpenes, include several biologically active compounds. 
Paclitaxel (Taxol), a natural diterpene isolated from Taxus plant, is considered an important 
anticancer agent. This compound inhibits cell proliferation by preventing mitotic spindle formation 
and causes cellular arrest at the G2/M phase of the cell cycle (Schiff and Horwitz, 1980; Wang et 
al., 1999; Gogas and Fountzilas, 2003). Diterpenes such as eleutherobin and epothilone also exhibit 
similar antitumour activities as paclitaxel (Altaha et al., 2002).
Triterpenes, constitute the largest group of phytochemicals that demonstrate potent anti­
proliferative effects to various tumour cells without having any cytotoxicity against normal cells 
(Setzer and Setzer, 2003; Laszczyk, 2009; Petronelli et al., 2009). Triterpenes such as oleanolic 
acid, ursolic acid, and rexinoids are highly effective antitumour and chemopreventive agents in 
many animal models (Liby et al., 2007). Other triterpenes such as actein asiatic acid (Lee et al., 
2002; Einbond et al., 2009), cucurbitacin (Takahashi et al., 2009) and astragaloside IV (Qi et al., 
2010) are shown to inhibit the growth of HepG2 human hepatic carcinoma cells. Terpenes as well 
as phenols and flavonoids may also inhibit carcinogenesis by decreasing oxidative stress (Bennett 
et al., 2012). Excessive production of free radicals such as reactive oxygen species,” (ROS) and 
“reactive nitrogen species” (RNS) lead to oxidative stress (Kowluru and Chan, 2007). Thus, these 
phytochemicals act as potent antioxidants which scavenge free radicals and prevent damage to 
nucleic acids, proteins, and lipids.
1.5 Free Radicals/Oxidants
A free radical is any species capable of independent existence that contains one or more 
unpaired electrons (Halliwell, 2006). The powerful reactivity of the free radical is due to the
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unpaired electron that occupies an atomic orbital (Miller et ah, 1990; Valko et ah, 2007a). Free 
radicals are formed within living cells and are involved in several metabolic processes (Valko et 
ah, 2006). There are generally two major classes of free radicals, oxygen free radicals known as 
“reactive oxygen species,” (ROS) and “reactive nitrogen species” (RNS).These free radicals are 
produced when cells are exposed to various types of radiations such as UV light, X-rays and gamma 
rays. Additionally, free radicals can be generated by metal-catalyzed reactions, by neutrophils and 
macrophages during inflammation, and by mitochondria-catalyzed electron transport reactions 
(Cadenas, 1989). ROS includes the superoxide radical O2*", hydrogen peroxide H2O2, and the highly 
reactive hydroxyl radical *OH. The molecule H2O2, although not a free radical itself, is involved in 
the pathway of formation of other radicals and hence considered a ROS (Waris and Ahsan, 2006; 
Vera-Ramirez et ah, 2011). On the other hand, nitric oxide (NO*) is the main RNS in biological 
tissues (Archer, 1993).
1.5.1 The role of ROS in carcinogenesis
Cancer development is a multistage process and it is characterized by three stages: initiation, 
promotion and progression. ROS can act in all these stages of carcinogenesis (Nakayama et ah, 
1983). The process of initiation involves a mutation in the DNA through oxidative damage of both 
exogenous and endogenous free radicals. Oxidative DNA lesions by free radicals include single- 
or double-stranded DNA breaks, nitrogenous base alterations, and DNA cross-links. For example, 
hydroxyl radicals tend to react with purine and pyrimidine bases of the DNA molecule to form 8- 
hydroxy-2’-deoxyguanosine (8-OH-dG) adducts leading to errors in the reading frame during 
replication (Dizdaroglu et ah, 2002). Several studies revealed that the size of tumours is highly 
correlated to the amount of 8-OH-dG adducts (Loft and Poulsen, 1996). All these nucleic acid 
alterations may result in either the induction or inhibition of transcription, errors in DNA
replication, and genomic instability, all of which are related to carcinogenesis (Mamett, 2000; 
Cooke et ah, 2003).
The promotion stage necessitates a continuous presence of the tumour promotion stimulus 
(Loft and Poulsen, 1996). Although the production of high levels of ROS is cytotoxic to normal 
cells, low levels of free radicals leads to the enhancement of cell proliferation and hence stimulates 
tumour growth. Furthermore, tumour promoters may exert a potent inhibitory effect on enzymatic 
antioxidants such as SOD and CAT. (Dreher and Junod, 1996).
1.5.2 Other biological effects of ROS
ROS are known to play a dual role in biological systems, as they can be either beneficial or 
harmful to cells (Valko et ah, 2004). Among these useful biological functions are their role in 
inflammatory responses against microbial infections and their participation in several signaling 
pathways involved in preserving cellular homeostasis. For instance, during inflammation, 
macrophages and neutrophils demonstrate increased oxygen consumption that results in the 
production of O2*" and H2O2. These radicals play a vital role in the first line of defence against 
infectious agents (Waris and Ahsan, 2006; Valko et ah, 2007b; Manda et ah, 2009; Vera-Ramirez 
et ah, 2011). In contrast, high concentrations of ROS cause severe damage to various cell structures 
such as membrane lipids and proteins (Poli et ah, 2004). The hydroxyl radical (OH*) is a strong 
oxidizing agent that can react with polyunsaturated fatty acids to produce peroxyl radicals. These 
radicals generate malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE) upon decomposition 
(Esterbauer et ah, 1991). The MDA can induce damage and loss of integrity of cell membranes 
(Thabrew et ah, 1987). Furthermore, several studies showed that ROS react with the protein 
polypeptide backbone to form alkoxyl radical derivatives of proteins which are capable of 
undergoing peptide bond cleavage resulting in protein damage (Davies et ah, 1987; Davies, 1987).
1.5.3 The role of ROS in cell signaling
ROS play a major physiological role in the modulation of intracellular signaling and the 
expression of several genes (Palmer and Paulson, 1997; Thannickal and Fanburg, 2000). High 
concentrations of ROS may cause cell death or necrosis, whereas low concentrations of radicals 
stimulate cell proliferation and enhance survival in many cell types (Hensley et ah, 2000; 
Thannickal and Fanburg, 2000). Previous studies indicated that ROS activate several signaling 
cascades, most importantly growth factor kinases, src/Abl kinase (Esposito et ah, 2003), MAPK 
(Esposito et ah, 2003), and PI3-kinase-dependent signaling pathways (Huang et ah, 2001). These 
signaling pathways are involved in the regulation of gene expression, proliferation, differentiation, 
and apoptosis. Additionally, the effect of metals and ROS on the MAPK pathway involves the 
activation of nuclear factors such as AP-1 (Whitmarsh and Davis, 1996), p53 (Renzing et ah, 1996) 
and NF-kappa p (Pinkus et ah, 1996).
1.6 Antioxidant defense mechanisms
The exposure of aerobic cells to free radical mainly ROS may have deleterious effects on 
cellular activities. However, the effect of reactive oxygen is balanced by two major antioxidant 
mechanisms including non-enzymatic antioxidants and antioxidant enzymes. These antioxidants 
provide an efficient mode of protection to biological systems. A good antioxidant is characterized 
by the ability to scavenge free radicals, chelate redox metals, regenerate other antioxidants and 
modulate cell signaling pathways which contribute to cancer prevention (Gupta and Sharma, 2006). 
The antioxidants produced by the body (endogenous) include enzymatic and non-enzymatic 
defense systems. The enzymatic defences involve superoxide dismutase (SOD), catalase (CAT), 
and glutathione reductase, peroxidase and transferase (Evans et ah, 2004; Manda et ah, 2009). 
These enzymes come under first line of defence and play a role in decreasing the levels of reactive
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oxygen species and preventing oxidative damage. The non-enzymatic defences include the 
tripeptide glutathione, reduced Coenzyme Q10, histidine peptides, melatonin, lipoic acid and 
plasma protein thiols (Valko et ah, 2006). On the other hand, exogenous antioxidants include non- 
enzymatic natural antioxidants derived from diet such as vitamins C, E, and A or from plant 
products such as carotenoids, phenols, flavonoids (polyphenols), and terpenes (McCall and Frei,
1999). All the non-enzymatic antioxidants constitute the second line of defence. The third line of 
defence is a group of antioxidants enzymes involved in the repair of damaged DNA, damaged 
proteins and oxidized lipids (Gupta and Sharma, 2006).
1.6.1 Enzymatic antioxidants
SOD is the most efficient intracellular antioxidant enzyme in protecting an organism against 
the superoxide anion 02*'. Superoxide dismutase enzymes (SODs) catalyze the dismutation of O2*' 
to O2 and into a less reactive compound H2O2 (McCord and Fridovich, 1969). Superoxide 
dismutase exists in three isoforms: cytosolic Cu, Zn-SOD which catalyze the conversion of 
superoxide anion to oxygen and water (MatÉs et ah, 1999); Mn-SOD, expressed in the 
mitochondrial matrix and is a highly effective antioxidant enzyme and has anti-tumour activity as 
well as extracellular SOD (EC-SOD) which is expressed selectively in limited types of tissues 
(Landis and Tower, 2005). Other antioxidant enzymes mainly catalases and glutathione 
peroxidases work simultaneously with SODs to eliminate H2O2 which would otherwise undergo 
the “Fenton reaction” and produce the highly reactive hydroxyl radical. Catalase hydrolyzes 
hydrogen peroxide into water and molecular oxygen, whereas glutathione peroxidases reduce it to 
water by coupling it to the oxidation of reduced glutathione (GSH) which is a thiol-containing 
tripeptide. Glutathione reductase enzymes eventually convert back the oxidized glutathione formed 
by this reaction to GSH (Rhee et al., 2005; Halliwell, 2006). As shown in figure 1.2, the oxidative
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balance and the inhibition of oxidative damage requires the collaboration of various antioxidant 
enzyme systems (Halliwell, 2006).
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Figure 1.2. Exogenous and endogenous sources of reactive oxygen species and the enzymatic antioxidant defense 
system. (“Literature review of a cantaloupe melon”, 2007)
1.6.2 Non-enzymatic antioxidant
The non-enzymatic antioxidants include essential nutrients such as Vitamin C, Vitamin E,
carotenoids, and thiol antioxidants including glutathione and lipoic acid. Vitamin C is a powerful
antioxidant which protects membranes against oxidation (Retsky et ah, 1999). Several reports
indicated the protective effect of Vitamin C in various types of cancer (Knekt et al., 1991; You et
al., 2000). Vitamin E is also considered an important antioxidant that plays a role in the protection
against lipid peroxidation (Burton and Ingold, 1989; Pryor, 2000). Both vitamins collaborate to
regenerate a-tocopherol in membrane lipids and lipoproteins, thus protecting membranes against
lipid peroxidation (Shosuke, 2004). On the other hand, the major non-enzymatic thiol antioxidant
is the tripeptide, glutathione (GSH). This compound is abundant in several cellular organelles such
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as cytosol, nuclei and mitochondria. GSH can act as a direct scavenger of singlet oxygen and 
hydroxyl radical, or as a cofactor of many detoxifying enzymes and is also capable of regenerating 
vitamins C and E into their active forms (Masella et ah, 2005).
1.6.3 Plant Antioxidants
In nature there are a wide variety of plants which are considered a rich source of natural 
antioxidants. These natural non-enzymatic antioxidants include phenols, flavonoids, carotenoids, 
terpenes and others. It has been reported that the antioxidant properties of phenolic compounds can 
be due to different mechanisms: (1) scavenging free radical such as ROS/RNS; (2) inhibiting 
ROS/RNS formation by inactivating enzymes or chelating metals ions involved in free radical 
production; (3) augmenting or protecting antioxidant defense system (Dai and Mumper, 2010). 
Furthermore, essential oils extracted from several plant species such as clove, thyme, oregano, basil 
and cinnamon, have a significant DPPH radical scavenging activity due to high phenolic content 
(Tomaino et ah, 2005). The antioxidant activity of essential oils cannot be attributed only to the 
presence of phenolic compounds but also to the presence of terpenes. Numerous reports indicated 
that terpenes of essential oils such as P-caryophellene, a-humelene, limonene, y-terpinene, linalool, 
P-pinene, caryophyllene oxide, p-selinene, p-bisabolene exhibit considerable antioxidant activities 
(Deba et ah, 2008; Ben Farhat et ah, 2009; Keawsa-ard and Kongtaweelert, 2012; Remya et ah, 
2013). Additionally, terpenoids and carotenoids derived from various plant species possess 
important antioxidant capacities. It has been suggested that carotenoids exert their antioxidant 
activities through three main ways. These mechanisms include quenching of singlet oxygen, 
hydrogen transfer, or electron transfer (Grassmann, 2005).
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1.6.4 The role of antioxidants in cancer chemoprevention
Chemoprevention consists of multiple intervention approaches, by means of either 
pharmacological or dietary agents which may hinder, halt or reverse the process of carcinogenesis 
at different stages. A variety of naturally occurring agents and dietary compounds has been shown 
to possess important chemopreventive effects. An important example is the phenolic compounds 
(flavonoids, polyphenols) which inhibit tumour formation in vivo by blocking the initiation phase 
of carcinogenesis or slowing down the promotion and progression phases of carcinogenesis 
(Singletary and MacDonald, 2000; Khor et al., 2006a; Khor et al., 2006b). As shown in figure 1.3, 
flavonoids are able to interfere or suppress carcinogenesis at different stages.
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Figure 1.3. Flavonoids block or suppress multi-stage carcinogenesis at different levels (Moon et al., 2006)
Phytochemical compounds demonstrate their cancer preventive effects through several cellular
mechanisms. One important mechanism is through the activation of the Nrf-2 signaling pathways
which play a significant role in the regulation of numerous phase II detoxifying and antioxidant
enzymes such as GST and HO-1 (Hu et al., 2006; Shen et al., 2006). By inducing these enzymes
through the activation of NrfZ/ARE-regulated genes, chemo-preventive phytochemicals accelerate
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the detoxification of carcinogenic agents and protect normal cells from oxidative damage, thus 
blocking the initiation stage and consequently reducing the risk of cancer (Thimmulappa et al, 
2002; Balogun et ah, 2003). Another mechanism involves the inhibition of uptake of toxic materials 
into cells and enhancement of DNA repair. In addition to these specific effects, many plant products 
have strong antioxidant effects, either as general antioxidants or as free radical scavengers, or by 
reducing redox imbalance following glutathione depletion (Hayes and McMahon, 2001). Another 
important approach in the regulation of carcinogenesis includes the slowing down of inappropriate 
or uncontrolled cell division of tumour cells by inducing cell cycle arrest or the induction of 
apoptosis in stressed or damaged cells. Several reports have indicated that natural products may 
promote apoptosis in several human cancer cell lines through the activation of caspases or 
modulating the PI3K/Akt signaling pathway and Bcl-2 pro-apoptotic and anti-apoptotic proteins 
(Chen et al., 2003; Hu et al., 2003; Qin et al., 2007). Other chemopreventive phytochemicals such 
as curcumin (Chen et al., 2004), resveratrol (Bràkenhielm et al., 2001), luteolin (Bagli et al., 2004), 
and genistein (Shih and Claffey, 2001) have been shown to act at later stages of carcinogenesis by 
inhibiting angiogenesis of the tumour by targeting angiogenic stimulators such as fibroblast growth 
factor (FGF), platelet-derived growth factor (PDEGF), matrix metalloproteinases (MMPs) and 
vascular endothelial growth factor (VEGF) families. Other cellular pathways involved in the cancer 
chemoprevention, is the nuclear factor-kappa B (NF-kB). Once activated, members of this protein 
translocate into the nucleus, where they activate the expression of a wide range of genes involved 
in various cellular events including cell proliferation, apoptosis, differentiation, metastasis, and 
inflammation. Several natural chemopreventive agents such as curcumin (Singh and Aggarwal, 
1995), resveratrol (Manna et al., 2000), betulinic acid (Takada and Aggarwal, 2003), ursolic acid 
(Shishodia et al., 2003), and gingerol (Kim et al., 2004) have been found to be potent inhibitors of 
NF-kB. Furthermore, activator protein-1 (AP-1) is another redox-sensitive transcription factor
43
involved in carcinogenesis. Activation of AP-1 has been implicated in the regulation of genes 
related to apoptosis and proliferation. Many natural products such as green tea catechins (Dong,
2000), quercetin (Lagarrigue et al., 1994), resveratrol (Manna et al., 2000), curcumin (Han et al., 
2002) and capsaicin (Han et al., 2001) have been shown to inhibit the AP-1 activation. Figure 1.4 
shows various molecular targets of dietary agents and natural compounds in the prevention and 
treatment of cancers (Aggarwal and Shishodia, 2006).
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Figure 1.4. Various molecular targets of dietary agents for cancer prevention and treatment (Aggarwal and 
Shishodia, 2006)
1.7 Mechanisms of apoptosis
Apoptosis, or programmed cell death, is an important physiological process required for 
normal cell proliferation and maintenance of tissue homeostasis. After severe DNA damage,
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apoptosis is the major control mechanism which mediates cell death (Lowe and Lin, 2000). Cell 
death involves two major mechanisms: necrosis and apoptosis. Cells undergo necrosis due to an 
external injury which disrupts the cell membrane leading to cell swelling and rupture, whereas, 
apoptosis, or programmed cell death, comprises a series of morphological and biochemical 
alterations. These modifications include nuclear and cytoplasmic condensation, DNA 
fragmentation, shrinkage of cells, and membrane blebbing (Hengartner, 2000). Apoptosis occurs 
through two main pathways. The first, referred to as the extrinsic pathway, is induced via the Fas 
death receptor at the plasma membrane. The second, is the intrinsic pathway, involves the release 
of cytochrome c from the mitochondria. Both pathways lead to the activation of caspases which 
trigger a sequence of events ending in cell death (Eamshaw et al., 1999). Once activated, the 
initiator caspases trigger a cascade of downstream caspase activation. The effector caspases-3 and 
-7 are responsible for massive proteolytic cleavage of structural and regulator proteins such as 
inhibitor of caspase-activated DNAase (ICAD) which is involved in DNA degradation (Enari et 
al., 1998), Poly (ADP-ribose) polymerase (PARP) which triggers DNA-repairing enzymes 
(Eamshaw et al., 1999), protease-activated factors (CAD) and a chromatin condensation factor 
called acinus, which induce apoptotic chromatin condensation resulting in cell death (Liu et al., 
1998; Samejima et al., 1998; Sahara et al., 1999).
1.7.1 Apoptosis related proteins
1.7.1.1 The Bcl-2 family
The Bcl-2 proto-oncogene was first discovered in human B-cell lymphomas from where its 
name is derived (Tsujimoto et al., 1985). The Bcl-2 gene has been implicated in various types of 
cancers such as breast, prostate, melanoma, and lung carcinomas (Hanahan and Weinberg, 2000; 
Cory et al., 2003). Most members of the Bcl-2 family share one or more homology (BH) domains
which are essential for the formation of dimers within its members (Danial and Korsmeyer, 2004).
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The Bcl-2 family is divided into pro-apoptotic and anti-apoptotic proteins according to structural 
and functional characteristics (Germain and Shore, 2003; Petros et ah, 2004). The pro-apoptotic 
Bcl-2 proteins include Bax, Bad, Bim, and Bid. The anti-apoptotic proteins include Bcl-2, Bcl-xL, 
and Bcl-w (Adams and Cory, 2007).
1.7.1.2 Caspases
Caspases are proteases that play essential roles in apoptosis and inflammation. Accordingly, 
caspases are classified according to their role in apopotosis (caspase-3,-6, -7, -8, -9) or 
inflammation (caspase-1, -4, -5, -12) (Mcllwain et ah, 2013). Apoptotic caspases are further 
subdivided into initiator caspases such as caspase-8 and -9 or executioner caspases such as caspase- 
3, -6 and -7 (Riedl and Shi, 2004). These proteases consist of 14 mammalian members that are 
initially produced as an inactive form (pro-caspases) and can be activated either by dimerization or 
by cleavage in response to different apoptotic stimuli (Kohler et ah, 2002). The pro-caspases 
possess four domains: a pro-domain, a large subunit, a small subunit, and a linker fragment that 
links both units (Eamshaw et ah, 1999). Caspase activation involves the enzymatic cleavage of the 
pro-domain and the linker region which results in the formation of a heterodimer. The active 
caspase is formed from the combination of the two heterodimers (Liang and Fesik, 1997). Once 
activated, the initiator caspase cleaves the executioner pro-caspase dimers allowing a 
conformational change in their active sites which in turn leads to active protease. Finally, the 
activated executioner caspases such as caspase-3 and -7 can cleave and activate other downstream 
protein substrates within the cell leading to apoptosis (Los et ah, 1999).
1.7.1.3 Poly ADP ribose polymerase (PARP)
PARP enzymes have been shown to be involved in several cellular activities including DNA
replication, repair, gene transcription, cell survival and apoptosis (DAMOURS et ah, 1999; Biirkle
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et al., 2005). Previous studies suggested that deficiency or defects in the regulation of PARP-1 may 
accelerate carcinogenesis (Masutani et al., 2003) and aging (de Boer and Hoeijmakers, 1999). The 
PARP enzymes, found in the nucleus, catalyze the formation of poly (ADP-ribose) (PAR) from 
NAD+ or indirectly from ATP. PARP consists of four domains: a DNA binding domain, a caspase 
cleaved domain, a catalytic domain and an auto-modification domain. Once PARP identifies single­
strand DNA breaks (SSB), it binds to the DNA molecule and starts the synthesis of PAR which 
will recruit other DNA-repairing enzymes (Isabelle et al., 2010). It is reported that activated PARP 
may contribute to cell death by depleting the cell of NAD and ATP (Berger, 1985; Berger and 
Petzold, 1985). PARP was also found to induce apoptosis through the production of PAR leading 
to apoptosis-inducing factor AIF release from the mitochondria (Yu et al., 2006). Other studies 
revealed that PARP was cleaved into 89- and 24-kDa fragments during drug-induced apoptosis in 
various types of cells (Kaufmann et al., 1993; Tewari et al., 1995). This cleavage leads to the 
inhibition of enzyme activity and hence preventing it to act in response to DNA strand breaks. 
Additionally, caspase-3, is mainly responsible for the cleavage of PARP during cell death (Tewari 
et al., 1995; Rhun et al., 1998).
1.7.2 The extrinsic pathway or the cytoplasmic pathway
Apoptosis can be initiated through the activation of several death receptors including Fas, 
TNFaR, DR3, DR4 and DR5 with their respective ligands (figure 1.5). When a death stimulus 
triggers the extrinsic pathway, the membrane-bound Fas ligand (Fas L) binds with the inactive Fas 
complexes and forms the death-inducing signalling complex, which in turn leads to the activation 
of the initiator caspases-8 and-10 through the adaptor protein Fas-associated death domain protein 
(FADD) (Wajant, 2002). Activated caspase-8 triggers apoptosis by cleaving and activating 
downstream caspase-3, or alternatively cleaving the proapoptotic protein Bid (member of the Bcl-
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2 family) in the intrinsic apoptotic pathway. Truncated Bid (tBid) translocates to the mitochondria, 
and causes the subsequent release cytochrome c, leading to the sequential activation of caspase-9 
and 3 (Ghobrial et ah, 2005).
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Figure 1.5. The two main pathways of apoptosis. The extrinsic pathway is activated through the Fas death receptor. 
The intrinsic pathway involves non-receptor mediated intracellular signals when stimulated leads to the release of 
cytochrome-c from the mitochondria and activation of the death signal. Both pathways converge to a final common 
pathway involving the activation of several caspases that cleave regulatory and structural proteins leading to cell death 
(Ghobrial et ah, 2005).
1.7.3 The intrinsic pathway or the mitochondrial pathway
The intrinsic signaling pathway for programmed cell death involves non-receptor mediated 
intracellular signals. These stimuli that initiate the intrinsic pathway cause perturbations in the inner 
mitochondrial membrane that results in the release of several pro-apoptotic proteins including AIF, 
endonuclease G (apoptosis inducing factor), Smac/Diablo, Omi/HtrA2, caspase-9 and cytochrome 
c, from the inter-membrane space into the cytoplasm (Costantini et al., 2000; Du et al., 2000; 
Kroemer and Reed, 2000; Verhagen et al., 2000; Martinou and Green, 2001). Cytochrome c binds 
and activates Apaf-1 as well as procaspase-9, forming an ‘apoptosome complex’ (Adrain and
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Martin, 2001). Once activated, caspase-9 can activate the executioner caspases- 3 and -7 leading to 
the breakdown of the nucleus (Figure 5). The other pro-apoptotic proteins such as Smac/Diablo 
and Omi/HtrA2 bind to and antagonize the of LAP proteins leading to caspase activation (Du et al., 
2000; Verhagen et al., 2000). On the other hand, AIF and endonuclease G translocate to the nucleus 
and cause chromatin condensation (Daugas et al., 2000; Ferri and Kroemer, 2000; Li et al., 2001) 
as well as DNA fragmentation initiated by cleavage of ICAD (inhibitor of caspase-activated 
DNase) and the inhibitor of the endonuclease CAD (caspase-activated DNase) (Figure 5) 
(Hengartner, 2000). These apoptotic mitochondrial events are under tight control of the Bcl-2 
family proteins. The Bcl-2 family includes several anti-apoptotic proteins such as Bcl-2, B c1-X l, 
Bcl-w and pro-apoptotic proteins including Bax, Bak, Bad, Bim and Bid. The Bim and Bid proteins 
have a BH domain which links the death receptor pathway (extrinsic) to the mitochondrial pathway. 
These proteins trigger the pro-apoptotic Bcl-2 proteins such as Bax to translocate from the 
cytoplasm to the outer mitochondrial membrane creating pore-like structures and subsequent 
release of cytochrome-c, thus promoting apoptosis (Antonsson and Martinou, 2000; Cheng et al.,
2001). Bcl-2 and B c1 -X l prevent apoptosis by inhibiting cytochrome c release via a direct effect on 
mitochondrial channels (Kroemer and Reed, 2000; Martinou and Green, 2001) or by sequestering 
BH3 domain-only proteins in stable mitochondrial complexes, hence preventing Bax translocation 
to the mitochondria (Cheng et al., 2001).
1.7.4 Targeting apoptosis pathways in cancer therapy
Many therapeutic agents exert their anticancer activities through the induction of apoptosis
(Mesner Jr et al., 1997). Some of these antitumour compounds are in clinical use or in clinical trials,
while others are still in preclinical stages. The activation of the apoptotic machinery by these agents
involves several pathways including the death receptor (extrinsic) pathway, the mitochondrial
(intrinsic) pathway, the common pathway (through caspases), or the modulatory proteins of
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apoptosis. Another approach is to classify the agents as either inducers of pro-apoptotic proteins or 
inhibitors of anti-apoptotic proteins (Ghobrial et ah, 2005).
1.7.4.1 Agents that target the extrinsic pathway
TNF-related apoptosis-inducing ligand (TRAIL), is a cytokine that is produced and secreted 
by most normal body cells. This protein binds to death receptors such as DR4 (TRAIL-RI) and 
DR5 (TRAIL-RII) and triggers apoptosis in tumour cells (Wiley et ah, 1995). TRAIL has been 
implicated in several anti-cancer treatments. TRAIL was found to induce apoptosis in breast and 
colon xenografts (Marsters et ah, 1996). Additionally, TRAIL has been shown to exhibit synergistic 
antitumour properties when combined with chemotherapy or radiation (Ghobrial et ah, 2005). 
Other studies indicated that cancer therapy-triggered apoptosis is mediated through the activation 
of Fas receptor/ligand system. These therapies include anticancer drugs that induce the synthesis 
of Fas Ligand, which in turn binds to Fas receptor leading to cell death. Several chemotherapeutic 
agents including doxorubicin (Friesen et ah, 1996; Fulda et ah, 1998), etoposide (Kasibhatla et ah, 
1998), methotrexate (Friesen et ah, 1997), and cisplatin (Fulda et ah, 1997) have been observed to 
increase Fas ligand mRNA in various cancer cell lines.
1.7.4.2 Agents That Target the Intrinsic Pathway
There is compelling evidence indicating that most cytotoxic drugs cause apoptosis via the
mitochondrial pathway. These include agents that target directly the mitochondrial inner
membrane. For instance, arsenic trioxide induces apoptosis by disrupting the mitochondrial inner
membrane potential (Hussein et ah, 2004; Chou and Dang, 2005). Another approach that has been
implicated in targeting the intrinsic pathway are agents which can inhibit the anti-apoptotic
members of the Bcl-2 family. In vitro and in vivo studies have demonstrated antitumour activity of
antisense oligonucleotides such as G3,139 which is a complementary sequence to the Bcl-2 m-
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RNA. This leads to the destruction of the m-RNA fragments by endonucleases and subsequent 
inhibition of Bcl-2 expression (Ackermann et al., 1999). Another study, showed that antisense Bcl- 
xL olignucleotide and bispecific antisense Bcl-2/Bcl-xL oligonucleotide, targeting the mRNA 
homology region of both Bcl-2 and Bcl-xL, down regulates the expression of both proteins, triggers 
apoptosis, and inhibits proliferation of diverse tumour types in vitro and in vivo (Zangemeister- 
Wittke et al., 2000). The Bcl-2 and Bcl-xL proteins are over expressed in many tumours such as 
prostate cancer, breast cancer, non-small cell lung cancer, small cell lung cancer, and melanoma 
(Selzer et al., 1998). This leads to the inhibition of apoptosis and enhancement of tumour promotion 
and progression.
1.7.4.3 Agents that target the common pathway
Activation of caspases can be considered as an important strategy for the treatment of cancer. 
Anticancer drugs that trigger caspases include synthetic activators of caspases which cause protein 
aggregation inside the cell that enhances caspase activation leading to apoptosis (MacCorkle et ah, 
1998; Shariat et ah, 2001). Another alternative approach to target the common pathway involves 
agents that are directed against inhibitor of apoptosis proteins (lAPs) such as survivin, XIAP, 
cIAPl, and cIAP2(01ie et ah, 2000; Sasaki et ah, 2000). Survivin is expressed in numerous human 
tumours while it is absent in normal cells and is involved in cell resistance to chemotherapy. Hence, 
survivin has become a potential target for cancer treatment (Wang et ah, 2003; Li, 2005). 
Furthermore, LAPs have been reported to prevent the activation of several caspases including 
caspase-3, -7, -8 and -9 (Salvesen and Duckett, 2002). Elevated levels of LAPs have also been 
reported in many tumours and it has been associated with adverse prognosis (Salvesen and Duckett, 
2002).
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1.8 Cell cycle regulation
The Cell cycle consists of four sequential phases: G0/G1-phase, S-phase, G2-phase and M- 
phase. The M-phase includes nuclear division (mitosis) and cytoplasmic division (cytokinesis). The 
cell cycle progression is controlled and regulated by two classes of molecules, cyclins and cyclin- 
dependent kinases in mammalian cells (Cdk). Cyclins represent the regulatory subunits and Cdks 
form the catalytic subunits of activated heterodimers. Once activated, the G1 cyclin-Cdk 
complexes promote the expression of several transcriptional factors that intern prepare the cell for 
S phase. The cell cycle progression starts when cyclin D binds to Cdk4 to form an activated 
complex that further phosphorylates the retinoblastoma susceptibility protein (Rb). Hyper­
phosphorylation of Rb causes the release of E2F transcription factor that become activated leading 
to the expression of various genes such as cyclin E, cyclin A, and DNA polymerases, which are 
required for entry into S-phase (Orlando et al., 2008). Several checkpoints exist to monitor and 
regulate cell cycle progression at specific points. The first checkpoint is between Gl/S-phase, and 
the second is between G2/M-phase. At these two check points, any damaged DNA would be 
detected and subsequently the progression of the cell cycle is halted until the damage can be 
repaired. Spindle assembly is another important checkpoint that detects any improper alignment 
of the spindle fibers or failure to connect to the kinetochores (Elledge, 1996).
1.8.1 The role of p53 in cell cycle regulation and apoptosis
Human p53 is a tumour suppressor protein encoded by TP53 gene located on chromosome 17. 
The p53 protein plays an important role in the regulation of various cellular processes including 
cell cycle progression, genomic stability, and inhibition of apoptosis as well as angiogenesis (Bai 
and Zhu, 2006). It has been reported that mutations of the TP53 gene are identified in nearly all 
human tumour types and constitutes more than 50% of cancer cases worldwide (Hollstein et al.,
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1991). The p53 activation involves an increase in the concentration of p53 protein and other 
posttranslational modifications that promote the expression of several p53-targeted genes (Fritsche 
et ah, 1993). One of the most notable responses of p53 is the induction of cell cycle arrest. In 
response to cellular stresses, activated protein kinases such as ATM and CHK2 proteins 
phosphorylate p53 resulting in cell cycle arrest and apoptosis (Banin et ah, 1998). It appears that 
p53 can halt cell cycle progression in the Gl, G2, and S phases of the cell cycle allowing sufficient 
time for the cell to repair the genomic damage (Agarwal et ah, 1995; Mirza et ah, 2003). Once 
activated, p53 up-regulates a cyclin-dependent kinase (CDK) inhibitor p21wafl/ClP1 which induces 
Gi cell cycle arrest (Wade Harper et ah, 1993). Another cellular response controlled by p53 is 
induction of apoptosis when severe and irreversible damage occurs in cells. The p53 may activate 
the expression of several apoptotic gene products involved in intrinsic apoptotic pathway 
(mitochondrial pathway) or extrinsic pathway (death receptor pathway) as shown in figure 1.6. 
Following DNA damage, various p53- regulated pro-apoptotic Bcl-2 family proteins such as Bax, 
Bid, Puma and Noxa translocate to the mitochondrial membrane and cause the release of 
cytochrome c and formation of apoptosome complex with Apaf-1 and caspase 9 leading to cell 
death (Oda et ah, 2000; Nakano and Vousden, 2001; Matsuda et ah, 2002). Furthermore, p53 may 
also promote apoptosis through the activation of the death receptor-mediated extrinsic pathway. 
These receptors include Fas/CD95 (O’Connor et ah, 2000), DR4 (Liu et ah, 2004) and DR5 
(Takimoto and El-Deiry, 2000).
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Figure 1.6. The role of p53 in apoptotic pathways. The p53 protein induces apoptosis mainly via the extrinsic and 
intrinsic pathways. The p53-associated extrinsic pathway is mainly achieved by triggering caspase-8 to induce 
apoptosis, however the p53- associated intrinsic pathway involves the release of cytochrome c and the activation of 
caspase-9 to induce apoptosis. Additionally, p53 can directly activate Apaf-1 to promote apoptosis (Bai and Zhu, 2006)
Phosphatidyl inositol 3-kinase (PBK)-Akt contributes for cell proliferation and cell cycle 
progression by supporting cancer cells to avoid apoptosis, and its expression is up-regulated in 
different cancer cell lines (pancreatic, bladder, thyroid, ovarian, colon, and breast) by stimulating 
its downstream gene Akt (Wu et al., 2009; Wang et al., 2010).
1.9.1 PI3K/Akt pathway activation and components
Akt also known as Protein Kinase B (PKB) is characterized as the human homologue of viral 
oncoprotein v-Akt, that is responsible for a type of leukemia in mice (Staal, 1987). Furthermore, it 
is a 57 kD serine/threonine kinase that has three isofonns expressed in different tissues in the body. 
Akt-1 being predominantly expressed in the lung, heart, and brain, while Akt-2 is mostly abundant
1.9 PI3K/Akt Pathway
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in the embryonic brown fat and skeletal muscles, and finally Akt-3 that is primarily expressed in 
the kidney, embryonic heart, and brain (Altomare et al., 1995; Brodbeck et al., 1999).
After being activated, PI3K begins with the phosphorylation of the inositol ring 3’-OH group 
in inositol phospholipids (Fruman et al., 1998). As shown in figure 1.7, the two receptors that are 
required for the activation of PI3K are: receptor tyrosine kinases (RTK) and the G-protein coupled 
receptor. Class I-PI3K is composed of a regulatory subunit (P85) and a catalytic subunit (pi 10). 
The p85 subunit is responsible for the recruitment and activation of PI3K after its interaction with 
the activated receptors, while pi 10 leads to the formation of phosphatidylinositol-3,4,5- 
trisphosphate (PI(3,4,5)P3), which functions as a docking site for Akt, from phosphatidylinositol-
4,5 bisphosphonate (PI(4,5)P2) (Vanhaesebroeck and Waterfield, 1999; Katso et al., 2001). 
Consequently, Akt is phosphorylated on two main sites (Thr 308 in kinase domain and Ser 473 in 
C-terminal regulatory domain) rendering it active leading to the phosphorylation of different 
proteins involved in anti-apoptotic and anti-proliferative functions (Alessi et al., 1996).
Furthermore, the effect of PI3K is reduced by phosphatase and tensin homolog (PTEN), a 
tumour suppressor gene, which removes the phosphate from the 3’-OH position and diminishing 
the availability of the PI(3,4,5)P3 and formation of the PI(4,5)P2 (Liu et al., 2009). In addition, 
another protein involved in the PDK/Akt pathway is the mammalian target of rapamycin (mTOR), 
a serine/threonine protein kinase, that contributes to the regulation of cell growth and proliferation 
by sensing the availability of nutrients and cellular energy (Watanabe et al., 2011) Finally, Akt is 
an important and essential survival factor in cancer cells and its activation of the downstream 
mTOR kinase signaling pathway promotes cell growth by the phosphorylation of proteins involved 
in the regulation of apoptosis (Downward, 2004).
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Figure 1.7. Model for the regulation of the PI3K-Akt signaling pathway. The binding of growth factors to their receptor 
tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) trigger the phosphorylation of phosphatidylinositol 3- 
kinase (PI3K) which consists of P85 and PI 10 subunits. PI3K transforms PI(4,5)P2 to PI(3,4,5)P3. Akt translocates to 
the cell membrane and interacts with PI(3,4,5)P3 through its PH domain which will be phosphorylated at two main 
sites leading to its activation. Carboxyl terminal modulating protein (CTMP) inhibits the phosphorylation of Akt. Once 
activated, Akt phosphorylates various downstream target proteins involved the regulation of cell cycle, cell survival 
and apoptosis (Osaki et ah, 2004).
1.9.2 PI3K/Akt pathway in human cancer
There are several mechanisms for the activation of Akt in cancer cells that include alternations 
in the Akt, PI3K, and PTEN genes. Firstly, the loss of the expression of PTEN in human cancer 
cells is mostly due to a genetic mutation or deletion that has been reported in cancers involving the 
thyroid, prostate, breast, colon, uterus, and central nervous system (Ittmann, 1998; Frisk et ah, 
2002; Garcia et ah, 2004; Nassif et ah, 2004). Therefore, the loss of PTEN leads to a permanent 
activation of the PI3K/Akt pathway and is associated with a poor prognosis and diminished survival 
in human cancers (LoPiccolo et ah, 2008). Furthermore, a mutation in PI3K catalytic subunit alpha 
(PI3KCA) leads to the activation of Akt and resulting in cellular proliferation and growth in several 
cancers such as cervical, ovarian, glioblastoma, hepatocellular carcinoma and endometrial cancers
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(Lee et a l, 2004; Hartmann et al., 2005; Levine et al., 2005; Janku et al., 2011). Finally, the 
amplification of the Akt gene is associated with different cancers as Akt-1 promotes cell survival 
by inhibiting apoptosis and Akt-2 contributes to tumour invasion and metastasis (Arboleda et al., 
2003; Irie et al., 2005). A mutation of Akt-1 due to a substitution of a lysine to glutamic acid at 
position 17 has been associated with human colorectal, endometrial, and ovarian cancers (Carpten 
et al., 2007). While overexpression of Akt-2 has been related to pancreatic and hepatocellular 
carcinoma, Akt-3 overexpression leads to increased VEGF secretion in ovarian cancer (Ruggeri et 
al., 1998; Xu et al., 2004; Liby et al., 2012).
1.9.3 Targeting the PI3K pathway in the treatment of Cancer
The permanent activation of the PI3K/Akt pathway due to a mutation in PTEN, amplification 
of the Akt gene, or a mutation in the PDKCA gene results in the development of cancer. Therefore, 
these mechanism and proteins in the PDK/Akt pathway have become a main and attractive target 
for the treatment of cancer. Firstly, PDK inhibitors were discovered and include two potent 
inhibitors that are LY294002, a flavonoid derivative, and wortmannin a fungal metabolite (Powis 
et al., 1994; Vlahos et al., 1994). The action of wortmannin is through binding to the PI 10 catalytic 
subunit and irreversibly inhibiting the PDK (Davies et al., 2000). Although wortmannin has been 
of great value in the progress of cancer treatment, its main disadvantage was its solubility in organic 
solvents and not water, thus limiting its use in clinical trials. Furthermore, wortmannin was 
modified to become water-soluble but its effects has been reduced in the inhibition of PD/Akt 
pathways (Varticovski et al., 2001). Perifosine, which is being tested in phase 3 clinical trials, is 
the most advanced Akt inhibitor that inhibits the binding of PIP3 to Akt (Bendell et al., 2012). 
Moreover, different proteins in the pathway are also being targeted and of research interest such as 
mammalian target of rapamycin (m-TOR) (Fasolo and Sessa, 2008). One important m-TOR
inhibitor is rapamycin and its derivatives where they can bind to m-TORCl and inhibits 
' downstream signalling (Dibble and Manning, 2013). Combination treatment of rapamycin with 
etoposide intensely enhances cytotoxicity effect against neuroblatoma (Li et ah, 2012). Other class 
of inhibitors such as NVP-BEZ235 block the activity of both PI3K and m-TOR by binding to ATP 
binding site leading diminished cell survival in leukemic cell lines without any cytotoxicity to 
normal hematopoietic progenitors (Chapuis et ah, 2010).
1.10 MAPK Pathway
The MAPK/ERK pathway is a chain of membrane signaling proteins and cytoplasmic protein 
kinases that transmit the extracellular signals to their intracellular targets mainly the nucleus and 
eventually controlling various cellular processes such as proliferation, differentiation, migration 
and apoptosis. The MAPK pathway includes three major groups of kinases including extracellular 
signal-regulated kinases (ERK), Jun N-terminal kinases (JNK), and p38 MAPKs which are 
deregulated in several cancers (Dhillon et ah, 2007; Wagner and Nebreda, 2009).
1.10.1 MAPK/ERK pathway activation and components
The MAPK/ERK pathway, also known as the Ras-Raf-MEK-ERK pathway, involves a chain
of protein kinases that couples the signals from cell surface receptors to transcriptional factors
which regulate gene expression. This cascade modifies the activity of several proteins that control
cell cycle progression, apoptosis or differentiation (figure 1.8) (Peyssonnaux and Eychène, 2001).
The signal starts when an extracellular signaling molecule binds to the membrane receptor on the
cell surface allowing Ras (a GTPase) to exchange its GDP to GTP which in turn activates the
protein kinase activity of RAF kinase. These kinases phosphorylate and activate the
tyrosine/threonine kinases MEK1 and MEK2 (also known as MAPKK) that are capable of
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activating the mitogen-activated protein kinases (MAPKs) ERK1 and ERK2 (extracellular signal- 
regulated kinases 1 and 2). Activated ERK1/2 can then dissociate from the Ras/Raf/MEK/ERK 
complex where they phosphorylate and regulate various transcription factors such as nuclear factor 
NF-kB (Palona et a l, 2006), AP-1, c-Jun, and c- Myc (Chong et al., 2003; Mercer and Pritchard, 
2003). The substrate-level phosphorylation by ERK leads to functional consequences including 
modifications in cellular motility and alterations in gene expression that triggers cell cycle 
progression, differentiation, cellular survival, and angiogenesis (Mercer and Pritchard, 2003). For 
example, activation of AP-1 transcriptional factor leads to the expression of D-type cyclins, key 
cell-cycle regulatory proteins, which allow cells to progress through the Gl phase of the cell cycle 
(Yamamoto et a l, 2006).
Growth and differentiation factors
N u c l e u s
Figure 1.8. T he M A P K /M E K /E R K  signaling  cascade and  therapeu tic  ta rgeting  by  po ten tial an ti-cancer agen ts . A ctivated  E rk  
regu lates the  expression  o f  several transcrip tional factors invo lved  in cell cycle p rog ression  and  cell survival (W ong, 2009).
1.10.1.1 Anti- apoptotic function of ERK1/2 MAP Kinases
Activation of the extracellular signal-related kinase (ERK1 and ERK2) leads to the inhibition 
of apoptosis in response to a wide range of stimuli such as Fas ligand, tumour necrosis factor (TNF),
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TNF-related apoptosis-inducing ligand (TRAIL) (Tran et al., 2001), radiation (Park et al, 1999), 
hydrogen peroxide (Wang et ah, 1998), and chemotherapeutic drugs (Anderson and Tolkovsky, 
1999). There are different mechanisms by which ERK1/2 can prevent apoptosis (figure 1.9). The 
anti-apoptotic effect of ERK1/2 can be demonstrated by down-regulating pro-apoptotic molecules 
of Bcl-2 family such as Bim (Biswas and Greene, 2002), BAD (Hayakawa et ah, 2000), and 
caspases 8 and 9 through a reduction in their activity or inhibition of their transcription (Allan et 
ah, 2003). Other modes by which ERK1/2 can induce cell survival is via the activation of anti- 
apoptotic proteins such as Mcl-1 (Domina et al., 2004), Bcl-XL, Bcl-2 (Boucher et al., 2000), and 
c-Flip (Aoudjit and Vuori, 2001).
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Figure 1.9. Anti-apoptotic role of ERK1/2 kinases. ERK1/2 activity is positive regulated by MEK1/2 phosphorylation 
and negatively regulated by MEKK1 and p38 MAPK activation (Lu and Xu, 2006).
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1.10.2 MAPK pathway in human cancer
It has been reported that the Ras/Raf/MEK/ERK pathway is activated in several types of 
cancer and its activation is associated witho cancer angiogenesis, invasion, and metastasis (Lu and 
Xu, 2006). Mutations in the Ras oncogene lead to the expression of constitutively-active Ras 
proteins which are observed in approximately 30% of human cancers (Flotho et al., 1999; Stirewalt 
et al., 2001). These mutations are related to the GTPase activity of RAS, preventing GAPs from 
promoting hydrolysis of GTP on RAS and therefore causing RAS to accumulate in the GTP-bound. 
As a result, cells acquire several of the characteristics of malignant transformation including 
increased proliferation due to stimulation of cell-cycle regulators such a cyclin D and resistance to 
apoptosis through AKT/PKB signaling pathway. Other effects of mutated RAS include induction 
of angiogenesis and increased invasiveness mediated by ERK (Downward, 2003). On the other 
hand, the Raf and specifically B-Raf oncogene has recently been shown to be mutated in various 
types of cancer mainly melanoma, colorectal cancer, and ovarian cancer (Davies et al., 2002; 
Fransén et al., 2004; Garnett and Marais, 2004; Libra et al., 2005). It has been reported that B-Raf 
mutated protein, referred as B-RafV600E, exhibits increased kinase activity compared to wild-type 
B-Raf (Davies et al., 2002). Moreover, B-RafV600E mutation triggers the downstream MEK/ERK 
signaling pathway independently of Ras-GTP and its expression is required to maintain the 
proliferative and oncogenic properties in several human cancer cell lines (Calipel et al., 2003; 
Hingorani et al., 2003; Karasarides et al., 2004). Other studies also revealed that Raf and MEKplay 
an essential role in cancer progression and in promoting cancer growth (Shields et al., 2000). 
Furthermore, several reports indicated that mutational activation of H-Ras, K-Ras, B-Raf, MEK1 
and MEK2 are present in several developmental disorders as well as cancer (Aoki et al., 2005; 
Niihori et al., 2006; Rodriguez-Viciana et al., 2006; Schubbert et al., 2006). Therefore, targeting
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Ras and its downstream effector molecules may have an important impact in the treatment of 
cancer.
1.10.3 Targeting the MAPK pathway in the treatment of Cancer
In addition to Akt pathways, MAPK has also been under extensive investigations as a target 
pathway for cancer prevention and therapy (Roberts and Der, 2007). Numerous therapeutic agents 
targeting individual components of the Ras/Raf/MEK/ERK pathway are being developed that are 
effective against many types of tumours especially when used in combination with other drugs. 
Inhibitors of kinases that are involved in the Ras/Raf/MEK/ERK signaling pathway have been 
under investigation for several years and some have entered clinical trials (Downward, 2003). 
These include inhibitors that target both the downstream of RAS, in particular the RAF/MEK/ERK 
pathway, and the upstream activators including epidermal growth factor receptor (EGER) and the 
Ras small guanosine triphosphatases (GTPases). Important drugs that act downstream of RAS, are 
MEK inhibitors such as PD98059 (Dudley et al., 1995) and U0126 (Favata et al., 1998) that 
effectively block ERK activation leading to the inhibition of proliferation, survival, and motility of 
several cancer cell lines (Sebolt-Leopold, 2000). Other drugs such as BAY43-9006 (Lyons et al., 
2001) are potent inhibitor of RAF and can effectively reverse ERK activation that is induced by 
RAS or B-RAF mutation which is present in melanomas (Davies et ah, 2002). On the other hand, 
several kinase inhibitors targeting pathways upstream of RAS are directed particularly against 
EGFR and its close relative ERBB2. Several approaches have been adopted including small- 
molecule tyrosine kinase inhibitors (Fabbro et ah, 2002; Wakeling, 2002) and antibodies directed 
against the receptor extracellular domains resulting in the inhibition of various downstream 
proliferative and anti-apoptotic pathways (de Bono and Rowinsky, 2002).
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1.11 Cytokines and Cancer
The term "cytokine" has been used to refer to the immunomodulating agents, such as 
interleukins and interferons. Cytokines are low-molecular weight regulatory proteins secreted by 
leukocytes and several other cells in the body in response to various stimuli. These proteins help in 
regulating the development of immune effector cells, by binding to specific receptors on the 
membrane of target cells and triggering signal-transduction pathways that ultimately alter gene 
expression in the target cells. Cytokines are involved in numerous biological activities including 
cellular and humoral immune responses, induction of inflammation and control of cellular 
proliferation (Platanias, 2005). Interestingly, cytokines in cancer can function in a bidirectional 
way. They can trigger the immune effector mechanisms that prevent tumour progression (Belardelli 
et al., 2002). For example, interferon-a (INF-a) has been used in the treatment of various types of 
cancer including leukemia and melanoma (Pfeffer et al., 1998). Whereas other cytokines such as 
Tumour necrosis factor (TNF) alpha (TNF-a) may be involved in malignant transformation, tumour 
growth, invasion, and metastasis (Coussens and Werb, 2002). Additionally, cytokines can 
negatively or positively modify stroma formation and angiogenesis (Colombo and Trinchieri, 2002; 
Dranoff, 2004).
1.11.1 Tumour necrosis factor (TNF) alpha and cancer
The cytokine tumour necrosis factor (TNF) alpha is a key cytokine that mediates
inflammation, immunity and cellular organisation. TNF is a 17 kDa protein that binds as a
homotrimer to two distinct cell surface receptors, TNFRI and TNFRII (Locksley et al., 2001). It is
now clear that TNF has contradictory roles in the evolution and treatment of cancer. Local treatment
of high dose of TNF-a, selectively inhibits the formation of tumour blood vessels and exhibit a
potent anti-cancer activities (Lejeune et al., 1998). The anti-cancer activities of TNF have also been
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under extensive investigations in animals. Several reports indicated that high doses of TNF injected 
directly into human tumour xenograft models resulted in their destruction (Balkwill et a l, 1986; 
Creasey et al., 1986; Talmadge et al., 1988; Watanabe et al., 1988). By contrast, low doses of 
chronically produced TNF-a may promote cancer growth, invasion and metastasis (Balkwill and 
Mantovani, 2001). Evidence for a role of TNF- a in human cancer has been demonstrated in some 
clinical studies. To date, high levels of TNF- a has been reported in various malignancies such as 
breast, ovarian, colorectal, prostate, bladder, melanoma, and leukemias (Szlosarek and Balkwill,
2003). The tumour promoting role of TNF-a may be mediated via several mechanisms. TNF-a may 
acts as a growth factor in certain tumour types, by up regulating cyclin-dependent kinases (cdk) 
involved in cell proliferation, as well as components of growth factor receptor signalling pathways 
such as Ras or c-myc (Wu et al., 1993; Gaiotti et al., 2000; Szlosarek et al., 2006). Furthermore, 
TNF-a triggers both DNA damage and inhibits DNA repair by increasing the nitric oxide (NO) 
(non cGMP)-dependent pathways (Jaiswal et al., 2000). Lastly, TNF-a is also able to stimulate 
angiogenesis via down-regulation of avp3 signaling and an increase in angiostatin (Leibovich et 
al., 1987; Weichselbaum et al., 2002) or through other mediators including vascular endothelial 
growth factor (VEGF) and its receptor (VEGFR2) (Bussolino et al., 1988).
1.11.2 IFN-y and cancer
Interferons (IFNs) are large class of glycoproteins known as cytokines produced and 
secreted by host cells in response to infections or tumour cells. These cytokines have the ability to 
inhibit viral replication within host cells, activate immune cells such as natural killer 
cells and macrophages and increase T-lymphocytes recognition by up-regulating antigen 
presentation in infected or cancer cells (Boehm et al., 1997). Interferons are divided into three 
classes depending on their structure and function: Type IIFN, Type IIIFN, and Type III IFN (Dunn
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et al., 2006). IFN-y, type II interferon, is a cytokine that has a crucial role in the innate and adaptive 
immunity against viral and intracellular bacterial infections (Wheelock, 1965; Jouanguy et al., 
1999). Abnormal IFN-y expression is linked to a number of autoinflammatory and 
autoimmune diseases. Additionally, these cytokines exhibit significant immunostimulatory and 
immunomodulatory effects (Schoenbom and Wilson, 2007). IFN-y has two types of receptors. The 
first is IFNGR1 glycoprotein that is responsible for ligand binding, ligand-trafficking through the 
cell, and is required but not sufficient for signal transduction. The second is LFNGR2 glycoprotein 
that has a minor role in ligand binding but is essential for IFN-y signaling. The antitumour 
mechanisms that might be induced by IFN-y include the capacity to prevent cellular proliferation 
(Bromberg et al., 1996; Chin et al., 1996), to promote apoptosis through effects on the expression 
of caspases, FAS and TRAIL (Chin et al., 1997; Xu et al., 1998; Takeda et al., 2002), and to stop 
angiogenesis (Luster and Leder, 1993).
1.10.3 Interleukin-10 (IL-10) and cancer
IL-10 is a glycoprotein that functions as an immunosuppressive and anti-inflammatory 
cytokine that inhibits the secretion of pro-inflammatory cytokines (IFN-y, TNF-a, IL-lpa 11-6) 
(Taga and Tosato, 1992), down-regulates the expression ofMHC class II antigens (de Waal Malefyt 
et al., 1991), and enhances B-cell survival, growth and antibody production (Itoh and Hirohata,
1995). The major source of IL-10 production is the T helper 2 subset of T cells (Th2 cells) 
(Mosmann et al., 1990) in addition to the T helper 1 and 17 (Thl and Thl7) subpopulations (Saraiva 
et al., 2009). Recent reports, however, revealed that IL-10 is also produced from stimulated B cells 
(Benjamin et al., 1992), macrophages (Boonstra et al., 2006), NK cells (Boonstra et al., 2006), 
dendritic cells (Dillon et al., 2004) and T regulatory cells (Sakaguchi et al., 2008). Furthermore, 
IL-10 has been expressed in a variety of human tumours including lung (Huang et al., 1995),
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ovarian (Pisa et al., 1992), breast (Venetsanakos et al, 1997), and skin squamous as well as basal 
cell carcinomas (Kim et al., 1995). IL-10, produced by tumour cells, down-regulates the expression 
ofMHC antigens on the surface of cancer cells to escape the attack by cytotoxic T cells and blocks 
the activation of macrophages and dendritic cells (Urosevic and Dummer, 2003). Thus, production 
of tumour derived EL-10 results in immune suppression and enhances tumour progression. In 
contrast, IL-10 is known to exhibit antitumour activities. Numerous in vitro and in vivo studies 
showed that treatment with IL-10 may mediate the regression of several tumours (Berman et al.,
1996). IL-10 may demonstrate its anticancer activity by inhibiting angiogenic factors such as 
vascular endothelial growth factor (VEGF), IL-lp and IL-6, or by enhancing antitumour NK cell 
activity (Kundu et al., 1996; Steams et al., 1999). The dual effect of IL-10 makes it hard to predict 
the therapeutic action of IL-10 in cancer treatment. Thus well-defined clinical investigations are 
necessary to gain a better understanding regarding the mechanisms that regulate the expression and 
signaling of IL-10 in carcinogenesis and related immune responses (Sato et al., 2011).
1.11.4 Interleukin-17 (IL-17) and cancer
IL-17 is mainly produced from pro-inflammatory Thl7 cells. Most of the Thl7-mediated 
effects are due to this cytokine. Several crucial cytokines including TGF-p and IL-6 are required 
for the stimulation, differentiation, and maintenance of Thl 7 cells (Bettelli et al., 2008). There are 
contradictory data concerning the role of IL-17 in carcinogenesis. Several studies revealed that 
forced over expression of IL-17 ectopically in tumour cells can either inhibit tumour development 
through enhanced antitumour immunity (Hirahara et al., 2001; Benchetrit et al., 2002). Another 
report demonstrated that tumour growth is enhanced in IL-17- deficient mice indicating that 
endogenous IL-17 may be involved in tumour immunity (Kryczek et al., 2009). Additionally, IL- 
17 has been shown to inhibit the proliferation of hematopoietic tumours by enhancing CTL activity
(Benchetrit et al., 2002). On the contrary, IL-17 over expression was shown to promote tumour 
progression through an increase in inflammatory angiogenesis (Numasaki et ah, 2005). IL-17 was 
shown to induce several angiogenic factors including VEGF, which markedly enhances tumour 
angiogenesis and invasion (Honorati et ah, 2006). Additionally, IL-17 stimulates the production of 
IL-8 which in turn augments angiogenic responses, and increase survival as well as metastasis of 
cancer cells (Kehlen et ah, 1999; Waugh and Wilson, 2008).
1.11.5 Vascular endothelial growth factor (VEGF) and cancer
The vascular endothelial growth factor (VEGF) family plays an essential role in angiogenesis. 
The human VEGF family consists of five members: VEGF (or VEGF-A),VEGF-B, VEGF-C, 
VEGF-D, and placental growth factor (P1GF) (Thomas, 1996). The VGEF ligands bind mainly 
through two receptor protein-tyrosine kinases including VEGFR1 (Shibuya et ah, 1990) and 
VEGFR2 (Terman et ah, 1992) identified on vascular endothelial cells (Vaisman et ah, 1990). It is 
reported that VGEF induces angiogenesis through a direct effect on endothelial cells (Pepper et ah, 
1992). An in vivo study revealed that VEGF increases vascular permeability, permitting the leakage 
of plasma proteins and the development of extravascular matrix leading to endothelial cell 
proliferation (Thomas, 1996). Additionally, VEGF plays an important role in tumourigenesis and 
progression of a wide variety of human cancers (Poon et ah, 2001). Several studies demonstrated 
that VEGF expression is significantly up-regulated in several cancers including lung, breast, 
melanoma, colorectal and other tumours (Banai et ah, 1994; Thomas, 1996; Fukumura et ah, 2001). 
Thus, VEGF could be a potential therapeutic target for the treatment of cancer. Different strategies 
have been implicated in cancer therapy including monoclonal antibodies or inhibitors to VEGF 
ligands or to VEGF-receptors (Ferrara, 2005).
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1.11.6 Immunomodulatory effects of natural products
Immunomodulation is a process by which synthetic or natural substances modify immune 
responses. Phytochemicals can stimulate, suppress, or modulate both the innate and adaptive 
immune responses and one important mechanism by which immunomodulatory agents exert their 
effect is through cytokine modulation (Santos, 2004). Generally, cytokines may be classified as 
pro- or anti-inflammatory depending on how they will influence inflammation. In addition, most 
cytokines seem to be involved in the activation of transcriptional factors such as NF-kB and AP-1 
and protein kinases such as MAPK and PKC which in turn modulate the expression of several 
inflammatory related genes (Haddad, 2002; Kracht and Saklatvala, 2002). A number of biologically 
active plant extracts such as phenols, flavonoids, terpenes and glycosides, have been found to 
exhibit potent immunomodulatory activities. For example, several phenolic and flavonoid 
compounds have been reported to inhibit LPS-stimulated TNF-a and IL-6 release in vitro and in 
vivo. Moreover, the same treatment was able to decrease the level of IL-4 and IL-6, whereas it 
induced an increase in IFN-y (Ueda et al., 2002; Das et al., 2003). Other naturally-occurring 
flavonoids including genistein, apigenin, quercetin, and luteolin inhibited several pro-inflammatory 
cytokines (TNF-a, IL-ip, IL-6, IFN-y) (Geng et al., 1993; Gerritsen et al., 1995; Krakauer et al., 
2001; Cho et al., 2003). Terpenic compounds isolated from various medicinal plants have been 
shown to suppress the production of pro-inflammatory cytokines TNF-a and IL-lp (Sylvester et 
al., 2001). In addition, in vitro studies demonstrated that sesquiterpene lactones and other terpenic 
compounds reduced the expression of TNF-a, IL-lp, IL-6 and IL-2 (Koch et al., 2001; Humar et 
al., 2003). Essential oils derived from several plant species were also reported to exhibit important 
anti-inflammatory and immunomodulatoy activities. For example, limonene and p-myrcene 
effectively suppressed NO, IFN-y and IL-4 production (Souza et al., 2003). The assessment of the 
immunomodulatory activity of orange juice and some of its major constituents, namely limonene,
linalool and a-terpineol showed a decrease in IL-6 formation and concomitantly an increase in the 
IL-10 formation (Held et ah, 2007). Other in vivo immunomodulatory activities of limonene, 
carvone and perillic acid displayed an increase in the total white blood cell count, the total antibody, 
and the antibody producing cells in spleen and bone marrow cellularity (Raphael and Kuttan, 2003).
1.12 Rationale, Hypothesis, Aim and Objectives
1.12.1 Rationale, Hypothesis and Aim
Plants have been utilized as a source of medication and treatment since early human history. 
Traditional medicine, also called herbal medicine, has been practised since early civilizations and 
cultures including Egyptian, Asian, and Western ones. The first written records describing 
medicinal uses of plants appeared about 2600 B.C in ancient communities such as those of the 
Sumerians and the Akkadians (Samuelson, 1999). In the early 19th century, research focused on 
phytotherapy which involves the use of herbal extracts as medicines. Phytotherapy seeks to 
preserve the complexity of compounds that constitute a given extract. Currently, phytotherapy is 
regarded as an alternative medicine that is widely spread and practised among a large number of 
populations for the treatment of a variety of diseases (Heinrich et al., 2012). The World Health 
Organization reports that approximately 80% of the world population relies on herbal medicine for 
their primary health care (Farnsworth et al., 1985). Later in 19th century, advancement in chemistry 
research successfully led to the isolation, purification and modification of numerous natural 
products in an attempt to produce biologically active compounds with high selectivity and 
minimum toxicity (Phillipson, 2001). In previous years, due to the limited availability of natural 
products in addition to the time consuming process required for their actual launch into the market, 
pharmaceutical companies have turned to the production of synthetic compounds (Koehn and 
Carter, 2005; Paterson and Anderson, 2005). Recently, however, owing to the harmful side-effects
of synthetic drugs on human health, industry has, once again, shifted the focus back to medicinal 
plants which are considered an abundant source of biologically active compounds (Ma et al., 2005; 
Palombo, 2011). It is to be noted that, nowadays, over 25% of medicinal drugs used are obtained 
from plants (Ma et al., 2005) and 90% of the current therapeutic agents are derived from the 
modification of natural products (WHO, 2002).
Nowadays, Cancer is considered one of the most serious medical problems. It was estimated that 
there were 10.9 million new cases, 6.7 million deaths, and 24.6 million individuals living with 
cancer around the world in 2002 (Parkin et al., 2005). With the enormous biodiversity of the planet, 
only small portion of phytochemicals have been explored for their therapeutic potential. Thus, 
plants would be a major source of potential anticancer agents or bioactive compounds for the 
development of new products to fight cancer diseases. The search for anti-cancer agents from plant 
sources started in the 1950s with the discovery and development of the vinca alkaloids, vinblastine 
and vincristine. It has been reported that over 3000 plant species have been used in the treatment 
of cancer and about 60% of the available anti-cancer drugs are of natural origin (Cragg and 
Newman, 2005). An extremely promising strategy for fighting cancer is chemoprevention which 
relies on the use of natural or synthetic agents to delay, prevent or reverse carcinogenesis in 
humans. This field has recently received a great deal of attention in drug development especially 
in cancer research. The National Cancer Institute, for example, has collected about 35,000 plant 
samples from 20 countries and has screened around 114,000 extracts for anticancer activity (Shoeb,
2006). Screening for new plant derived anticancer agents will be considered a crucial step towards 
minimizing the adverse effects associated with cancer therapies as natural products and their semi­
synthetic derivatives can be less toxic than synthetic drugs. In addition, uncovering the underlying 
mechanisms of action of these potential extracts will be essential if these products are to be used in 
cancer therapy.
Indeed, previous studies in our laboratories have shown that the oil extract from the wild carrot 
demonstrates anticancer effects against promyelocytic leukemia HL-60 cells (Diab-Assaf et ah,
2007) and against the DMBA/TPA skin carcinogenesis model in mice (Zeinab et ah, 2011). The 
active components of these extracts, however were not elucidated, nor the underlying mechanism/s 
of action.
The hypothesis to be tested in this project, therefore, is that Daucus carota oil and its fractions will 
possess peculiar chemical composition with significant in vivo and in vitro anticancer activities as well 
as antioxidant, hepatoprotective and immunomodulatory effects.
The aim of the work in this thesis was to explore the potential in vivo and in vitro anticancer and 
antioxidant activities as well as the in vivo immunomodulatory effects oî Daucus carota oil extract 
(DCOE) and its fractions, and to investigate the possible mechanisms of action involved.
1.12.2 Specific Objectives
> To extract the crude oil from Daucus carota umbels using methanol-acetone solvent 
system and to separate the crude extract into several fractions using chromatography 
techniques.
> To identify the major compounds of the crude extract and its fraction by GC/MS and 
HPLC methods.
> To assess the in vitro antioxidant activity of crude extract and fractions using DPPH 
(2,2-di-phenyl-1 -picrilhydrazyl) free radical scavenging, FIC (ferrous Ion Chelating) 
ability and FRAP (Ferric Reducing Antioxidant Power) assays and determine the total 
phenol and flavonoid contents of the crude extract and fractions.
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> To assess the in vivo antioxidant and hepatoprotective effects of the oil fractions in 
CCU-induced hepatotoxicity in mice.
> To evaluate the in vitro anticancer activities of crude extract and fractions against seven 
human cancer cell lines including breast cancer cells (MCF-7, MDA-MB-231), colon 
cancer cells (HT-29, Caco-2), skin cancer cells (HaCat-II4, HaCat-A5) as well as 
normal skin cell lines (HaCat) using trypan blue exclusion and WST-1 assays.
> To investigate the in vivo anticancer activities of the most active oil fraction against the 
DMBA/TPA skin carcinogenesis model in mice.
> To evaluate the effect of FI and F2 fractions on the cell cycle and apoptosis in breast 
(MDA-MB-231) and (HT-29) adenocarcinoma cell lines by flow cytometry analysis.
> Conduct western blot analysis to assess the effects of FI and F2 fractions on the 
expression of several pro-apoptotic and anti-apoptotic proteins in breast (MDA-MB- 
231) and (HT-29) adenocarcinoma cell lines.
> Conduct western blot analysis to elucidate the possible mechanisms of action, including 
MAPK/ERK and PI3K/AKT signaling pathways, involved in the anti-survival action of 
FI and F2 fractions.
> To investigate the in vivo immunomodulatory activities of the crude extract and 
fractions on pro-inflammatory cytokines (TNF-a, IFN-y), anti-inflammatory cytokines 
(IL-10) and cancer related cytokine (VEGF) as well as IL-17 using ELISA kits.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Chemicals and Reagents
Folin Ciocalteu reagent, l,l-Diphenyl-2-picryl hydrazyl (DPPH), (2,4,6-tri(2-pyridyl)-l,3,5- 
triazine (TPTZ), quercetin, vanillic acid, chlorogenic acid, syringic acid, caffeic acid, ellagic acid, 
myricetin, luteolin, kaempferol, apigenin, ferrozine, gallic acid, trolox, pyrogallol, 1-chloro-2,4- 
dinitrobenzene (CDNB), dimethyl sulphoxide (DMSO), Dulbecco’s modified Eagle’s medium 
(DMEM), Trypsin, 7,12-Dimethylbenz(a)anthracene (DMBA), 12-O-tetradecanoylphorbol-13- 
acetate(TPA), lipopolysaccharide (EPS, L-6143), and Trypan blue were purchased from Sigma- 
Aldrich, St. Louis, USA, Annexin V/PI apoptosis detection kit was purchased from Abeam pic, 
Cambridge, UK and WST-1 reagent was purchased from Roche, Mannheim, Germany. Silica gel 
60 was purchased from ACROS organics, New Jersey, USA, and Silica gel 40 (35-70) mesh were 
purchased from Sigma Aldrich, St. Louis, USA. All other chemicals used in the experiments were 
of analytical grade.
2.2 Tested Organisms
All in vivo experiments were performed on male and female adult BALB/c mice (6 weeks old) 
bred in the animal facility of the Biology Department at the Lebanese American University. Mice, 
weighing 27-30 g were housed under optimum conditions of temperature set at 22 ± 2° C, humidity 
at 50 ± 5% and an alternating cycle of light and dark. The animals were supplied with standard 
laboratory chow diet and water. All experimental protocols were approved by the Animal Ethical 
Committee of the Lebanese American University, which complies with the Guide for the Care and 
Use of Laboratory Animals (Committee for the Update of the Guide for the Care and Use of 
Laboratory Animals, 2010).
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2.3 Sample collection and oil extraction
Mature umbels of Daucus carota ssp. carota were collected at the post flowering period 
between August and September from their natural habitat in Lebanon. The plant was identified 
according to the characteristics described in “Handbook of Medicinal Herbs” (Van Wyk and Wink,
2004) and confirmed by Dr. A. Houri, a Lebanese plant expert at the Lebanese American 
University. The extraction procedure was carried out according to the method described by (Zeinab 
et al., 2011). Briefly, 1 kg of air dried umbels were cut into small pieces and soaked in 5 liters of 
methanol/acetone (1:1) for 72 h. The extraction was repeated twice and the extracts were collected, 
filtered and evaporated to dryness under reduced pressure. The residue was centrifuged at 500 rpm 
and the oil was removed and dried over anhydrous sodium sulfate yielding 34.7g of crude oil 
extract, which was stored in a closed amber bottle at 4°C until use.
2.4 Oil Fractionation
Thirty grams of Daucus carota oil extract (DCOE) were chromatographed on a silica gel 
column (35-70 mesh, 75 x 4 cm) using mobile phases of increasing polarities and monitored by 
thin layer chromatography (TLC) and similar fractions were combined. The first fraction (FI) was 
eluted with pentane (100%), the second fraction (F2) with pentaneidiethyl ether (50:50), the third 
fraction (F3) with diethyl ether (100%) and the fourth fraction (F4) with chloroform: methanol 
(93:7). Fractions were analyzed by TLC using hexane: ethyl acetate (93:7) as mobile phase and 
plates were stained with 2% anisaldehyde (Appendix D).
2.5 Gas Chromatography and Mass Spectroscopy (GC-MS) analysis
The composition of DCOE or oil fractions was analyzed using GC-MS (Hewlett Packard,
HP6890 series) fitted with a fused silica HP5-MS 5% phenyl methyl siloxane cap column (30 m
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x 0.25 mm i.d., film thickness 0.25) and directly coupled to the MS. The carrier gas was helium 
with splitless injection and the flow rate of 1.2 ml/min was applied. The temperature program was 
as follows: 2.0 min at 70°C, from 70° to 130°C at 8°C/min and hold for 5 min, from 130° to 180°C 
at 2°C/min and hold for 10 min, from 180° to 220°C at 15°C/min and hold for 2 min and then from 
220° to 280°C at 15°C/min and hold for 22 min. Identification of the components was performed 
by comparing their mass spectra with the literature (NIST 11 and W9). Areas for all detectable 
peaks were recorded, and percent composition was calculated by dividing individual areas by total 
chromatogram area x 100.
2.6 HPLC analysis of oil fractions
The analysis of phenolic acids and flavonoids was performed on a Shimadzo HPLC system 
(Shimadzu Corp., Kyoto, Japan) consisting of LC 10-AD VP pump, SCL 10A system controller 
coupled with a photo-diode array detector (SPD-M20A), FCV-10AL Low Pressure Gradient, 
Rheodyne injector (Model 7125), DGU-20A online degasser, Shim-pack VP-ODS column, 4.6 mm 
i.d. x 150 mm), Pre-column (10 x 4.6 mm i.d. 5 pm) equipped with LC solution 1.23 SP1 software 
(Shimadzu, Kyoto, Japan). The column was operated at 25°C. The mobile phase consisted of 
10:2:88-water: acetic acid: methanol v/v/v (solvent A) and 90:2:8-water: acetic acid: methanol 
v/v/v (solvent B) at a flow rate of 1.5 ml/min. The gradient elution program was as follows: 0-15 
min solvent A, 15-30 min solvent followed by washout period for 10 min and the wavelength of 
detection was set at 280 nm. The phenolic acids and flavonoids were identified by matching the 
retention time and their spectral characteristics with those of the standard compounds.
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2.7 Total flavonoid content determination
An aluminium chloride colorimetric technique was used for flavonoid estimation of crude oil 
and oil fractions (Chang C., 2002). Briefly, 0.5ml of the oil samples (ranging from 0.2 to 5 mg/ml) 
in methanol was separately mixed with 1.5 ml of methanol, 0.1 ml of 10% aluminium chloride, 0.1 
ml of 1 M potassium acetate and 2.8 ml of distilled water. The absorbance of the reaction mixture 
was then measured spectrophotometrically at 415 nm. Different concentrations of quercetin (12.5 
to 200 pg/ml) in methanol were used as a standard curve.
2.8 Total phenolic content determination
Total phenolic content of the crude oil extract or oil fractions was determined according to the 
method described by Rossi et ah (2007). Briefly, 0.3 ml of the oil sample in methanol (0.5 to 5mg) 
was mixed with Folin Ciocalteu reagent (2.5 ml, 1:10 diluted with distilled water) for 5min. Then, 
2ml of aqueous NazCOs (7.5 % w/v) was added and the mixture allowed to stand for 30 min at 
25°C. The absorbance was then measured at 760 nm using a spectrophotometer. The total phenolic 
content was determined using the standard gallic acid calibration curve, and the results were 
expressed as mg gallic acid equivalent (GAE)/g of extract or fractions.
2.9 DPPH (2,2-di-phenyl-l-picrilhydrazyl) free radical scavenging assay
The 1,1-Diphenyl-2-picryl hydrazyl (DPPH) assay was determined according to the method
described by Mossa and Nawwar (2011). Samples of 200pl crude oil of (0.25 to 5 mg/ml) or oil
fractions of (0.025 to 1 mg/ml) were mixed with 1.5 ml of O.lmM DPPH in methanol, and the final
volume was made up to 3.5 ml with DMSO. The mixture was shaken vigorously and allowed to
stand for 30 min in the dark at room temperature. The absorbance was determined
spectrophotometrically at 517 nm. DMSO was used as a blank and Trolox was used as a reference
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compound. The absorbance of DPPH in DMSO was used as a control. The percent inhibition of 
DPPH free radical by the samples was calculated according to the following formula:
% Inhibition = [fAc - AsJ/Ac] x 100
where Ac and As are the absorbance of the control and the sample respectively. The IC50 value 
represented the concentration of the oil extract that caused 50% inhibition.
2.10 FIC (Ferrous Ion-chelating) ability assay
The ferrous ion-chelating (FIC) assay was carried out according to the method described by 
Dinis et a l (1994) with some modifications. An aliquot (1 ml) of different concentrations of crude 
oil or oil fractions (0.25 to 4 mg/ml) was mixed with 1 ml FeCb ^HaO (0.1 mM). After 5 min of 
incubation, the reaction was initiated by the addition of 1ml ferrozine (0.25 mM). The absorbance 
of the solution was measured spectrophotometrically at 562 nm. The absorbance decreases with 
increased ferrous ion chelating ability, where the percentage of chelating ability or percentage is 
expressed by the following formula:
% Chelating ability = [fAo-As/Ao] x 100
Where Ao = absorbance of control sample (the control contains FeCh and ferrozine) and A s =  
absorbance of a tested sample. NaiEDTA was used as a positive control.
2.11 FRAP (Ferric Reducing Antioxidant Power) assay
The total antioxidant power of the DCOE or oil fractions were determined according to the 
method described by Benzie and Strain, 1996 (Benzie and Strain, 1996) with some modifications. 
The FRAP reagent was prepared by mixing 300 mM of acetate buffer (pH 3.6), 10 mM TPTZ in
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full in 40 mM HC1 and 10 mM FeCb at a ratio of 10:1:1. Aliquots (200jil) of crude oil or oil 
fractions (0.25 to 4 mg/ml) in methanol were added to 2.8 ml of the FRAP solution and the 
absorbance was recorded spectrophotometrically at 593 nm. Vitamin C was used as a positive 
control. The antioxidant power of the sample was calculated from the calibration curve of FeSCb 
solution and expressed as pmol FeSCb equivalent per gram of sample.
2.12 CCU-induced hepatotoxicity model
Liver damage was induced in BALB/c mice by intraperitoneal injection of CCL in olive oil 
(1:1, v/v) at a dose of 2 ml/kg body weight (Coballase-Urrutia et al., 2011). The mice were divided 
randomly into 15 groups of 6 animals each. Group I served as a normal control and was injected 
i.p with DMSO (2 ml/kg) for 5 days and olive oil on days 2 and 3. Group II served as a CCL control 
and was injected i.p with DMSO (2 ml/kg) for 5 days and CCL/olive oil on days 2 and 3. Group 
III, positive control, was injected i.p with vitamin E (100 mg/kg body weight) in DMSO (2 ml/kg) 
for 5 days and CCL/Olive Oil on days 2 and 3. Groups IV, V, and VI served as treated groups and 
were injected i.p with 50, 100 and 200 mg/kg body weight of FI fraction in DMSO (2 ml/kg) 
respectively for 5 days and CCL/olive oil on days 2 and 3. Similarly, Groups VII, VIII and IX were 
injected i.p with the F2 fraction, Groups X, XI, XII were given i.p the F3 fraction, and groups XIII, 
XIV, and XV were given i.p the F4 fraction. At the end of the experiment (day 6) blood was 
collected from overnight fasted mice under mild ether anesthesia and the serum was analyzed for 
marker enzymes aspartate transaminase (AST) and alanine transaminase (ALT) using 
commercially available kits (SPINREACT, Girona, Spain) according to the manufacturer’s 
instructions. The animals were later sacrificed by cervical dislocation under mild ether anesthesia 
and the liver was excised, washed and homogenized in ice-cold phosphate buffer (0.1 M; pH = 7) 
and centrifuged at 9000 g for 15 min at 4°C. The obtained supernatant was used to determine total
protein content (Bio-Rad Protein Assay) and to evaluate CAT, SOD and glutathione S-transferase 
(GST) activities.
2.13 Catalase (CAT) assay
Catalase activity was assayed on the basis of H2O2 disappearance at 240 nm (Pedraza-Chaverri 
et ah, 2005). A 5 pi aliquot of the 1:40 diluted supernatant was added to 720 pi of 30 mM H2O2 in 
10 mM potassium phosphate solution. The decomposition of H202by CAT contained in the sample 
was measured at 240nm for a period of 15 seconds. The reaction follows first order kinetics given 
by the equation k = 2.3/t log (A o/A ), where k is the first order reaction rate constant, t is the time 
over which the decrease of H2O2 was measured, and Ao and A are the optical densities at times 0 
and 15s respectively. The results were expressed in k/mg protein.
2.14 Superoxide Dismutase (SOD) assay
SOD activity was assayed according to the method described by Naskar et al. (2009). Briefly, 
50 pi of the homogenized liver supernatant was added to 2.8 ml Tris-EDTA (50mM Tris, 1.2 mM 
EDTA; pH = 8.5) and 100 pi of 2 mM pyrogallol. The optical density (OD) of the mixture was 
read at zero and three minutes at 420 nm against the control which consisted of Tris-EDTA and 
pyrogallol. One unit of SOD is the amount of enzyme that inhibits the rate of auto-oxidation of 
pyrogallol by 50%. The results were calculated according to the following equations:
Rate (R) = (final OD -  initial OD)/3
% inhibition= [(R control - R)/R control] x 100
Enzyme unit (U) = (% inhibition/50) x dilution factor
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2.15 Glutathione S-transferase (GST) assay
GST activity was assayed according to the method described by Al-Saffar et al. (2011). Two 
solutions were prepared (sample and reference) each of 3 mL from the following: 2.2 ml of 0.1 M 
potassium phosphate buffer (pH 6.5), 100 pi of 30 mM CDNB ( 1 -chloro-2,4-dinitrobenzene) and 
100 pi of 30 mM glutathione reduced (GSH). The solutions were allowed to stand for 1 min at 
room temperature (25 °C), and 600 pi of the liver supernatant was added to the sample solution and 
mixed thoroughly. The absorbance was read at 340 nm after 1 minute and the activity of GST was 
expressed in nmol of GSH-CDNB conjugates formed/min/mg protein using an extinction 
coefficient of 9.6 mM^cm"1.
2.16 Cell lines and culture
MCF-7, HT-29, MDA-MB-231, Caco-2, HaCaT (non-tumourigenic), HaCaT-AS (non- 
invasive), and HaCaT-II4 (invasive) cell lines were purchased from American Type Culture 
Collection (ATCC, Rockville, USA). The seven cell lines were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (EES), 100 
pg/mL streptomycin and 100 U/mL penicillin. Cells were maintained in a humidified atmosphere 
containing 5% CO2 at 37 °C.
2.17 Cytotoxicity and cell survival assays
The proliferation of the MCF-7, HT-29, MDA-MB-231, Caco-2, HaCaT (non-tumourigenic), 
HaCaT-AS (non-invasive), and HaCaT-II4 (invasive) cell lines was tested using WST-1 assay. 
Cells were plated in 96-welled plates at a concentration of 1 x 105 cell/ml for 24 h. Afterwards, 
both cell lines were treated with increasing concentrations (10,25, 50, and 100 pg/ml) of the crude 
oil or oil fractions dissolved in DMSO for 48 hrs. At the end of the treatment period, WST-1
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reagent (Roche Applied Science, Penzberg, Germany) was added to the cells and incubated in a 
humidified incubator at37 °C and 5% CO2 atmosphere for 3 hours. For the wortmannin 
experiments, MDA and HT-29 cells were incubated with or without wortmannin (IpM) for 1 h in 
a serum-free complete MEM prior to treating cells with 25 and 50pg/ml of FI and F2 fractions for 
48 hr. WST-1 is a water soluble tétrazolium salt which is cleaved by the mitochondrial 
dehydrogenases in metabolically active cells. The intensity of produced formazan produced was 
quantified at 450 nm using Multiskan FC microplate ELISA reader (Thermo fisher Scientific, 
Rockford, IE, USA). The viability percentage of the four cancer cell lines were measured with 
Trypan blue exclusion method technique of (Strober, 2001). Cancer cells (2xl05 cells/ml) were 
seeded in 12-well plates for 24 h and then treated with increasing concentrations (10, 25, 50, and 
100 pg/ml) of the crude oil for 24 and 48 h. Next, trypan blue (0.4%) was added to the cells for 5 
min and viable and dead cells were counted. Cells were plated in triplicates in three independent 
experiments.
2.18 DAPI and Annexin V staining
MDA- cells were seeded on 25 mm square glass cover slips placed in 35 mm diameter culture 
dishes. After treatment, cells were washed with PBS and fixed with 3.7% paraformaldehyde for 10 
min at room temperature. Fixed cells were permeabilized with a 0.1% solution of Triton X-100 in 
PBS and then stained by Annexin V conjugated to FITC using apoptosis detection kit (Abeam pic, 
330 Cambridge Science Park, Cambridge UK) or with 1 pg/ml of 4,6-diamidino-2-phenylindole 
(DAPI, Sigma) solution for 20 min. The cells were washed with PBS and observed with 
fluorescence microscope.
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2.19 Cell cycle analysis
The effect of FI and F2 fractions on cell cycle distribution was assessed by flow cytometry 
after staining the MDA and HT-29 cells with propidium iodide (PI). Briefly, both cells lines 
(lx l0 5cells/ml) were treated with different concentrations (25 and 50pg/ml) of both fractions and 
cultured in 6-well plates for 48 h. The treated cells were harvested, washed with PBS and fixed 
with 70% ethanol on ice. Then cells were washed with cold PBS, suspended in 200 pL IX 
Propidium Iodide + RNase staining solution and incubate at 37°C in the dark for 30 minutes. 
Propidium Iodide Flow Cytometry Kit (Abeam, Cambridge, UK) was used for cell cycle analysis. 
DNA content of the cells was measured by C6 flow cytometer (BD Accuri Cytometers, Ann 
Arbor, MI USA) and the population of each phase was determined using CFlow Plus analysis 
software (BD Accuri Cytometers, Ann Arbor, USA).
2.20 Apoptotic cell assay
The apoptotic effect of the most potent DCOE fractions (FI, F2) on MDA-MB-231 and HT- 
29 cells was determined by Annexin V-FITC staining assay and measured by C6 flow cytometer 
(BD Accuri Cytometers, Ann Arbor, USA). The MDA cells (lx l0 5cells/ml) were treated with 
different concentrations (25 and 50pg/ml) of both fractions and cultured in 6-well plates for 48 h. 
Treated cells were harvested, washed with phosphate-buffer saline (PBS) and then centrifuged at 
500g for 5 min. Then the cell pellet was suspended in 500 pL of Annexin V-FITC/PI apoptosis 
detection kit (Abeam pic, 330 Cambridge Science Park, Cambridge UK) at room temperature for 
5 min in the dark. Annexin V-FITC binding was analyzed by flow cytometry (Ex = 488 nm; Em = 
530 nm) FL1 channel for detecting Annexin V-FITC staining and FL3 channel for detecting PI 
staining. Annexin V-positive, Pi-negative cells were scored as early apoptotic, and double-stained 
cells were considered as late apoptotic.
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2.21 Cell lysate preparation and protein quantification for Western blot
MDA and HT-29 cells were seeded onto 6-well plates in the presence of different 
concentrations (25 and SOpg/ml) of FI and F2 fractions, and treated for 48h. The adherent and non­
adherent cells were collected on ice and washed twice with PBS and lysed with IX SDS sample 
buffer [62.5 mM Tris HC1 (pH 6.8), 10% glycerol, 50mM DDT, protease inhibitors (ImM phenyl 
methyl sulfonyl fluoride (PMSF), 0.01% (v/v) aprotinin, 5pg/ml of pepstatin)], sonicated for 10 
min, centrifuged at 12,000g for 10 min at 4°C and then stored at -80 °C for western blotting. Total 
proteins of cell lysate was determined by DC Bio-Rad Protein Assay kit (Bio-Rad, Hercules, CA) 
according to the manufacturer’s instructions. 10 pi of cell lysate of treated and control groups of 
both cell lines was mixed with 50 pi of reagent A (alkaline copper tartrate solution) and 400 pi of 
reagent B (Folin reagent) and incubated at room temperature for 15 min. The absorbance was then 
measured at 750 nm. Total protein content was determined using standard Bovin Serum Albumin 
(BSA) curve.
2.22 Sodium Dodecyl Sulphate-PolyAcrylamide Gel Electrophoresis and Western blot 
analysis.
Cell lysate samples of MDA and HT-29 cells were further treated with 10% 2- 
mercaptoethanol, and heated at 95-100°C for 5 minutes. Equal protein concentrations of each 
sample were then loaded and resolved under reducing conditions by SDS-PAGE using 5% stacking 
gel, 10% separating gel and IX running buffer (0.3% Tris Base, 1.4% glycine, 20% SDS, pH =
8.3) at 90 V for 30 min and then at 120 V for 2 h. Proteins were then transferred to PVDF membrane 
(Pall Corporation, Ann Arbor, USA) using semi-dry electro blotter (PEQLAB, Erlangen, Germany) 
and IX transfer buffer (25mM Tris base, 0.2 M glycine, 20% methanol, pH 8.5) at 10V for 90 min.
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The membranes were blocked with blocking buffer (IX TBS, 0.1% Tween-20, 5% skim milk) for 
2 h and then probed with primary rabbit polyclonal antibodies to Caspase-3, PARP, Akt, p-Akt, 
Erk, and p-Erk (Abeam, Cambridge, UK) and mouse monoclonal antibodies to actin, p53, Bcl-2, 
Bax (Santa Cruz, CA) at dilution ranging from 1/3000 to 1/10000 at 4°C overnight. Later, the 
primary antibodies were washed away with TBST for 2 h and the membranes were treated with 
horseradish peroxidase (HRP)-coupled secondary antibodies in blocking buffer at a dilution of 
1/5000 (Abeam, Cambridge, UK) for 1 hour, and washed with TBST afterwards. Finally, detection 
of each protein was performed using the chemiluminescence ECU kit (Abeam pic, Cambridge, 
UK). According to the manufacturer’s instructions, membranes were incubated with enhanced 
chemiluminescence reagents A and B in 1:1 ratio for 3-5 min and proteins were then detected for 
chemiluminescence by exposing blots to Kodak X-AR film (Eastman Kodak Co., Rochester, NY).
2.23 Tumour promotion experiment
The dorsal surface of BALB/c mice was shaved using electric clippers. Papillomas were 
initiated by a single topical application of 190 nmol of 7,12-Dimethylbenz(a)anthracene (DMBA) 
in 0.2 ml acetone. One week after initiation, papilloma formation was promoted twice weekly by 
topical application of 8 nmol TPA in 0.2 ml acetone to the shaved of mouse back (Indra et al.,
2007). Thirty minutes before TPA promotion, three groups of mice (n=10) received intraperitoneal 
injections of F2- fraction dissolved in DMSO with increasing doses 10mg/kg, 50mg/kg, 200mg/kg, 
and a fourth control group of mice (n=10) received intraperitoneal injections of an equivalent 
amount of DMSO. The incidence of papillomas was observed weekly for 21 weeks. The effect of 
F2 fraction on growth of papillomas was done through weekly recording bases of the tumour 
incidence, and tumour yield %. Tumour yield was expressed as the average number of papillomas 
per mouse in each group. Tumour incidence was assessed as the percentage of mice in each group
having tumours on their back. Also the tumour volume was measured at week 15, 17, 20. Tumour 
volume was estimated in comparison to specific reference volume models provided by our labs. 
Briefly, papillomas length and width were measured using a caliper and matched with similar clay 
tumour models of known standardized volumes (Zeinab et al., 2011). Mice in each group were 
weighed at week 5, 13, and 21.
2.24 In vivo immunomodulatory assays
2.24.1 Mice
The immunomodulatory effect of the crude oil and oil fractions on the levels of interferon- y 
(INF- y, vascular endothelial growth factor (VGEF), interleukin (IL-10), interleukin (IL-17), 
tumour necrosis factor (TNF-a) in the spleens in comparison to the effect of 2 pg of LPS were done 
using BALB/c mice. The mice were divided randomly into 7 groups of 12 animals each. Group I 
served as a vehicle control and was injected i.p with DMSO (2 ml/kg). Group II served as a positive 
control and received 2 pg of LPS in DMSO per mouse. Groups III, IV, V, VI, and VII were injected 
i.p with 200 mg/kg of DCOE, FI, F2, F3, and F4 fractions in DMSO respectively. Mice were 
sacrificed by cervical dislocation either at 6 or 24 h (Matalka et al., 2007; Alshaker et al., 2011) 
post treatment and the spleens were removed onto ice, weighed, placed in pre-chilled tubes 
containing 1ml RIPA buffer (25mM Tris-HCl, pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS) for 30 min. The tissues were then homogenized, and centrifuged at 
10,000 g for 30 min at 4°C. The obtained supernatant was transferred to labeled micro-centrifuge 
tubes and stored at -80° C until cytokine assays.
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2.24.2 Cytokine analysis
Quantitative measurement of mouse cytokines, IFN-y, VGEF, IL-10, IL-17, TNF-a were 
performed using Mini ELISA Development Kit (Peprotech, UK). According to the manufacturer’s 
instructions, ELISA microplates were prepared by adding 100 pi of capture antibody specific for 
each cytokine onto the wells and incubated for 24h at room temperature. After washing, 300 pi of 
blocking buffer was added to each well for Ih. Afterwards, 100 pi of standard or spleen supernatant 
samples of control and treated groups were added to their corresponding wells and incubated at 
room temperature for at least 2 h followed by the addition of a 100 pi of biotinylated detection 
antibody (Biotin Conjugate) into each well except the chromogen blanks and incubated for 
additional 2 h. During the period of incubation, the specific antigen (cytokine) binds simultaneously 
to the immobilized (capture) antibody on one site, and to the solution phase biotinylated antibody 
on a second site. After the removal of excess detection antibodies by repeated washing, a 100 pi of 
Avidin-HRP conjugate (enzyme) was added into each well which binds to the biotinylated antibody 
to complete the four member sandwich. Thirty minutes following incubation, wells were washed 
several times to remove all unbounded enzyme and 100 pi of ABTS liquid substrate (chromogen) 
was for color development at room temperature. Plates were read at 450 nm using the Multiskan 
FC microplate ELISA reader (Thermo fisher Scientific, Rockford, IL, USA) and absorbance was 
then transformed to cytokines concentrations (pg/ml) and then to (pg/g) of tissue based on weight 
of tissue per ml.
2.25 Statistical analysis
Data was analyzed for statistical significance using one way analysis of variance (ANOVA). 
Values of the different tested parameters within each group are presented as mean ± SEM. 
Significant main effect differences were tested using Bonferroni post hoc test for multiple
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comparisons. All data were analyzed with the statistical package SPSS 18, and differences between 
groups were considered statistically significant if p < 0.05. The IC50 was calculated by a nonlinear 
regression curve with the use of Prism Graph Pad Prism version 5.0 software for Windows.
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CHAPTER 3: PHYTOCHEMICAL ANALYSIS OF DCOE AND
ITS FRACTIONS
3.1 Rationale and Aims
Daucus carota ssp. carota or wild carrot is an aromatic plant used in traditional medicine 
since ancient times in Lebanon and various regions of the world. The oil extracted from this herb 
has been subjected to several investigations and numerous chemical components have been 
identified (Mazzoni et ah, 1999; Mockute and Nivinskiene, 2004; Staniszewska et ah, 2005; Kula 
et ah, 2006; Wu et ah, 2006; Rossi et ah, 2007). However, not all reports mention the subspecies 
of the plant used for their extractions. Since Daucus carota is considered a polymorphic species 
comprising eleven interconnected subspecies (Castroviejo, 2003), the subspecies used could 
substantially affect the range of components identified and their relative abundancies. Furthermore, 
it has been indicated that the part of the plant, the stage of development as well as the geographical 
allocation of the harvest can significantly influence the composition of the oils obtained from this 
species (Gonny et al., 2004b; Mockute and Nivinskiene, 2004; Staniszewska et al., 2005; Rossi et 
al., 2007; Maxia et al., 2009). To the best of our knowledge, there is only one study to date based 
on the essential oil composition of Lebanese Daucus carota ssp. Maximus (Saad et al., 1995). In 
order to fully characterise the active chemical components which may be responsible for the wide 
range of pharmacological effects attributed to it in anecdotal folk medicine reports worldwide, the 
qualitative and quantitative analysis of the chemical composition of the crude oil of the wild carrot 
is necessary, especially as no detailed study has been conducted in Lebanon and the Middle East 
region.
The aim of this chapter, therefore, was first to extract the crude oil from the umbels of the wild
carrot and identify the components using GC-MS and to match the mass spectral data with the
NIST 11 and Wiley9 Mass Spectral libraries. Since the Daucus carota oil is a mixture of organic
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compounds with variable polarity, the second objective was to separate it into four major mobile 
fractions (FI, F2, F3, and F4) using Si-Gel column chromatography based on TLC elution profiles. 
Finally, GC-MS and HPLC analyses were essential to identify the major compounds that 
constituted each fraction.
3.2 Results
3.2.1 Chemical composition of DCOE
Previous studies (Gonny et al., 2004b; Mockute and Nivinskiene, 2004; Staniszewska et al., 
2005; Rossi et al., 2007; Maxia et al., 2009) have shown that the composition of DCOE varies 
significantly among different European countries. This indicates that geographical distribution 
highly affects the chemical constituents of the oil. Therefore, it was necessary to identify the 
components of DCOE derived from wild carrot grown in Lebanon.
As described in chapter 2 (section 2.3 and 2.5), DCOE was obtained from wild carrot leaves 
soaked in methanol/acetone mixture and then analyzed by GC-MS for the determination of their 
components by comparing their mass spectra with the literature (NIST11 and W9) and computing 
their percent composition from GC peak. The results are summarized in Table 3.1. The major 
components identified in the oil consisted of sesquiterpenes (73.69%) and phenylpropanoids (12.07 
%). The major sesquiterpene identified in DCOE was 2-himachalene-6-ol which constituted 
36.29%, followed by a-humelene (9.23%), a-longipinene (6.32 %), (3-caryophyllene (5.98%), p- 
selinene (4.54%), 10s, 11 a-Himachala-3( 12),4-diene (3.65%), y- selinene (2.35%), a-selinene 
(1.89%), p-himachalene (1.63%), P-bisabolene (1.11%) and other sequiterpenes with lower 
percentages including longicyclene (0.43%) and aromadendrene (0.12%). Monoterpenes such as 
linalool (0.1%) and a-pinene (0.11%) were detected in trace amounts. Another group of
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phytochemicals identified in DCOE were the phenylpropanoids, represented by elemicin at 6.91% 
and (E)-methylisoeugenol at 5.16%.
Table 3.1. Main identified components (> 0.1%) of the essential oil of Daucus carota L. ssp. carota in this study and 
summary of components from the literature.
Percentage in Daucus carota crude oil
Retention 
Time (min) Compounds DCOE Staniszewska 
et a l ,  2005
Gonny et 
a l, 2004
Rossi et 
a l, 2007
Maxia et a l , 2009 
Portugal Italy
6.93 Linalool 0.1 2.2 0.2 - 1.6 0.2
8.86 a- Pinene 0.11 17.2 16 15.9 13 1.5
11.88 (+)-a-longipinene 6.32 - - - - 3.1
12.38 Longicyclene 0.43 - - - - -
13.33 10s,l la-Himachala-3(12),4-diene 3.65 - - - - -
13.36 Methyl eugenol 0.86 - - 0.2 - -
13.88 P-Caryophyllene 5.98 0.3 - - 1.3 0.2
15.14 a-humelene 9.23 - 0.3 - 0.1 -
16.03 Aromadendrene 0.12 - - - - -
16.54 P-Selinene 4.54 0.1 - 0.5 0.1 0.3
16.87 a-Selinene 1.89 - - 0.9 - 0.3
17.01 (E)- Methylisoeugenol 5.16 - 34 21.8 1.3 10
17.37 P-Bisabolene 1.11 0.1 5.5 21.3 0.5 51
17.63 y-Selinene 2.35 - - - - -
17.87 P-Himachalene 1.63 - - - - 1.3
19.55 Elemicine 6.91 - 10.9 16.3 1.6 5.2
20.80 Caryophyllene oxide 1.94 - - - - -
23.77 2-Himachalen-6-ol 36.29 - - - - -
25.22 a-Asarone 0.25 - 1.5 0.8 0.5 -
28.39 3,5,6,7,8,8a-Hexahydro-4,8a-dimethyl-6-(l- 
methylethenyl)-2( 1 H)-naphthalenone
1.29 - - - - -
3.2.2 Chemical composition of oil fractions
DCOE was further fractionated by column chromatography using mobile phases of increasing 
polarities of solvents and monitored by thin layer chromatography (TLC) and similar fractions were
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combined. Four fractions were obtained: Pentane fraction (FI), pentane/diethyl ether fraction (F2), 
diethyl ether fraction (F3) and chloroform/methanol fraction (F4) which were then analysed by 
GC/MS and HPLC techniques as described in chapter 2 (section 2.4 and 2.5).
As shown in Table 3.2, fraction FI was predominantly composed of sesquiterpenes mainly a- 
humelene (28.2%), p-caryophyllene (17.2%), a-longipinene (7.18%), a-selinene (4.26%), y- 
selinene (3.53%), p-selinene (2.86%) and p-himachalene (2.58%). Fraction F2 was markedly 
dominated by the sesquiterpene 2-himachalen-6-ol (61.4%) and noticeable amounts of three 
phenylpropanoids: elemicin (10.9%), (E)-methylisoeugenol (12.5%) and methyl eugenol (2.28%). 
On the other hand, fewer compounds were identified in fractions F3 and F4 with a-longipinene and 
p-selinene being the major identified components (F3: 5.6% and 2.38% respectively; F4: 8.18% 
and 5.33% respectively). The more polar fractions F3 and F4 were further analyzed by HPLC and 
the results are displayed in Figure 3.1. Both fractions contain several polyphenolic (flavonoids) 
compounds. The chromatogram of F3 showed several identified peaks, at retention times of 16.45 
min, 31.81 min, 34.22 min, and 34.59 min, while F4 presented five prominent peaks out of which 
four were identified at retention times of 30.5 min, 32.02 min, 34.35 min, and 34.89 min. A number 
of compounds were identified in both fractions by comparing them with reference standards of 
phenolic acids and flavonoids on the basis of their HPLC retention times (Figure 3.1. A).
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Table 3.2. Main identified components (> 0.5 %) in the wild carrot oil fractions FI, F2, F3 and F4.
Retention Component Percentage in fractions
Time FI F2 F3 F4
11.88 (+)-a-longipinene 7.18 - 5.60 8.18
12.38 Longicyclene 1.72 - - -
13.26 methyl eugenol - 2.28 - -
13.33 10s,lla-Himachala-3(12),4-diene 6 - - 0.59
13.88 p-Caryophyllene 17.2 - - 0.78
15.08 l /lA8-tetramethyl-cis/cis,4,7/10-cycloundecatriene - - - 1.25
15.14 a-humulene 28.2 - - -
16.03 Aromadendrene 0.75 - - -
16.54 P-Selinene 2.86 - 2.38 5.33
16.70 Y-Selinene - - 0.56 1.86
16.87
16.95
cc-Selinene
P-Himachalene
4.26
2.07
- -
17.01 (E)- Methylisoeugenol - 12.5 - -
17.22 P-Bisabolene - - 0.62 2.59
17.47 2,3-Dicyano-6-ethyl-5,7-dimethyl-6H-l,4-diazepine - - - 3.82
17.63 y-Selinene 3.53 - - -
17.87 P-Himachalene 2.58 - - -
18.31 5-Benzyl-4-isopropyl-lH-imidazole 0.79 - - -
18.38 (-)-.alpha.-Panasinsen 1.08 - - -
19.55 Elemicine - 10.9 - -
20.50 Caryophyllene oxide 5.20 0.66 - -
23.53 2-Himachalen-6-ol - 61.4 0.79 1.67
25.22
28.39
P-Asarone
3,5,6,7,8/8a-Hexahydro-4/8a-dimethyl-6-(l-methylethenyl)-2(lH)-
- 1.05 - -
naphthalenone 1.92 - - -
61.05 Methanesulfonic acid, 9-oxabicyclo [3.3.1]non-3-ylmethyl ester - - - 0.78
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Figure 3.1. HPLC profiles of F3 and F4 fractions. A. HPLC chromatograms of a standard mixture of phenolic acids. 
Peaks: 1 = gallic acid; 2 = chlorogenic acid; 3 = vanillic acid; 4 = syringic acid; 5 = caffeic acid; 6 = ellagic acid; 7 = 
myricetin; 8 = quercetin; 9 = luteolin; 10 = kaempferol; 11 = apigenin. B and C. HPLC chromatograms of F3 and F4 
oil fractions of the wild carrot extract. HPLC conditions: mobile phase, water: acetic acid: methanol; 10:2:88 (solvent 
A) and water: acetic acid: methanol; 90:2:8 (s'olvent B), flow rate; 1.5ml/min, detection; LTV at 280 nm.
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Luteolin, kaempferol, and apigenin were present in both fractions, while caffeic acid was only 
present in F3 and quercetin in F4. The concentration of the identified components was calculated 
by using the obtained calibration curves and listed in Table 3.3. Luteolin (55.85 pg/mg) and 
apigenin (50.75 pg/mg) were the major components of F3, while kaempferol (103.00 pg/mg) and 
apigenin (118.00 pg/mg) were the major components of F4. In addition, the peak at 12.5 min was 
tentatively assigned to /?-coumaric acid based on spectral data and relative retention time 
(Rodriguez-Delgado et al., 2001)
Table 3.3. Concentrations of phenolic acids and flavonoids in F3 and F4 fractions of DCOE.
Component Concentration (pg/mg) of dry extract
F3 Fraction F4 Fraction
Caffeic acid 9.13 ND
Quercetin ND 69.70
Luteolin 55.85 83.10
Kaempferol 13.72 103.00
Apigenin 50.75 118.00
ND: Not Detected
3.3 Discussion
The oil extract of wild carrot grown in different locations of the world consists mainly of 
phenols, flavonoids, monoterpenes, sesquiterpenes, and phenylpropanoids (Gonny et al., 2004a; 
Mockute and Nivinskiene, 2004; Staniszewska et al., 2005; Maxia et al., 2009; Shebaby et al., 
2013). However, the percentage composition of the DCOE collected from Lebanon has been shown 
to vary greatly with different geographical origins (Shebaby et al., 2013). In the present study, 
DCOE was isolated and the chemical composition was elucidated which showed the presence of 
18 major (> 0.1%) constituents. Sesquiterpenes exhibited the highest concentration (73.69%) 
followed by phenylpropanoids (12.07 %) and trace amounts of monoterpenes. A similar oil
composition was obtained from Daucus carota from Sardinian mature umbels in which 
sesquiterpenes and phenylpropanoids constituted 61.6% and 15.2% respectively (Maxia et al., 
2009). Conversely, the essential oil of mature umbels from Poland was rich (81%) in monoterpene 
hydrocarbons with relatively low percentage of sesquiterpenes (Staniszewska et al., 2005). 
Furthermore, the oil derived from Portuguese mature umbels was mainly composed of oxygenated 
monoterpenes (68.7%) and monoterpene hydrocarbons (19.3%) (Maxia et al., 2009). This shows 
the significance of the geographical location on the chemical composition of Daucus carota oil.
Phytochemical analysis of the four oil fractions of wild carrot showed that sesquiterpenes 
were the major constituents of fractions FI and F2 with the latter containing phenylpropanoids as 
well. On the other hand, several phenolic and flavonoid compounds were detected in fractions F3 
and F4. The major sesquiterpene in F2 (61.4%) was identified as 2-himachalen-6-ol by GCMS 
(NIST Library 2011, 96% match). According to the available literature (Gonny et al., 2004a; 
Mockute and Nivinskiene, 2004; Staniszewska et al., 2005; Rossi et al., 2007; Maxia et al., 2009) 
and to the best of our knowledge, this is the first time that 2-himachalen-6-ol has been reported to 
be present in the wild carrot plant or related subspecies. This compound was first isolated from the 
heartwood of Juniperus chinensis that belongs to the family Cupressaceae (Shiu et al., 1999). The 
identification of 2-himachalen-6-ol in DCOE is considered an important finding since it is very 
abundant in Lebanese Daucus carota and there are no previous studies concerning the biological 
activity of this phytochemical.
Similarly, 10s,l la-himachala-3(12),4-diene (3.65% of DCOE and 6% of FI) and y-selinene
(1.89 % of DCOE, 3.53% of FI, 0.56% of F3, 1.86% of F4) sesquiterpenes have also not been
identified in any other subspecies of Daucus carota in the literature. Other prominent
sesquiterpenes such as p-caryophyllene (5.98% of DCOE, 17.2% of FI) and a-humelene (9.23%
of DCOE, 28.2% of FI) were found in trace amount or even not detected in the crude oil of the
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plant worldwide. Furthermore, a-longipinene (6.32% of DCOE, 7.18% ofF l, 5.6% of F3, 8.18% 
of F4) and p-himachalene (1.63% of DCOE, 2.07% of F2) appear to be present only in the wild 
carrot grown in Italy. The monoterpenes linalool and a-pinene, which existed in a limited amount 
in DCOE, were however, identified in a significant percentage in the oil of the wild carrot from 
various countries (Gonny et al., 2004a; Mockute and Nivinskiene, 2004; Staniszewska et al., 2005; 
Rossi et al., 2007; Maxia et al., 2009). When considering different subspecies of Daucus carota 
worldwide, the chemical composition of the extracted crude oil has exhibited remarkable 
variations in its composition (Pinilla et al., 1995; Saad et al., 1995; Kula et al., 2006; Wu et al., 
2006; Glisic et al., 2007; Tavares et al., 2008; Jabrane et al., 2009).
In conclusion, the results indicated that the chemical composition of DCOE is unique and 
rather different from those of other origins. This stresses the importance of geographical location 
as well as diversity of the Daucus carota subspecies and its effect on the plant chemical 
composition which may influence the biological activity.
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CHAPTER 4: ANTIOXIDANT AND HEPATOPROTECTIVE ACTIVITIES 
OF DCOE AND ITS FRACTIONS
4.1 Rationale and Aims
There is growing evidence that many human diseases are caused by oxidative stress, which 
partially results from an imbalance between the formation and neutralization of pro-oxidants (Hazra 
et ah, 2008). Oxidative stress is induced by free radicals, mainly reactive oxygen species (ROS), 
which include the superoxide radical (O2' ), hydrogen peroxide (H2O2), and hydroxyl radical ("OH). 
ROS molecules are highly reactive against macromolecules such as DNA, proteins, and membrane 
lipids in living cells causing types of changes which are associated with the development of cancer, 
cardiovascular disease, aging and inflammatory disease (Hemnani and Parihar, 1998; Braca et ah, 
2002). The human body has natural defense mechanisms that protect against free radicals and 
oxidative damage. These mechanisms are both enzymatic, such as the ones catalyzed by superoxide 
dismutase (SOD), catalase (CAT), and the glutathione system (glutathione, glutathione reductase, 
peroxidase and transferase) and non-enzymatic, such as the ones provided by low molecular weight 
antioxidants such as vitamins A, E and C (Evans et ah, 2004; Manda et ah, 2009). Although ROS 
exist in all aerobic cells, they are normally in equilibrium with antioxidants to maintain low free 
radical levels (Waris and Ahsan, 2006). However, if the balance between free radicals and the 
antioxidant levels is compromised, the need for antioxidant supplements becomes necessary to 
combat oxidative damage (Shukla et ah, 2009). Over the last few decades, the literature has 
revealed the importance of natural products as a source of potent antioxidants (Mantle et ah, 2000). 
Among the most described are phenolic acids, polyphenols, monoterpenes, sesquiterpenes and 
phenylpropanoids which have been found to possess antioxidant activity (Sibanda et ah, 2004; 
Medina-Holgum et ah, 2008).These compounds have the capacity to scavenge free radicals and to 
increase the levels of antioxidant enzymes thus protecting the body cells against carcinogenesis
and oxidative damage (Tachakittimngrod et al., 2007; Terao, 2009). The wild carrot is commonly 
consumed as a salad in the Mediterranean diet or used as an additive in some recipes (Nehir El and 
Karakaya, 2004). Its flower umbels are edible and usually deep-fried, and its seed oil, which is 
commercially available, is used to flavour beverages and food products (Leung, 1980). In Lebanon, 
people eat its young taproot cooked and use the plant in folk medicine for the treatment of cancer, 
gastric ulcer, diabetes, muscle pain and to protect against hepatic diseases 
(http://wildedibleplants.info). In addition, several plant extracts rich in biologically active 
substances such as a-humelene, (3-caryophyllene which are also present in DCOE exhibit 
significant antioxidant effects (Deba et al., 2008; Ben Farhat et al., 2009; Remya et al., 2013a).
There are no previous in vitro and in vivo studies involving the antioxidant activities of DCOE 
and its toxicity in animal models. Thus, the first aim of this chapter was to evaluate the in vitro 
antioxidant activity of DCOE and its fractions by various antioxidant assays including 1,1- 
diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay, ferrous ion-chelating (FIC) ability 
assay and ferric reducing antioxidant power (FRAP) assay.
Since phenolic compounds are well known to possess significant antioxidant properties (Yin et 
al, 2008; Zheng and Wang, 2001), the determination of the total phenol and flavonoid contents of 
DCOE and its fractions were another aim of this study.
In order to discover a possible correlation with their antioxidant activities, the next objective 
was to investigate the in vivo antioxidant and hepatoprotective potentials of DCOE fractions in 
CCL-induced hepatotoxicity murine models. The in vivo antioxidant activities of DCOE fractions 
were assessed by determining the activities of the liver antioxidant enzymes CAT, SOD and GST 
in control and experimental mice. Finally, the hepatoprotective capacity of the DCOE fractions was 
evaluated by measuring the serum levels of ALT and AST which are indicators of liver injury.
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4.2 Results
4.2.1 Total phenolics and flavonoid content of DCOE and fractions
The phenolic and flavonoids compounds are considered effective free radical scavengers and 
antioxidants. Thus, total phenolic and flavonoid contents of DCOE as well as oil fraction samples 
were determined using the Folin Ciocalteu reagent and aluminium chloride colorimetric technique 
respectively as described in chapter 2 (section 2.7 and 2.8). The total phenolic and flavonoid 
contents of oil extract were 65.3 ± 2.35 mg GAE/g of DCOE and 18 ± 1.2 mg QE/g of DCOE 
respectively (Table 4.1).
Table 4.1. Total phenol and flavonoids contents and antioxidant activities of DCOE.
Sample
Total phenol 
Content 
(mg GAE/g)
Flavonoid 
Contents 
(mg QE/g)
DPPH radical 
scavenging, 
IC5o(mg/ml)
FRAP 
pmol FeSOVg
Fe2+ chelating 
activity 
ICso(mg/ml)
DCOE
Trolox
Vitamin C
Naz-EDTA
65.3 ±2.35 18 ± 1.2 2.1 ±0.11 
0.18 ±0.03
164 ±5.5 
69x103± 1535
0.43 ± 0.02 
0.054 ±0.0001
Values are the mean SEM from three experiments
The results for the oil fraction in Table 4.2 reveals that F4 fraction showed the highest phenolic 
content, followed by F3, FI and F2. Flavonoid content in the different fractions displayed similar 
trend to phenolics.
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Table 4.2. Phenolic content, flavonoid content, DPPH, FRAP and FIC assay of the different oil fractions of Daucus 
carota L. ssp. carota.
Sample Phenolic 
content 
(mg GAE/g)
Flavonoid 
Content 
(mg QE/g)
DPPH radical 
scavenging ICso 
(mg/ml)
FRAP 
pmol FeSOVg
Fe2+ chelating 
activity ICso 
(mg/ml)
Fl-fraction 48.6 ± 2.8 3.5 ±0 .2 >2.5 ±0.25* 19.7 ±0.9* 0.28 ± 0.03*
F2-fraction 40.1 ± 1.9 2.0 ±0 .1 >1.8 ±0.30* 38.5 ±1.3* 1.45 ±0.15*
F3-fraction 108.5 ± 2.9 35.5 ± 1.5 0.29 ±0.01* 225.1 ±5.6* >5.0 ± 0.30*
F4-fraction 147.1 ±3.1 56.0 ±2.3 0.38 ± 0.02* 437.5 ± 6.9* >7.2 ± 0.45*
Trolox - - 0.06 ± 0.01* - -
Vitamin C - - - 610 0 0 ± 1258* -
Naz-EDTA - - - 0.07 ± 0.012*
The values are expressed as Mean ± SEM from three experiments. Means followed by an asterisk are significantly 
different (P < 0.05)
4.2.2 In vitro antioxidant assays
To evaluate the in vitro antioxidant potential of DCOE and its fractions, three of the most 
common in vitro antioxidant assays were performed including 1,1 -diphenyl-2-picrylhydrazyl 
(DPPH) radical scavenging assay, ferrous ion-chelating (FIC) ability assay and ferric reducing 
antioxidant power (FRAP) assay. The DPPH assay is used to measure the capacity of DCOE and 
its fractions to scavenge free radicals. On the other hand, the FIC assay determines the ability of 
DCOE and its fractions to chelate the redox active Fe2+ ions, and hence prevent the metal-induced 
free radical formation. The FRAP assay directly measures the reductants or antioxidants in DCOE 
and its fractions. Thus the results obtained by the three above assays would give a true reflection 
of the antioxidant power of DCOE and its fractions.
4.2.2.1 DPPH radical-scavenging activity
The DPPH assay measures the capacity of DCOE and its fractions to reduce stable DPPH* free 
radical, 1,1 -diphenyl-2-picryl hydrazyl (purple) to a diphenyl picryl hydrazine (yellow). The 
DPPH* radical shows a maximum absorption at 517 nm (purple) and accordingly as the reaction
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between the antioxidant and the DPPH radical progresses, the absorbance at 517 nm decreases. 
Thus, the antioxidant activity is directly proportional to the disappearance of DPPH* in test samples. 
In general, the lower DPPH ICso values, the higher the radical scavenging activity of the plant 
extract. In this experiment, the DPPH free radical scavenging activity of DCOE was determined by 
mixing different concentrations of the oil samples with methanolic solution of DPPH. The 
absorbance of the mixture was then measured at 517 nm and compared with that of the commercial 
antioxidant Trolox as described in chapter 2 (section 2.9). As shown in Figure 4.1, the extract 
showed dose-dependent DPPH scavenging activities.
100
Trolox
80
DCOE
tao
40
CL
0 21 3 4 65
Concentration mg/ml
Figure 4.1. DPPH scavenging activity of DCOE. The scavenging activity of DCOE and Trolox at different 
concentrations (0.25, 0.5, 1, 2, and 5mg/ml) on DPPH radicals. The mixture was incubated in the dark at room 
temperature for 30 minutes after which absorbance was measured spectrophotometrically at 517 nm. The data 
represents the % radical scavenging activity. Trolox used as positive control. Data are the mean ± SEM from three 
experiments.
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The IC50 values were worked out using nonlinear regression curve as mentioned in chapter 2 
(section 2.25) and came to 0.18 ± 0.03mg/ml and 2.1 ± 0.11mg/ml for Trolox and DCOE 
respectively (Table 4.1).
The DPPH scavenging activities of the oil fractions at various concentrations were also 
determined and compared with that of the standard antioxidant Trolox (Figure 4.2). The F3 and F4 
fractions revealed the strongest scavenging activity with the lowest ICso of 0.29 ± 0.01 mg/ml and 
0.38 ± 0.02 mg/ml respectively, while FI fraction showed the lowest activity with highest ICso >  
2.5 ± 0.25 mg/ml. Trolox, on the other hand, displayed the highest scavenging activity with an ICso 
= 0.06 ± 0.01 mg/ml. The results are summarized in Table 4.2.
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Figure 4.2. DPPH scavenging activity of DCOE fractions. Percentage DPPH scavenging activity of DCOE fractions 
(FI, F2, F3, and F4) and Trolox at different concentrations (0.025, 0.05, 0.1, 0.5, and 1.0mg/ml) on DPPH radicals. 
The mixture was incubated in the dark at room temperature for 30 minutes after which absorbance was measured 
spectrophotometrically at 517 nm. The data represents the % radical scavenging activity. Trolox used as a control. Data 
are the mean ±  SEM from three experiments.
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4.2.2.2 Fe2+ chelating activity
The ferrous ion-chelating (FIC) assay relies on the complex formation between ferrozine and 
Fe2+ ions. In the presence of other chelating substances, the ferrozine complex formation is 
disrupted which results in the decrease in red color of the complex. Therefore, the chelating ability 
of the chelator can be estimated by measuring the decrease in the absorbance at 562 nm (Wannes 
et al., 2010). The FIC chelating activity of DCOE and fraction samples at different concentrations 
were determined as described in chapter 2 (section 2.10). The chelating effect of DCOE (Figure
4.3) on ferrous ion as compared to NazEDTA displayed a dose dependent increase between 0.125 
and 1 mg/ml, reaching a plateau (78%) beyond 0.8 mg/ml. The IC50 for DCOE was found to be 
0.43 ± 0.02 mg/ml (Table 4.1). NaiEDTA showed very strong activity with an IC50 of 0.054 mg/ml.
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Figure 4.3. Metal chelating activity of DCOE. The Fe2+ chelating activity of DCOE and Na^EDTA at different 
concentrations (0.125, 0.25, 0.5, 0.75 and 1 mg/ml) on ferrous ions. Samples were incubated with FeCFand ferrozine 
for 5 minutes after which absorbance was measured spectrophotometrically at 562 nm. The data represents the % 
chelating activity of ferrous ions. Na?-EDTA used as positive control. Data are presented as mean ± SEM from three 
experiments.
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The DCOE fractions were also tested for their ability to chelate ferrous ions. As shown in Figure 
4.4, the FI fraction demonstrated the highest FIC activity among all fractions with an IC50 = 0.28 
± 0.03 mg/ml and F4 showed the least FIC effect with an IC50 > 7.25 ± 0.45 mg/ml (Table 4.2). 
These results are in contrast to the DPPH assay data where FI exhibited the lowest DPPH 
scavenging activity.
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Figure 4.4. Metal chelating activity of DCOE fractions. The chelating activity of oil fractions (FI, F2, F3, and F4) 
and NazEDTA at different concentrations (0.25, 0.5, 1, 2 and 4 mg/ml) on ferrous ions. Samples were incubated with 
FeCh and ferrozine for 5 minutes after which absorbance was measured spectrophotometrically at 562 nm. The data 
represents the % chelating activity of ferrous ions. Naz-EDTA used as positive control. Data are presented as mean ± 
SEM from three experiments.
4.2.2.3 Ferric reducing antioxidant power (FRAP)
The FRAP assay measures directly the capacity of antioxidants to reduce a ferric 
tripyridyltriazine complex (Fe3+-TPTZ) to the ferrous complex (Fe2+-TPTZ) (Alanôn et al., 2011). 
The reduction of Fe3+-TPTZ complex to Fe2+ form by an antioxidant under acidic conditions leads 
to a deep blue color with maximum absorption at 593 nm (Benzie and Strain, 1996). This method 
was used to determine the reducing capacity of DCOE and fractions samples at various
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concentrations as described in chapter 2 (section 2.11). The antioxidant power of DCOE was 
compared with vitamin C as a reference antioxidant (Table 4.1). The FRAP value for DCOE was 
164 ± 5.5pmol FeSOVg.
The reducing power of DCOE fractions was also estimated and the results are summarized in 
Table 4.2. The F4 fraction demonstrated the highest FRAP value (437.59 ± 6.94 pmol FeSOVg), 
whereas the FI fraction showed the lowest value (19.70 ± 0.92 pmol FeSOVg). Vitamin C showed 
significant reducing power with a FRAP value of 61000 pmol FeSOVg.
4.2.3 In  vivo antioxidant activity
The in vivo antioxidant properties of the oil fractions were assessed by determining the CAT, 
SOD and GST activities using CC14-induced hepatotoxicity mice model as described in chapter 2 
(section 2.12, 2.13, 2.14 and 2.15) (Figure 4.5). As expected, there was a marked decrease in the 
enzymatic activity of the three liver enzymes in the CCU treated control group when compared to 
the normal control group (p < 0.05). Groups pretreated with the four oil fractions, had significantly 
(p < 0.05) increased GST activity when compared to the CCU treated control group. Treatment 
with FI (200 mg.kg'1) and F4 (50, 100 and 200 mg.kg'1) markedly (p < 0.05) elevated the CAT 
activity when compared to that of the CCU treated control group. Similarly, the level of SOD 
activity in the liver homogenates was significantly (p < 0.01) improved after treatment with FI at 
200 mg.kg'1 and F4 at all used doses. On the other hand, groups pretreated with the F2 and F3 
fractions failed to restore the normal CAT and SOD activities.
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Figure 4.5. In vivo antioxidant activity of DCOE fractions. Effect of DCOE fractions (FI, F2, F3, and F4) and
vitamin E on the activity of SOD, CAT, and GST antioxidant liver enzymes of CCU -intoxicated mice. Homogenized 
liver supernatants of various groups were mixed with H2O2, pyrogallol, or CDNB and GSH for CAT, SOD and GST 
assays respectively. The absorbance was then read at 240,420, and 340 nm for CAT, SOD and GST assays respectively. 
Each column represents the mean ± SEM, with n = 6 animals in each group. (A) SOD, superoxide dismutase; (B) CAT, 
catalase; (C) GST, Glutathione-S-transferase. ap < 0.05 compared to normal control group; bp < 0.05; cp < 0.01; dp < 
0.001 compared to CCU-control treated group.
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4.2.4 Hepatoprotective activity
The activities of serum ALT and AST for the control and experimental groups of the CC14- 
induced hepatotoxicity mice model were analyzed using commercially available kits (SPINREACT, 
Girona, Spain) according to the manufacturer’s instructions.as described in chapter 2 (section 2.12). As 
presented in Table 4.3, the results indicated that the levels of ALT and AST were significantly 
elevated in the CCU treated control group compared to the normal control. Pretreated groups with 
FI and F4 fractions exhibited significant (p < 0.01) hepatoprotective capacity and restored the liver 
enzyme activities to normal values. However, F2 and F3 fractions were less effective and showed 
moderate hepatoprotective activity.
Table 4.3. Effect of DCOE fractions and vitamin E on AST and ALT in mice after CCU application.
Groups Dose (mg/kg) Parameters
AST (U/L) ALT (U/L)
Control 80.7 ± 6.9 34.5 ± 5.6
ecu 200.8 ± 22= 184.2 ± 19=
Vitamin E 131 ±7.7b 107 ± 4 .3b
F I 50 95 ± 1 1 .Ie 89.3 ± 3.4e
100 74.5 ± 9.8e 94.0 ± 17.3e
200 70.2 ± 3 .4d 73.6 ± 6.1d
F2 50 156.3 ±36.5ns 174 ± 25.2“
100 163 ± 33.9= 119.3 ±19.5b
200 179.2 ± 4 0 ns 120.2 ±13.6b
F3 50 170.7 ±23.9“ 130.3 ±25.9“
100 117.5 ±25.6“ 182.3 ±48.3“
200 148.5 ±29.8“ 116 ± 18.5b
F4 50 126.7 ±4 .8b 75.0 ± 4.0e
100 86.0 ± 17.0b 71.0 ± 6.2d
200 82.3 ± 5.2e 78.3 ± 4 .9C
The values are expressed as Mean ± SEM for n=6. Where ns: non-significant compared to CCU, 
a (p < 0.0001 compared to control) 
b (p < 0.05 compared to CCU) 
c (p < 0.01 compared to CCU) 
d (p < 0.0001 compared to CCU)
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4.3 Discussion
In this study, we have examined the in vitro and in vivo antioxidant activities of DCOE and 
separation fractions. As reported earlier in chapter 3, DCOE and fractions are rich in phenols, 
flavonoids and terpenes. These compounds are among natural non-enzymatic antioxidants, which 
play an important role in quenching and neutralizing free radicals and protect against oxidative 
stress and tissue damage (Ajith and Janardhanan, 2001). In this study, DCOE showed considerable 
radical scavenging activity when compared to that of Trolox (61% vs 90.8%). This is consistent 
with a previously reported antioxidant effect of dichloromethane-methanol extract of wild carrot 
(Akgul et al., 2009). The FRAP values obtained suggested that DCOE might act as an electron 
donor and might react with free radicals transforming them into more stable compounds. 
Furthermore, the F3 and F4 fractions were found to possess the highest antioxidant activity in the 
DPPH and FRAP assays. Such an effect could be partially attributed to the presence of phenolic 
compounds such as luteolin, kaempferol, apigenin, caffeic acid and quercetin, all of which reported 
to possess antioxidant activity (Skerget et al., 2005; Park et al., 2006; Boots et al., 2008;Yin et al.,
2008). Phenols, flavonoids and terpenes are among natural non-enzymatic antioxidants, which play 
an important role in quenching and neutralizing free radicals and protecting against oxidative stress 
and tissue damage (Ajith and Janardhanan, 2001). The antioxidant capacity of the DCOE fractions 
evaluated by DPPH is strongly correlated with the phenolic (r = 0.93) and flavonoid (r = 0.93) 
contents. A high positive correlation was also observed between FRAP antioxidant power and 
phenolic (r = 0.98) as well as flavonoid (r = 0.99) contents. Such an observation is in accordance 
with earlier studies which demonstrate a direct relationship between antioxidant capacity and total 
phenolic content in certain herbs, vegetables and fruits (Velioglu et al., 1998; Zheng and Wang, 
2001; Sun et al., 2002). The antioxidant activity of these phenolic compounds is believed to be 
attributed to the presence of hydrogen-donating hydroxyl groups on the aromatic rings (Heijnen et
al., 2002). On the other hand, the ferrous ion chelating effect of DCOE fractions did not correlate 
with their phenolic (r = - 0.81) or flavonoid contents (r = - 0.82). This is consistent with previous 
work that showed a similar relationship between total phenolic content and metal ion chelating 
capacity of plant extracts (Wang et al., 2009). One possible explanation could be due to the 
diversity of the polyphenols’ chemical structures with respect to the number and position of 
phenolic hydroxyl groups which could influence their Fe2+chelating ability (Mladënka et al., 2011). 
The sesquiterpene-rich fraction FI showed moderate DPPH scavenging activity, which could be 
attributed to the presence of a-humelene and p-caryophyllene, the major constituents of the FI 
fraction ((Deba et al., 2008; Ben Farhat et al., 2009; Remya et al., 2013b). Furthermore, the 
sesquiterpene a-longipinene, present in FI, F3, and F4, was also found in many plants that possess 
antioxidant activities (Yang et al., 2010; Kumar et al., 2012). Additionally, FI and F2 fractions 
were shown to possess strong Fe2+ chelating activity. Metal ions such as Fe2+ play an essential role 
in producing hydroxyl radicals through the Fenton reaction which accelerates lipid peroxidation 
(Benedet and Shibamoto, 2008). Therefore, FI and F2 may have an inhibitory effect on lipid 
peroxidation by stabilizing the Fe2+ metal ions. (3-caryophyllene, a major compound present in FI 
fraction, was reported to inhibit significantly lipid peroxidation by reacting with peroxyl radicals 
(Khunkitti et al., 2012).
The in vivo antioxidant activity was also evaluated using CCU-induced hepatotoxicity in mice. CCU 
is metabolized by the cytochrome P450 in the hepatic endoplasmic reticulum to produce the 
chemically reactive species, trichloromethyl (CCU*) and trichloromethyl peroxyl (CCI3O2*) free 
radicals, which attack membrane lipids and proteins leading to lipid peroxidation and ultimately 
cell damage (Johnston and Kroening, 1998; Shenoy et al., 2001). As expected, mice treated with 
CCU developed a significant hepatic damage marked by a substantial increase in serum levels of 
AST and ALT which are considered as specific markers of liver injury (Vozarova et al., 2002;
109
Ferreira et al., 2010). However, pretreatment with FI and F4 fractions significantly decreased the 
activities of these enzymes compared to the CCU-treated control, hence minimizing hepatic damage 
and exerting hepatoprotective activity. Additionally, the decrease in the activity of antioxidant liver 
enzymes SOD and CAT caused by CCU treatment was reversed by F4 and to a lesser extent by FI 
pretreatment. SOD is a key defense enzyme that catalyzes the conversion of O2* to O2 and H2O2 . 
The latter is then metabolized by CAT into molecular oxygen and water, protecting cells against 
free radical induced damage (Lee et al., 2003). Therefore, inhibition or reduction in the activity of 
these protective enzymes may lead to excessive cellular damage due to the accumulation of free 
radicals. The antioxidant and hepatoprotective effects of DCOE fractions, mainly FI and F4, can 
be attributed to the presence of sesquiterpenes in the FI and flavonoids and phenolic compounds 
in the F4 fractions. These compounds may act as primary antioxidants or as free radical scavengers, 
resulting in the protection of these defense enzymes as shown in several previous in vivo studies 
(Naskar et al., 2009; Oyedemi et al., 2010; He et al., 2012; Jain et al., 2012). Furthermore, the 
present data showed a significant increase in the activity of GST in the four pretreated groups 
compared to the CCL-treated control. GST is a phase-II metabolic enzyme that catalyzes the 
glutathione conjugation reaction involved in the detoxification of endogenous substances and 
xenobiotics providing protection against chemical toxicity and carcinogenesis (Yang et al., 2001).
In conclusion, the current study demonstrates the importance of DCOE fractions F3 and F4 
as potential sources of antioxidants, and FI and F4 as hepatoprotective remedies.
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CHAPTER 5: IN  VITRO AND IN  VIVO ANTICANCER ACTIVITIES OF 
DCOE AND ITS FRACTIONS
5.1 Rationale and Aims
Cancer has become the primary cause of death in developed countries and the second in the 
western world (Siegel et ah, 2011). The present treatment approaches, whether surgery, 
chemotherapy, immunotherapy or radiotherapy are usually accompanied with adverse side-effects 
and often a high level of toxicity in patients. Furthermore, acquired patient resistance to these 
treatments poses a continuing problem that compromises the effectiveness of anti-cancer therapy 
(Luqmani, 2008). Thus, there has been a renewed interest in studying natural products and 
identifying novel agents with effective anticancer activities and limited side effects. The antitumour 
properties of medicinal plants are attributed to the presence of plant secondary metabolites which 
includes phenols, terpenes and alkaloids (Akahane et ah, 2003; Reddy et ah, 2003; Sibanda et ah, 
2004; Dai and Mumper, 2010). As shown in chapter 3, Daucus carota oil extract (DCOE) and 
fractions are shown to comprise various phytochemicals such as sesquiterpenes, phenols and 
flavonoids, as well as the major compound 2-himachalen-b-oh Unlike the edible carrot Daucus 
carota L.ssp. sativus, few reports exist about the potential therapeutic uses of the wild carrot. 
Previous research conducted in our laboratories has revealed significant anti-tumour promoting 
effect of DCOE against DMBA/TPA skin carcinogenesis model in mice (Abu Zeinab et ah, 2011) 
and therefore, the assessment of potential in vitro and in vivo anticancer potentials of DCOE and 
its fractions is of great importance towards obtaining pharmacologically active anticancer 
compounds as well as decreasing the side effects associated with traditional cancer therapies.
The first aim of this study, therefore, was to evaluate the in vitro anti-proliferative effect of
DCOE and fractions against seven human cancer cell as well as to identify the most active fractions.
Since colon cancer remains the third leading cause of death in the United States (Pisani et ah, 2002)
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and breast cancer is the first leading cause of death in women globally (Jemal et al., 2011), breast 
cancer cells (MCF-7, MDA-MB-231) and colon cancer cells (HT-29, Caco-2), were selected for 
the present study. The skin cancer cells (non-invasive HaCaT-II4, invasive HaCatT-A5) and 
immortalized skin cells (non-tumerigenic HaCaT) were chosen for the in vitro anticancer screening 
to assess any selective cytotoxicity of DCOE fractions among them. Additionally, these cells are 
considered the counterparts of the chemically induced squamous cell carcinoma in the DMBA/TPA 
skin carcinogenesis model in mice. Following treatment with different concentrations of DCOE 
and fractions, cell viability was determined using trypan blue exclusion method and water soluble 
tétrazolium salt (WST-1) assay.
The next aim of this study was to investigate whether growth inhibition of the most potent 
DCOE fractions (FI, F2) on MDA-MB-231 and HT-29 cancer cells involves cell cycle arrest and 
apoptosis. For the cell cycle analysis, non-treated and Flor F2 treated cells were stained with 
propidium iodide (PI) and then the cell population of each phase of the cell cycle was determined. 
As for the apoptotic effect of the FI and F2 fractions on cells was analyzed by Annexin V-FITC/PI 
staining and early apoptotic as well as late apoptotic populations were determined. Furthermore, 
apoptotic morphological changes of control and treated cells were also examined using fluorescent 
microscopy.
Another important aim of this study was to further investigate the apoptotic death of FI and 
F2-treated cells by western blot analysis of several pro-apoptotic and anti-apoptotic proteins and 
elucidate possible mechanisms of action involved, including MAPK/ERK and PI3K/AKT signaling 
pathways.
In this study we also aimed to further assess the in vivo anticancer potential of the most active 
DCOE fraction (F2) in the DMBA/TPA skin carcinogenesis model in mice. The anti-tumour
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promoting effect of F2 was evaluated through the analysis of tumour incidence, yield, and volume 
in control and DCOE fraction 2 treated mice.
5.2 Results
5.2.1 Effect of DCOE and fractions on cell viability
Having established the antioxidant effect of the DCOE and its fractions using in vitro (DPPH, 
FRAP, and FIC) and in vivo (SOD, CAT and GST) assays and knowing the close relationship 
between antioxidants and survival and apoptosis pathways, the anticancer potential of the extract 
was tested. We started by testing the effect of the extract in vitro on the viability of several human 
cancer cell lines. Cell viability was measured using the Trypan blue exclusion method as described 
in Chapter 2 (section 2.17). As shown in Figures 5.1 and 5.2, the growth curves of the cell lines 
demonstrated an increase in cell number after 48 hours, in untreated cells or cells treated with the 
vehicle DMSO alone.
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Figure 5.1. Effect of DCOE on cell viability of colon cancer cells. HT-29 cells (A), Caco-2 cells (B) were left 
untreated (black circles, white bars), treated with DMSO (black squares, light gray bars), treated with 10mg/ml DCOE 
(white triangles, dotted bars), 25mg/ml DCOE (black triangles, dark gray bars) or with 50mg/ml DCOE (crosses, black 
bars) for 24 or 48 hours. The cells were then stained with Trypan blue and live (clear) cells counted. Data are presented 
as fold increase from cells at time zero. Data are the mean ± SEM from 3 experiments. ** denotes p < 0.01 compared 
with DMSO group as measured by one-way ANOVA.
This increase was significantly inhibited in cells treated with increasing concentrations of DCOE. 
The extract exhibited a dose dependent effect, which was particularly apparent in Caco-2, MCF-7 
and MDA-MB-231 cells. Cells treated with the vehicle (DMSO) alone had a fold increase in 
numbers of viable cells ranging between 1.5 and 2.5 (HT-29, MCF-7 and MDA-MB-231) or 5.5 
and 6.5 (Caco-2). This was reduced to only a 0.5 fold increase (HT-29, MCF-7 and MDA-MB- 
231) or 2-fold increase (Caco-2) in cells that were treated with 50pg/ml oil for 48 hours. Significant 
decreases in the number of cells after 24 and 48 hours of treatment with DCOE, compared to time 
zero were observed in all of the cell lines tested (p < 0.05).
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Figure 5.2. Effect of DCOE on cell viability of breast cancer cells. MCF-7 cells (A) and MDA-MB-231 cells (B) 
were left untreated (black circles, white bars), treated with DMSO (black squares, light gray bars), treated with 
10mg/ml DCOE (white triangles, dotted bars), 25mg/ml DCOE (black triangles, dark gray bars) or with 50mg/ml 
DCOE (crosses, black bars) for 24 or 48 hours. The cells were then stained with Trypan blue and live (clear) cells 
counted. Data are presented as fold increase from cells at time zero. Data are the mean ± SEM from 3 experiments. 
** denotes p < 0.01 compared with DMSO group as measured by one-way ANOVA.
Conversely significant increases in cell death after treatment with the extract were observed (Figure 
5.3). The percentage of dead HT-29, Caco-2, MCF-7 and MDA-MB-231 cells increased as the 
concentration of DCOE increased (Figure 5.3 A, B, C and D respectively). The levels of dead cells 
were the highest for all the cell lines at an oil concentration of 50pg/ml. In HT-29, MCF-7, and 
MDA-MB-231 cells, the dead cells percentages varied between 70 and 80%, while the percentage 
of dead Caco-2 cells was 44% for the same oil concentration (50pg/ml) after 48 hours of treatment. 
Lower concentrations of DCOE (10 and 25pg/ml) showed lower effects on cell death in all four 
cell lines.
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Figure 5.3. Effect of DCOE on cell death of colon and breast cancer cells. HT-29 cells (A.), Caco-2 cells (B.), 
MCF-7 cells (C.) and MDA-MB-231 cells (D.) were left untreated (white bars), treated with DMSO (light gray bars), 
treated with 10mg/ml DCOE (dotted bars), 25mg/ml DCOE (dark gray bars) or with 50mg/ml DCOE (black bars) for 
24 or 48 hours. The cells were then combined with Trypan blue and dead (stained) cells counted. Data are presented 
as percentage dead cells to total number of cells. Data are the mean ± SEM from 3 experiments ** denotes p < 0.01 
compared with the group treated with DMSO as measured by one-way ANOVA.
In order to elucidate whether DCOE and fractions exerted a specific effect on cell growth, we 
treated cells with DCOE or fractions at 10, 25, 50 and 100pg/ml for 48 hours and looked for anti­
proliferative effects using the WST-1 proliferation assay as described in Chapter 2 (section 2.17). 
As shown in Figure 5.4, the oil induced a concentration-dependent inhibitory effect on cell 
proliferation in all cell lines and at all concentrations tested after 48 hours of incubation. 
Concentrations of 50 and 100pg/ml DCOE exhibited significant anti-proliferative effects (p < 0.05 
and p < 0.01 respectively). The ICso values of the extract were 34,27, 33, and 30pg/ml for HT-29, 
MDA-MB-231, MCF-7 and Caco-2 cell lines, respectively.
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Figure 5.4. Effect of DCOE on cell proliferation of breast and colon cancer cells. HT-29 cells (A.), Caco-2 cells 
(B.), MCF-7 cells (C.) and MDA-MB-231 cells (D.) were treated with DCOE at 10,25, 50, and 100pg/ml for 48 hours. 
Inhibition of cell survival was assessed using the WST-1 assay. Data are expressed as % survival of cells relative to 
the control. Etoposide was used as a positive control and exhibited an IC50 < 5pg/ml against the four cell lines tested. 
Data are the mean ± SEM from three experiments. * denotes p < 0.05 and ** denotes p < 0.01 vs. DMSO group as 
measured by one-way ANOVA.
To evaluate the effect of the DCOE fractions on cell growth, the four cancer cell lines were treated 
with different concentrations (10 -lOOjag/ml) of all fractions (FI, F2, F3, and F4) for 48 hours 
(Figures 5.5 and 5.6). Treatment of all cell lines with the different fractions appeared to be dose- 
dependent with maximum inhibition of cell proliferation at the higher concentrations (50 and 
lOOpg/ml). As shown in Figure 5.5, MCF-7 cells showed the least responsiveness to the oil 
fractions when compared to its more malignant counterpart the MDA-MB-231 cell line (Tze- 
Chenhsieh et al., 1999).
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Figure 5.5. Effect of DCOE fractions on cell proliferation breast cancer cells. MDA-MB-231 cells (A) and MCF- 
7 (B) cells were treated with oil fractions (FI, F2, F3, and F4) at concentrations of 10, 25, 50, and 100pg/ml for 48 
hours. Inhibition of cell proliferation was assessed using the WST-1 assay. The IC50 values of FI, F2, F3, and F4 
fractions for MDA-MB-231 were 17, 11, 27, and 23pg/ml and for MCF-7 were 22, 32, 48 and 43pg/ml respectively. 
Data are expressed as % survival of cells relative to the control. Data are the mean ± SEM from 3 experiments. ** 
denotes P < 0.01 vs. DMSO group as measured by one-way ANOVA.
The FI and F2 fractions exhibited the greatest inhibition of cell proliferation and at a 
concentration of 25 pg/ml, more than 50% inhibition of proliferation in both cell lines (up to 80% 
inhibition in some cases) was observed. As shown in Table 5.1, the IC50 values of the four oil 
fractions FI, F2, F3, and F4 for MCF-7 were 22, 32,48 and 43pg/ml and for MDA-MB-231 were 
17,11,27, and 23pg/ml respectively. The oil fractions also significantly inhibited the proliferation 
of HT-29 cells (Figure 5.6A) and that of Caco-2 cells (Figure 5.6B) in a dose-dependent manner.
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Figure 5.6. Effect of DCOE fractions on cell proliferation of colon cancer cells. HT-29 (A) and Caco-2 (B) cell 
lines were treated with oil fractions (FI, F2, F3, and F4) at concentrations of 10, 25, 50, and lOOpg/ml for 48 hours. 
Inhibition of cell proliferation was assessed using the WST-1 assay. Data are expressed as % survival of cells relative 
to the control. The IC50 values of FI, F2, F3, and F4 fractions for HT-29 were 22, 17.5, 34 and 40pg/ml and for Caco- 
2 were 19, 19, 37, and 39pg/ml respectively. Data are the mean ± SEM from 3 experiments. * denotes P < 0.05 and ** 
denotes P < 0.01 vs. DMSO group as measured by one-way ANOVA.
The IC50 values of the four oil fractions FI, F2, F3, and F4 for HT- 29 were 22, 17.5, 34 and 
40jig/ml and for Caco-2 were 19, 19, 37, and 39jig/ml respectively (Table 5.1). Furthermore, the 
decrease of survival induced by FI and F2 was significantly greater than the decrease induced by 
F3 and F4 at 25pg/ml (P < 0.05). As a result, these data indicated that the pentane fraction (FI) and 
pentane/diethyl fraction (F2) showed the highest cytotoxicity against both cell lines with the lowest 
IC50 (p < 0.05).
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Table 5.1 .The IC50 ((ig/ml) of DCOE fractions against different human tumourigenic and non-tumourigenic cell lines.
Fractions Cell line
MDA-MB-231 MCF-7 HT-29 Caco-2 HaCat-A5 HaCat-II HaCat-N
FI 17 ± 0.20*'' 22 ± 0.57a’2’3 22 ± 1.12a’3 19 ± 0.60a’3>4 26 ± 0.5 8a’5 26 ± 0.90a-5 34 ± 0.58a>6
F2 11 ±0.16b'1 32 ± 0.65b’2 17 ± 0.73b’3 19 ± 0.55a’3 32 ± 0.76b-2*4 24 ± 0.67a’5 37 ± 0.60a’6
F3 27 ± 0.58e'1 48 ± 0.63e"2 34 ±  0.53e-3 37 ± 0.60b’3’4 38 ± 0.98c’4 39 ± 0.62b’4 50 ± 0.75b’2
F4 23 ± 0.75d-1 43 ± 0.67^ 40 ± O.SO42’3 39 ± 0.52b’3’4 36 ± 0.96c’4’5 34 ± 0.58c'5 45 ± 1.1 Ie’2’6
Values are the mean ± SEM from three experiments. Values in a column not sharing a common superscript letter are 
significantly different (p < 0.05) and values in a row not sharing a common superscript number are significantly 
different (p < 0.05) as measured by one-way ANOVA.
The anti-proliferative effect of the four fractions on the three types of tumourigenic and non- 
tumourigenic HaCaT skin cell lines also showed a dose-dependent inhibition where FI and F2 
fractions demonstrated the strongest (p < 0.05) effect compared to F3 and F4 fractions (Figures 5.7, 
5.8 and 5.9).
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Figure 5.7. Effect of DCOE fractions on cell proliferation on HaCaT (non-tumourigenic). Fl-fraction (A), Ef­
fraction (B), F3-fraction (C), F4-fraction (D) at concentrations of 10, 25, 50, and lOOjig/ml for 48 hours. Inhibition of 
cell proliferation was assessed using the WST-1 assay. The IC50 values of FI, F2, F3, and F4 fractions were 34, 37, 50 
and 45p.g/ml respectively. Etoposide was used as a positive control and exhibited an IC50 = 12pg/ml. Data are expressed 
as % survival of cells in relation to the control. Data are the mean ± SEM from 3 experiments. * denotes P < 0.05 vs. 
DMSO group as measured by one-way ANOVA.
The non-tumourigenic HaCat cell line was most resistant to cytotoxicity than the other two 
malignant counterparts (p < 0.05). Treatment with lOpg/ml of either fraction produced a slight 
decrease in cell survival (< 10%) in these cells (Figure 5.7). Whereas, a significant (p < 0.05) 
reduction in percent survival (> 30%) in HaCat-A5 (non-invasive) (Figure 5.8) and HaCat-II4 
(invasive) cells (Figure 5.9) was observed. Moreover, treatment with 50pg/ml of either fraction 
reduced cell survival to more than 50% in non-tumourigenic cells (up to 80% inhibition with F2 
fraction).
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Figure 5.8. Effect of DCOE fractions on cell proliferation on HaCaT-A5 (non-invasive). Fl-fraction (A), F2- 
fraction (B), F3-fraction (C), F4-fraction (D) at concentrations of 10, 25, 50, and lOOpg/ml for 48 hours. Inhibition of 
cell proliferation was assessed using the WST-1 assay. The IC50 values of FI, F2, F3, and F4 fractions were 26, 32, 38 
and 36pg/ml respectively. Etoposide was used as a positive control and exhibited an IC50 = 7pg/ml. Data are expressed 
as % survival of cells in relation to the control. Data are the mean ± SEM from 3 experiments. * denotes P < 0.05 vs. 
DMSO group as measured by one-way ANOVA.
However, the same concentration with either fraction produced more than 90% inhibition in both 
tumourigenic cells (Figure 5.8 and 5.9). The IC50 values of FI, F2, F3, and F4 fractions in non- 
tumourigenic HaCat cells were 34, 37, 50 and 45pg/ml respectively which were significantly (p < 
0.05) higher than that of HaCat-A5 (non-invasive) cells with IC50 values o f26,32,38 and 36pg/ml 
respectively and of HaCat-II4 (invasive) cells with IC50 values of 26, 24, 39 and 34pg/ml
respectively (Table 5.1). The latter cells were found to be the most sensitive to treatment and 
produced the strongest growth inhibition (p < 0.05).
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Figure 5.9. Effect of DCOE fractions on cell proliferation on HaCaT-II4 (invasive). F1 -fraction (A), F2-fraction 
(B), F3-fraction (C), F4-fraction (D) at concentrations of 10, 25, 50, and lOOpg/ml for 48 hours. Inhibition of cell 
proliferation was assessed using the WST-1 assay. The IC50 values of FI, F2, F3, and F4 fractions were 26, 24, 39 and 
34pg/ml respectively. Etoposide was used as a positive control and exhibited an IC50 = 8pg/ml. Data are expressed as 
% survival of cells in relation to the control. Data are the mean ± SEM from 3 experiments. * denotes P <0.05 vs. 
DMSO group as measured by one-way ANOVA.
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5.2.2 Effect of FI and F2 fractions on cell cycle progression and induction of apoptosis
To determine whether inhibition of cell proliferation by the most potent fractions (p < 0.05) 
of DCOE (FI and F2) on human breast cancer cells MDA-MB-231 and human colon cancer cells 
HT-29 was due to cell cycle arrest, we performed flow cytometric analyses of propidium iodide 
(PI) staining as described in Chapter 2 (section 2.19). As shown in Figure 5.10, treatment of MDA- 
MB-231 cells with FI and F2 (25 and 50pg/ml) for 48 hours resulted in a significant increase of 
cells in the sub-Gl phase compared to the control and DMSO treated groups (p < 0.01). This 
increase in cells with hypodiploid nuclei, indicated that both fractions may have caused DNA 
fragmentation which is a characteristic of late apoptosis. This increase was coupled with 
significantly fewer cells in the G1, S and G2/M phases (p < 0.05 and p < 0.01).
A similar trend was observed in HT-29 cells treated with either fraction (Figure 5.11) where 
important increase (p < 0.01) in cell population was observed in the Sub- G1 phase compared to 
the control and DMSO treated groups with a subsequent decrease in the S and G2/M phases. Thus, 
it appears that both fractions were capable of inhibiting proliferation by promoting cell cycle arrest 
in both cell lines at the sub-Gl phase which is an indication of apoptosis.
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Figure 5.10. Effect of FI and F2 fractions on the cell cycle distribution in MDA-MB-231 cells. (A) Cells were 
treated with 25 and 50|rg/ml of FI or F2 fractions and control cells were treated with 0.5% DMSO for 48 hours, after 
which cells were stained with PI and analyzed for DNA content by flow cytometry. The sub-Cl peak is considered as 
the apoptotic portion. The results shown are representative of 3 independent experiments. (B) Bar graph shows the cell 
distributions of each phase of the cell cycle. Data are means ± SEM of three independent experiments. * denotes P < 
0.05 and ** denotes P < 0.01 vs. DMSO group as measured by one-way ANOVA.
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Figure 5.11. Effect of FI and F2 fractions on the cell cycle distribution in HT-29 cells. (A) Cells were treated with 
25 and 50jig/ml of FI or F2 fractions and control cells were treated with 0.5% DMSO for 48 hours, after which cells 
were stained with PI and analyzed for DNA content by flow cytometry. The sub-Cl peak is considered as the apoptotic 
portion. The results shown are representative of 3 independent experiments. (B) Bar graph shows the cell distributions 
of each phase of the cell cycle. Data are means ± SEM of three independent experiments. * denotes P < 0.05 and ** 
denotes P < 0.01 vs. DMSO group as measured by one-way ANOVA.
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To further investigate whether apoptosis had been induced in these cells, an annexin V-FITC 
staining assay as described in Chapter 2 (section 2. 20) was performed on both MDA-MB-231 and 
HT-29 cells treated with FI and F2 fractions. As shown in Figure 5.12, treatment of MDA-MB- 
23 1 cells with 25 pg/ml of either fractions showed an increasing trend in both the early and late 
apoptotic cell populations. However, a significant increase in the late apoptotic cell population was 
observed after treatment with 50pg/ml of FI or F2 (p < 0.05)
HT-29 cells were less sensitive to induction of apoptosis by FI and F2 than MDA-MB-231 cells. 
As shown in Figure 5.13, there was no significant increase in the early apoptotic cell population 
when treated with 25pg/ml of F lor F2, whereas treatment with 50pg/ml showed a statistically 
significant increase in the late apoptotic cell population but less effective compared to the results 
of MDA cells (p < 0.05)
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Figure 5.12. Apoptotic effect of FI and F2 treatment on MDA-MB-231 cells. (A) Flow cytometric analysis of 
Annexin V-FITC and propidium iodide (PI) quantifying the F1 and F2-induced apoptosis in MDA-MB-231. Dot plots 
of MDA-MB-231 cells treated with 25 and 50pg/ml of FI or F2 fractions and cells treated with 0.5% DMSO for 48 
hours. Viable cells are in the lower left region (negative for both annexin V-FITC and PI). Early apoptotic cells are 
located in the lower right region (annexin V-FITC positive). Late apoptotic cells demonstrating extensive cellular and 
nuclear membrane damage are locate in the upper right region (double positive). Necrotic cells with destroyed cell 
membrane are in the upper left region (PI positive). The results shown are representative of 3 independent experiments. 
(B) Bar graphs showing the percentages of early and late apoptotic of non-treated and treated MDA-MB-231 cells. 
Data are means ± SEM of three independent experiments. * denotes P < 0.05 vs. DMSO group as measured by one­
way ANOVA.
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Figure 5.13. Apoptotic effect of FI and F2 treatment on HT-29 cells. (A) Flow cytometric analysis of Annexin V- 
FITC and propidium iodide (PI) quantifying the FI and F2-induced apoptosis in HT-29 cells. Dot plots of HT-29 cells 
treated with 25 and 50pg/ml of FI or F2 fractions and cells treated with 0.5% DMSO for 48 hours. Viable cells are in 
the lower left region (negative for both annexin V-FITC and PI). Early apoptotic cells are located in the lower right 
region (annexin V-FITC positive). Late apoptotic cells demonstrating extensive cellular and nuclear membrane damage 
are locate in the upper right region (double positive). Necrotic cells with destroyed cell membrane are in the upper left 
region (PI positive). The results shown are representative of 3 independent experiments. (B) Bar graphs showing the 
percentages of early and late apoptotic of non-treated and treated HT-29 cells. Data are means ± SEM of three 
independent experiments. * denotes P < 0.05 vs. DMSO group as measured by one-way ANOVA.
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Treatment with either fractions at 25 jag/ml was observed to cause condensation of chromatin in 
MDA-MB-231 cell (Figure 5.14A) and HT-29 cell (Figure 5.15) nuclei as visualized by DAPI stain 
and confocal microscopy. Furthermore, annexin staining of MDA-MB-231 cells (Figure 5.14B), 
showed that treatment with either fractions induced phosphatidylserine (PS) translocation in the 
cell membrane which is indicative of apoptosis followed by membrane leakage (late apoptotic cell).
DMSO 25 FI 25 F2
DMSO 25 FI 25 F2
Figure 5.14. Apoptotic morphological changes of MDA-MB-231 cells treated with FI or F2 fractions. Fluorescent 
micrographs of control (DMSO) and MDA-MB-231 cells treated with 25 jag/ml of FI or F2 fractions for 48 hours and 
stained with DAPI (A) or Annexin (B) and examined by fluorescence microscopy. Arrows in A indicate apoptotic 
bodies of nuclear fragmentation. Scale bar is 10pm.
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Figure 5.15. Apoptotic morphological changes of HT-29 cells treated with FI or F2 fractions. Fluorescent 
micrographs of control (DMSO) and cells treated with 25pg/ml of FI or F2 fractions for 48 hours and stained with 
DAPI and examined by fluorescence microscopy. Arrows indicate apoptotic bodies of nuclear fragmentation. Scale 
bar is 1 Opm.
5.2.3 Effect of FI and F2 fractions on the expression of apoptosis related proteins in MDA- 
MB-231 and HT-29 cells.
To explore the mechanism by which FI and F2 induced apoptosis, the expression levels of various
pro-apoptotic and anti-apoptotic proteins was evaluated by western blot analysis as described in
Chapter 2 (section 2.21 and 2.22). Total cell lysates of control (DMSO treated) and FI and F2
treated MDA-MB-231 and HT-29 cells were analyzed to detect the expression of Poly ADP ribose
polymerase (PARP), caspase -3, Bel-2, Bcl-2-associated protein (Bax), and p53 in relation to actin
by western blotting. Treatment of MDA-MB-231 cells (Figure 5.16) and HT-29 cells (Figure 5.17)
with 25 and 50pg/ml F lor F2 caused a significant decrease in the relative level of caspase-3
(inactive procaspase-3) to actin (p < 0.05). Similarly, in response to treatment, the relative level of
the 116-kDa PARP (in relation to actin) also decreased and the level of the cleaved 85-kDa
fragment increased in both cell lines. The decrease in the level of procaspase-3 indicates that it was
cleaved to an activated protease which in turn triggered proteolytic cleavage and inactivation of
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PARP. Furthermore, the results of the western blot analysis showed that the level of the anti- 
apoptotic protein Bcl-2 significantly declined in both cell lines after treatment with 25 and 50pg/ml 
of Flor F2 (p < 0.05 and p < 0.01 respectively), whereas the level of pro-apoptotic protein BAX 
was significantly increased (p < 0.05 and p < 0.01 respectively). The relative expression of p53 
protein was also assessed by western blot analysis and showed a marked increase in F 1 and F2 
treated MDA-MB-231 and HT-29 cells (p < 0.05 and p <0.01) as shown in Figures 5.16 and 5.17 
indicating the activation of p53.
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Figure 5.16. Western blot analysis of apoptosis related proteins in MDA-MB-231 cells. (A) Effect of FI and F2
fractions on the expression level of PARP, p53, procaspase-3, Bcl-2, and Bcl2-associated X (BAX) proteins. Expression 
of (3-actin was used as an internal control. MDA-MB-231 cells were treated with 25 and 50pg/ml of FI or F2 fractions 
and control cells were treated with 0.5% DMSO for 48 hours. Western blots are representative of three independent 
experiments. (B) The densitometer-intensity data of the proteins of each blot is presented as mean ± SEM from three 
independent experiments.* denote P < 0.05 and ** denotes P < 0.01 vs. control (0.5% DMSO) as measured by one-way 
ANOVA.
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Figure 5.17. Western blot analysis of apoptosis related proteins in H T -29 cells. (A) Effect of FI and F2 fractions 
on the expression level of PARP, p53, procaspase-3, Bcl-2, and Bcl-2-associated X (BAX) proteins. Expression of |3- 
actin was used as an internal control. HT-29 cells were treated with 25 and 50pg/ml and control cells were treated with 
0.5% DMSO for 48 hours. Western blots are representative of three independent experiments. (B) The densitometer- 
intensity data of the proteins of each blot is presented as mean ± SEM from three independent experiments. * denotes 
P < 0.05 and ** denotes P < 0.01 vs. control (0.5% DMSO) as measured by one-way ANOVA.
5.2.4 Effect of FI and F2 fractions on PI3K-Akt and MAP kinase pathways in MDA-MB- 
231 and HT-29 cells.
The phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway is known to regulate several
cellular functions such as transcription, translation, proliferation, growth, and survival. Activation
of Akt induces cell proliferation and survival (Vivanco and Sawyers, 2002). PI3K activation,
1 3 3
therefore, was measured using western blot analysis to look for the relative expression of 
phosphorylated Akt (p-Akt) in relation to non-phosphorylated Akt (Akt) in MDA-MB-231 and HT- 
29 treated cell lysates.
Upon treatment of MDA-MB-231 cells with FI or F2 fractions, no significant change in the 
relative level of phosphorylated Akt was observed in comparison with the control (DMSO-treated) 
cells (Figure 5.18). In contrast, the relative level of phosphorylated Akt significantly decreased 
after treatment of HT-29 cells with increasing concentrations of either fraction (p < 0.05 and p < 
0.01 respectively) (Figure 5.19).
On the other hand, to explore another possible pathway by which FI and F2 fractions induced 
apoptosis in both cancer cell lines, we determined if the MAP kinase pathway was inhibited in 
MDA-MB-231 and HT-29 treated cells. This was accomplished by using antibodies against both 
total and phosphorylated Erk. Upon analysis using western blots, a significant decrease in the 
relative level of p-Erk was observed following treatment of MDA-MB-231 cells with FI or F2 
fractions in comparison with the control (DMSO) treated cells (p < 0.05 and p < 0.01 respectively) 
(Figure 5.18).
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Figure 5.18. Western blot analysis of PI3K/Akt and MAPK/Erk pathways in MDA-MB-231 cells. (A) Effect of FI 
and F2 fractions on the expression level of Akt, p-Akt, Erk, p-Erk proteins. MDA-MB-231 cells were treated with 25 
and 50pg/ml of FI or F2-fractions and control cells treated with 0.5% DMSO for 48 hours. Western blots were 
representative of three independent experiments. (B) The densitometer-intensity data of the proteins of each blot is 
presented as mean ± SEM from three independent experiments. * denotes P < 0.05 and ** denotes P < 0.01 vs. control 
(0.5% DMSO) as measured by one-way ANOVA.
Similarly, FI or F2 treatment of HT-29 cells resulted in significantly lower levels of phosphorylated 
Erk in comparison to total Erk in the cell lysates (p < 0.05 and p < 0.01 respectively) (Figure 5.19). 
These data suggested that apoptosis in HT-29 cells is mediated via both the PBK/Akt and the 
MAPK/Erk pathways, whereas it is only mediated through PI3K/Akt pathway in MDA-MB- 
231 cells.
135
A. B. 1.0
Fl-fraction F2-fraction  
Conc.|ng/ml) Ctrl 25 50 Ctrl 25 50
Akt
p-Akt
Erk
p-Erk
<  0.6 -
<  0.4 -
O rl Fl-25 Fl-SO Ctrl F2-2S F2-S0
Ctrl F I 25 FI SO Ctrl F2 25 F2 50
Figure 5.19. Western blot analysis of PI3K/Akt and MAPK/Erk pathways in HT-29 cells. (A) Effect of FI and F2
fractions of DCOE on the expression Akt, p-Akt, Erk, p-Erk proteins. HT-29 cells were treated with 25 and 50pg/ml of 
FI or F2-fractions and control cells treated with 0.5% DMSO for 48 hours. Western blots were representative of three 
independent experiments. (B) The densitometer-intensity data of the proteins of each blot is presented as mean ± SEM 
from three independent experiments. * denotes P < 0.05 and ** denotes P < 0.01 vs. control (0.5% DMSO) as measured 
by one-way ANOVA.
Since neither the FI nor the F2 fraction inhibited the phosphorylation of Akt in MDA-MB-231 
cells, we investigated whether the combined treatment of each fraction with wortmannin, a 
selective PI3K inhibitor, would have an additive effect on the inhibition of cell proliferation. 
Western blot analysis of cell lysate of MDA-MB-231 (Figure 5.20) and HT-29 (Figure 5.21) cells 
treated with 1 pM wortmannin for 24 hours in the presence or absence of either fraction revealed 
that the drug down regulated Akt phosphorylation. Furthermore, a WST-1 cell survival assay was 
carried out to investigate the effect of the combination of wortmannin and FI or F2 treatment on 
cell survival. The results showed that there was a significant decrease in cell survival of the MDA-
136
MB-231 cells treated with 25jag/ml of the FI or F2 with wortmannin (l|iM ) compared to the 
treatment of the cells with each fraction alone (p < 0.05 and p < 0.05) (Figure 5.20B). Conversely, 
the WST-1 survival assay results of the HT-29 cells showed no significant decrease in cell survival 
upon treatment with 25pg/ml of FI or F2 with wortmannin (IpM) compared to cells treated with 
either fraction alone (p > 0.05 and p > 0.05) (Figure 5.21B).
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Figure 5.20. Effect of the combined treatment of FI or F2 with w ortmannin on MDA-MB-231 cells. (A) Cells 
were treated with 25 or 50 tig/ml of FI or F2 or DMSO for 48 in the presence or absence of IpM wortmannin for 24 
h. Cells were lysed and blotted for Akt and pAkt. (B) Effect of FI and F2 fractions on MDA-MB-231 cell survival at 
concentrations of 25 or 50pg/ml for 48 hours in the presence or absence IpM wortmannin. Inhibition of cell survival 
was assessed using the WST-1 assay. Data are expressed as % survival of cells. Data denote mean ± SEM from three 
independent experiments. * denotes P < 0.05 vs. control (0.5% DMSO) and ** denotes P < 0.05 vs. Fl-25 or to F2-25 
groups as measured by one-way ANOVA.
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Figure 5.21. Effect of the combined treatment of FI or F2 with wortmannin on HT-29 cells. (A) Cells were treated 
with 25 or 50 jag/ml of FI or F2 or DMSO for 48 in the presence or absence of IpM wortmannin for 24 h. Cells were 
lysed and blotted for Akt and pAkt. (B) Effect of FI and F2 fractions on HT-29 cell survival at concentrations of 25 or 
50pg/ml for 48 hours in the presence or absence IpM wortmannin. Inhibition of cell survival was assessed using the 
WST-1 assay. Data are expressed as % survival of cells. Data denote mean ± SEM from three independent 
experiments.* denotes P < 0.05 versus control (0.5% DMSO) and means followed by different letters are significantly 
different (P < 0.05) as measured by one-way ANOVA.
5.2.5 Effect of the F2 fraction of DCOE on tumour promotion in mice
Previous studies in our group have shown significant antitumour activities of DCOE against 
DMBA-induced skin cancer (Abu Zeinab et al, 2011). Since all the major components of F2 
fraction of DCOE were identified (mainly 2-himachalene-b-ol constituting more than 60%) and 
have demonstrated potent in vitro anticancer activity and since there are no previous reports 
concerning the in vivo anticancer activity of this compound, it was essential to evaluate the
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chemopreventive effect F2 fraction in DMBA/TPA-induced mouse skin carcinogenesis. As 
described in Chapter 2 (section 2.23), DMBA/TPA induced mice treated with various 10, 50 or 
200mg/Kg of F2 were monitored for 21 weeks to study its effectiveness against papilloma 
incidence, yield, and volume.
The percentage of papilloma incidence (mice with papillomas) and the average number of 
papillomas per mouse are presented in Figures 5.22 and 5.23 respectively. As demonstrated in 
Figure 5.22, papilloma incidence in the control (DMSO) group as well as the treated groups was 
recorded as early as week 6. This increased rapidly reaching 100% at week 10 for the control group. 
In the treated groups, papilloma incidence reached 90% at week 13 for the all treated groups.
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Figure 5.22. Effect of intraperitoneal injections of F2-fraction on papilloma incidence in DMBA/TPA-induced 
mouse skin carcinogenesis. Initiation was accomplished with a single topical application of 190 nmol of DMBA. 
For papilloma promotion, 8 nmol TP A in 0.2 ml acetone was applied twice a week after initiation until 21 weeks on 
the dorsal surface of BALB/c mice. Intraperitoneal injections of F2-fraction with three doses 10, 50, and 200mg/kg 
were performed 30 minutes prior to the application of TPA. The number of mice with papilloma was observed weekly. 
Data are expressed as the percentage of mice bearing papillomas with time (weeks). Each group included 10 mice.
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As shown in Tables 5.2, 5.3, and 5.4, the percentage of papilloma incidence in the control group 
was still 100% at weeks 15, 18, and 21, whereas in the F2-treated groups (10, 50, and 200mg/kg) 
the papilloma incidence had significantly decreased. The inhibition of papilloma incidence was the 
highest (50%) in the 200mg/kg treated group at the end of the experiment (week 21) (Table 5.4).
Table 5.2. The inhibitory effects of different concentrations of F2-fraction on the promotion of mouse skin
papilloma at week 15
Papilloma Yield Papilloma Incidence
Treatments B/o Survival Weeks of 
1st PAPS
PAPS/ Mouse % Inhibition % Mice with 
PAPS
% Inhibition
Control (DMSO) 100 6 14.7 ±  0.55 0 100 0
10 mg/Kg 100 6 12.5 ± 0.34* 15 90 10
50 mg/Kg 100 7 122 ± 0.33* 17 80 20
200 mg/Kg 100 7 9.1 ±  0.46* 38 SO 20
Values are mean = SEM. n=10.* denotes P<0.05 and **denotes P<0.01 vs control as measured by one-way ANOVA.
With respect to papilloma yield, treatment with the F2-fraction also decreased the number of 
papillomas per mouse in a dose-dependent manner (Figure 5.23). At week 15, treatment with F2 at 
doses 10, 50, and 200mg/kg inhibited papilloma yield by 15, 17, and 38% respectively (Table 5.2). 
At week 18, three weeks before the end of the experiment, the inhibition was 13, 20, and 35% at 
the three respective doses (Table 5.3). At the end of the experiment (week 21) the effect of the three 
doses on inhibition of papilloma yield was modified to 18,28, 42%, respectively (Table 5.4).
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I  able 5.3, The inhibitory effects of different concentrations of F2-fraction on die promotion of mouse skin papilloma
at week IS.
Papilloma Yield Papilloma Incidence
Treatments % Survival Weeks of 
P: PAPS
PAPS/ Mouse % Inhibition % Mice with 
PAPS
% Inhibition
Control (DMSO) 100 6 13.6 ± 0.30 0 100 0
10 mg/Kg 100 6 11.9 ±0.32* 13 so 20
50 mg/Kg 100 10.9 ±  0.35** 20 60 40
200 mg/Kg 100 7 S.S ±0.44** 35 60 40
Values are mean = SEM. n=10. * denotes P < 0.05 and ** denotes P < 0.01 vs control as measured by one-way ANOVA.
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Figure 5.23. The effect of intraperitoneal injections of F2-fraction on the number of papilloma per mouse in 
DMBA/TPA-induced mouse skin carcinogenesis. Initiation was accomplished with a single topical application of 
190nmol of DMBA. For papilloma promotion, Snmol TPA in 0.2ml acetone was applied twice a week after initiation 
until 21 weeks on the dorsal surface of BALB/c mice. Intraperitoneal injections of F2-fraction with three doses 10, 
50, and 200mg/kg were perfonued 30 minutes prior to the application of TPA. The number of mice with papilloma 
was observed weekly. Data are expressed as the percentage of mice bearing papillomas with time (weeks). Each 
group included 10 mice.
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Table 5.4. The inhibitory effects of different concentrations of F2-fraction on the promotion of mouse skin papilloma
at week 21
Papilloma Yield Papilloma Incidence
Treatments % Survival Weeks of 
1st PAPS
PAPS/ Mouse % Inhibition Yo Mice with 
PAPS
Yd Inhibition
Control (DMSO) 100 6 13.3 ±  0.29 0 100 0
10 mg/Kg 100 6 10.9 ±  0.52* 18 80 20
50 mg/Kg 100 7 9.6 ±050** 28 60 40
200 mg/Kg 100 7 7.7 ±0.71** 42 50 50
Values are mean = SEM n=10.* denotes P < 0.05 and **denotes P < 0.01 vj control as measured by one-way ANOVA
The effect of the F2 fraction on the volume of the papillomas was also studied (Figure 5.24). 
Treatment of mice with F2 at doses of 10, 50, and 200mg/Kg significantly decreased the papilloma 
volume at weeks 15, 18 and 21 (p < 0.05, p < 0.01 and p < 0.01 respectively). As shown in Table 
5.5, the average volume size of the papillomas of control group obtained at week 15 was 83.5 mm3; 
at this same stage, F2 treatment with the three doses showed significant inhibition of papilloma 
volume by 28.5,46.3, and 58.8 %, respectively. Comparable results were obtained at week 18 and 
at the end of the experiment (week 21) (Table 5.4).
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Figure 5.24. Effect of F2 treatment on papilloma volume of mice. Average variations in papilloma volume (mm3) 
of all groups (10, 50, and 200mg/kg) measured at weeks 15,18, and 21. Bars represent mean papilloma volume ± SEM 
from groups of 10 mice. * denotes P < 0.05 and ** denotes P < 0.01 compared to control (DMSO) mice as measured 
by one-way ANOVA.
Table 5.5. The inhibitory effects of different concentrations o f F2-fraction at different concentrations on the volume 
of papilloma (mm3) at weeks 15,18.21.
Treatments
WeeklS WeeklS WeekZl
Tumor Volume %Inhibition T uznoi Volume
%
Inhibition Tumor Volume
%
Inhibition
Control (DMSO) 535 ± 6.0 0 1055 ± 5.0 0 133.3 ± 6.8 0
10 mg/Kg 59.7 ± 55* 28.5 85.5 ± 4.2* 18.8 116.0 ± 3.6* 13.0
50 mg/Kg 44.8 ± 5.7** 46.3 60.6 ± 2.8** 42.5 82.9 ±  3.8** 37.8
200 mg/Kg 34.4 ± 4.2** 58.8 40.0 ± 2.7** 62.0 61.2 ±  3.0** 54.0
Values are mean == SEM. n=l 0. * denotes P<0.0 5 and ** denotes P<0.01 vr control as measured by one-way ANOVA.
The body weight of control (DMSO) and experimental animals in each group is shown in Figure
5.25. Generally, the variations of body weight of mice reflect toxic effects after exposure to the
plant extract (Auletta, 1995). If the body weight loss is greater than 10% of the initial value then it
will be a significant indicator for the adverse effects of the plant extract (Teo et al., 2002). The
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control (DMSO) treated group showed normal body weight gain during the experimental period 
(weeks 5, 13 and 21). Whereas, F2 treatment at the three different dose resulted in a slight loss of 
body weight over the same period of time (< 10%).
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Figure 5.25. Effect of F2 treatment on body weight of mice. Average variations in the body weight of the mice of 
all groups (DMSO, 10, 50,200mg/Kg) measured at weeks 5,13, and 21. Bars represent mean of body weight ± SEM 
from groups of 10 mice. * denotes P < 0.05 compared to week 5 as measured by one-way ANOVA
5.3 Discussion
Natural products play a major role in the treatment of different types of cancers and exert their 
effects through different mechanisms, including cell cycle arrest, induction of apoptosis or 
inhibition of metastasis and tumour angiogenesis (Surh, 2003; Mehta et al., 2010). The potential 
anticancer effects of DCOE and its isolated fractions were tested in several cancer cell lines and in 
a murine model of skin cancer in an attempt to elucidate the active component of Daucus carota.
□ weeks
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Using the Trypan blue exclusion method, it was demonstrated in this chapter that treatment 
with DCOE had a significant effect on the viability of the colon cancer cell lines: HT-29 and Caco- 
2 and the breast cancer cell lines: MCF-7 and MDA-MB-231 over a 48 hour period. Furthermore, 
treatment of DCOE fractions on the skin cancer cell lines: the invasive HaCaT-114 and non-invasive 
HaCaT-A5 as well as the non-tumourigenic HaCaT cells resulted in significant decrease in viability 
over the same time period both in terms of % increase in viable cells and % cell death.
The present study also demonstrated that DCOE and its fractions had significant dose- 
dependent anti-proliferative effects on all the cell lines tested, with FI and F2 being the most potent. 
These anticancer activities might be attributed to the major components present in the oil fractions. 
For example, a-humulene and p-caryophyllene (major sesquiterpenes of FI) present in the essential 
oil of the plant Casearia sylvestris have been reported to exhibit cytotoxic activity against HeLa 
cell lines (human cervical carcinoma), A-549 (human lung carcinoma), HT-29 (human colon 
adenocarcinoma) (Silva et al., 2008). In another study, a-humulene and p-caryophyllene of Salvia 
officinalis essential oil were also shown to exhibit potent inhibitory effect against human breast 
cancer MCF-7 and human colon cancer HCT-116 (El Hadri et al., 2010). Oil extracts of various 
plants rich in a-humulene demonstrated antitumour activity against several cancer cell lines 
including colon (MCF-7), prostate (PC-3), lung (A-549), and cervical (Hela) (Legault et al., 2003; 
Hou et al., 2007). Other reports also indicated that p-caryophyllene of essential oil was found to be 
very active against lung carcinoma cell line A-549 and human colon adenocarcinoma cell line, 
DLD-1 (Sylvestre et al., 2005; Sylvestre et al., 2006).
Similarly, the sesquiterpene y5-selinene and the phenylpropanoids, (E)-methylisoeugenol and
elemicin, identified in F2 fraction demonstrated anti-proliferative activity and tumouricidal effects
against several human cell lines including cervical (Hela) and uterine (AN3CAy) (Andrea L.
Medina-Holgum, 2008). The anti-proliferative activity of the F2 fraction may be attributed to the
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presence of the major compound which is tentatively identified via GC-MS as 2-himachalene-6-ol. 
To the best of our knowledge, this compound has not been reported in any of the wild carrot species 
around the world and there are no previous studies concerned with its anticancer activity. However, 
widdrol, a structural isomer of 2-himachalen-6-ol, extracted from Juniperus chinensis, has been 
shown to exhibit a potent anti-cancer activity against colon adenocarcinoma cells HT-29 by 
inhibiting their proliferation and inducing cell cycle G1 arrest (Kwon et ah, 2010a). In another 
study, widdrol induced G1 arrest through the induction of Chk2, p53 phosphorylation and CDK 
inhibitor p21 expression as well as inhibition of cyclin E, cyclin-dependent kinase (CDK2) and 
retinoblastoma protein (pRB) (Kwon et ah, 2010b). Targeting the effects of potentially therapeutic 
agents on cell cycle and apoptotic pathways in cancer cells is an important approach for cancer 
treatment and anti-cancer drug development (Hu and Kavanagh, 2003). Therefore, many studies 
have been conducted to isolate and identify compounds that induce cell cycle arrest and apoptosis 
(Kim, 2005). In this study, we found that fractions FI and F2 induced apoptosis in both MDA-MB- 
231 and HT-29 cells, as verified by the formation of apoptotic nuclei that are characterized by 
chromatin condensation and DNA fragmentation. These results were strengthened by the finding 
of an accumulation of cells in the sub-Gl apoptotic phase. The increase in the p53 protein level 
along with the previously mentioned observations suggested that both fractions induced p53- 
dependent apoptosis in these cells. The cell cycle analysis also revealed a decrease in cycling cells 
characterized by accumulation of cells in the sub-Gl phase, which is indicative of cell cycle arrest.
The tumour suppressor p53 plays an important role in response to DNA damage or other 
genomic instability and it is well established that activation of p53 can lead to cell cycle arrest or 
apoptosis (Zhang et al., 2010). Thus, the up-regulation of p53 could explain the observed cell cycle 
arrest and increase in apoptosis observed in HT-29 cells. In contrast, MDA-MB-231 cells are
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characterized by the presence of a mutant form of p53 (Hui et ah, 2006) indicating that cell cycle 
arrest and growth inhibitory effect of FI and F2 fractions are p53-independent.
To gain an understanding of the mechanisms controlling apoptosis induced by treatment of 
cancer cells with the FI and F2 fractions, we examined several components of the apoptotic 
pathways. The proteins of the Bcl-2 family play an essential role in apoptosis and are considered 
as a target for anticancer therapy (Baell and Huang, 2002; Goodsell, 2002). The Bcl-2 protein 
exhibits an anti-apoptotic effect while BAX is a pro-apoptotic protein of the Bcl-2 family (Sedlak 
et ah, 1995; Kluck et ah, 1997). Several studies have indicated that the ratio of Bcl-2 to BAX 
proteins decreases during apoptosis (Salomons et ah, 1997; Elmore, 2007; Marzo and Naval, 2008). 
In this study, a decrease in the expression of Bcl-2 and an increase in the expression of BAX were 
observed after treatment of MDA-MB-231 and HT-29 cells with FI or F2 fractions. Additionally, 
the caspase family of proteins participates in the regulation and execution of apoptosis (Lavrik et 
ah, 2005). Activated caspase-3 plays a crucial role in the final step of apoptosis and it is a key 
protease for the cleavage and inactivation of the downstream PARP protein. This nuclear enzyme 
is involved in DNA repair and maintenance of genomic integrity and it has been used as an 
important marker of apoptosis (Herceg and Wang, 2001). The data in this study demonstrated that 
cleavage of caspase 3 and PARP occurred after treatment of both cell lines with FI and F2 which 
is also indicative of apoptosis induction (Mantena et ah, 2006). This is in agreement with previous 
studies which indicated that (3-caryophyllene a major constituent of FI fraction induced a 
significant induction of apoptosis accompanied by enhanced activity of caspase 3 (Amiel et ah, 
2012).
The MAPK/Erk pathway plays an important role in several cellular processes such as cell 
survival, cell proliferation and apoptosis (Lawlor and Alessi, 2001; Yang et ah, 2013). It is reported 
that constitutively activated Erk is responsible for high levels of cell growth in various cancers
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(Dhillon et al., 2007; Yang et al., 2012). On the other hand, down-regulation of Erk activity is 
highly associated with apoptosis (Salminen et ah, 2010). In this study, treatment of MDA-MB-231 
and HT-29 cells with either FI or F2 significantly decreased the phosphorylated Erk in comparison 
to the DMSO treated control cells and total Erk expression. Therefore, induction of apoptosis by 
both fractions may be mediated through the inhibition of the MAPK/Erk pathway. Several 
anticancer natural products induce apoptosis through the inhibition of the MAPK signaling 
pathway (Agarwal et ah, 2000; Roccaro et ah, 2008).
The PI3K/Akt is another important intracellular signaling pathway in regulating cell 
proliferation and apoptosis. The serine/threonine protein kinase Akt is a downstream molecule 
which is involved in the inactivation of several pro-apoptotic proteins and the activation of anti- 
apoptotic proteins. The Akt pathway has an essential role in regulating cell proliferation and 
survival in cancer (Gupta et ah, 2005; Gupta et ah, 2007). Our results revealed that apoptotic 
concentrations of the FI or F2 fractions on MDA-MB-231 cells did not show any significant effect 
on levels of phosphorylated Akt compared to the control. However, a combined treatment with a 
potent PI3K inhibitor (wortmannin) had additive effect on apoptosis potentially through the 
inhibition of both MAPK and PI3K pathways. This shows that wortmannin and oil fractions are 
acting on distinct pathways. In contrast, FI and F2 caused a significant decrease in Akt 
phosphorylation in HT-29 cells reflecting an inhibition of the PI3K/Akt pathway. This is consistent 
with previous report showing that p-caryophyllene oxide, a major component of FI, induces 
apoptosis through the suppression of the PI3K/Akt/mTOR pathway (Park et ah, 2011). 
Furthermore, a combined treatment of FI or F2 with a PI3K inhibitor to HT-29 cells showed no 
increase in the anticancer activity, indicating that the fractions and the PI3K inhibitor exert their 
effect through the same pathway.
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Chemoprevention is another important approach available in controlling the process of 
carcinogenesis and drugs or chemical agents can be used to interfere either at the initiation, 
promotion or progression stage of carcinogenesis. Targeting cancer at the promotion stage can be 
crucial, because in some cases this is a reversible event that requires repeated and long term 
exposure to the promoting agent (DiGiovanni, 1992; Bowden, 2004). In this chapter, we 
investigated the efficacy of the F2 oil fraction administered intraperitoneally on DMBA/TPA- 
induced mouse skin carcinogenesis. The F2 fraction was selected for the in vivo study since it 
possessed (along with the FI fraction which will be considered in future work) the strongest in 
vitro anticancer activity. The percent inhibition of papilloma incidence (mice with papillomas), 
papilloma yield (average number of papillomas per mouse) and tumour volume were significant 
when compared to control (DMSO) group. These results were comparable to previous study 
conducted in our research group where DCOE treatment in mice caused important inhibition for 
the same three main criteria (Zeinab et al., 2011). Since F2 treatment started one week after the 
initiation stage, its chemopreventive and antitumour promoting effects would mainly be at the 
promotion and progression stages. Additionally, the in vivo antitumour effects of F2 were 
consistent with the in vitro results obtained in the invasive and non-invasive HaCaT cell lines which 
are considered counterparts to the human invasive squamous cell carcinoma (papilloma). In fact, 
the F2 fraction exhibited potent anticancer effect in both cancer models. Many natural compounds 
including phenols, flavonoids (polyphenols) and terpenes (diterpenes, triterpenes, sesquiterpenes) 
have been found to inhibit tumour promotion in two-stage carcinogenesis in mouse skin (Hora et 
al., 2003; Banno et al., 2005; Chaudhary et al., 2007) which agrees with our findings. The 
chemopreventive potential of these phytochemicals could be due to their antioxidant capacity, or 
to the augmentation in the activity of antioxidant enzymes such as SOD, CAT and GST.
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In conclusion, it was demonstrated in this chapter that the pentane fraction (FI) and 
pentane/diehtylether fraction (F2) have potent anticancer activity against several human cancer cell 
lines. Both fractions inhibited cell proliferation by inducing cell cycle arrest and apoptosis in the 
MDA-MB-231 human breast cancer cells and in the HT-29 human colon cancer cells. This 
induction of apoptosis was mediated through the inhibition of the MAPK/Erk pathway in the MDA- 
MB-231 cells, whereas it is mediated through both the PI3K/Akt and the MAPK/Erk pathways in 
HT-29 cells. The present study provides evidence that F2 fraction has an inhibitory effect on two- 
stage carcinogenesis on mouse skin and the anti-tumour-promoting activity could be attributed to 
the major sesquiterpene 2-himachalene-6-ol. The results suggest that the wild carrot could be 
considered a potential source for natural anticancer compounds. Future work will focus on isolation 
and characterization of various identified major compounds and will explore the prospective in 
vitro and in vivo anticancer capabilities.
150
CHAPTER 6: IN  VIVO IMMUNOMODULATORY EFFECTS OF DCOE
AND ITS FRACTIONS
6.1 Rationale and Aims
Many natural compounds are known to possess anti-inflammatory or immunomodulatory 
activities potentially causing the activation of the host immune system and may be considered an 
alternative approach for cancer prevention and treatment. The plant metabolites discussed in the 
previous chapters have similarly been shown to exert antioxidant, anticancer and potential 
chemopreventive effects by inducing or suppressing multiple cell signaling pathways. Importantly, 
a number of other studies have revealed that many of the cellular systems and signaling cascades 
that act at different levels of carcinogenesis are linked to regulation of the immune system and to 
inflammation, further justifying the potential use of immunomodulatory natural products for the 
treatment of cancer (Marx, 2004; DMITR and GABRILOVICH, 2004; Stix, 2007). These 
phytochemicals can induce or modulate the release of several proinflammatory and anti­
inflammatory cytokines thus shaping the tumour and its microenvironment.
At present, various immunomodulatory phytochemicals are classified as: (1) blocking agents, 
which prevent the initiation phase of carcinogenesis through the activation of several antioxidant 
enzyme systems; or (2) suppressing agents, which slow down the promotion and progression phases 
of carcinogenesis by the inhibition of tumour cell proliferation (Duvoix et al., 2005; Nandakumar 
et al., 2008).
Earlier studies in our laboratory (Zeinab et al., 2011) and the present work on DCOE
pentane/diethyl fraction (F2) demonstrated significant in vivo antitumour promoting effects against
the DMBA/TPA skin carcinogenesis model in mice, thus it was important to investigate cytokine
modulation by DCOE and its fractions in vivo. Previous reports indicated that cytokines are
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released in response to various stimuli or cellular stresses and are involved in several biological 
activities including induction of innate and adaptive immune responses as well as regulation of pro- 
inflammatory and anti-inflammatory responses (Haddad, 2002; Platanias, 2005; Dinarello, 2000; 
Opal and Depalo, 2000). Several cytokines including TNF-a, IFN-y, IL-10, IL-17 and VEGF are 
known to regulate many essential processes of tumour promotion and progression (Belardelli et al., 
2002; Coussens and Werb, 2002; Sato et al., 2011; Murugaiyan and Saha, 2009; Balkwill, 2002; 
Bceda et al., 2002; Roskoski Jr, 2007). The aim of this study, therefore, was to examine the in vivo 
immunomodulatory activities of DCOE and its fractions by measuring the levels of above cytokines 
in the spleens of mice.
6.2 Results
6.2.1 Modulation of spleen IFN-y by DCOE and its fractions
The immunomodulatory effect of DCOE and its fractions on the levels of IFN-y, TNF-a, IL- 
10, IL-17, and VEGF in spleen tissues of B ALB/c mice were assessed 6 and 24 hours post treatment 
using an ELISA kit as described Chapter 2 (section 2.23). According to the literature, cytokine 
induction was prominent within these time intervals (Alshaker et al., 2011; Matalka et al., 2007). 
A concentration of 200mg/Kg b.w of DCOE and its fractions was selected as a suitable dose to 
modulate cytokine production as this dose was shown to exhibit potent antitumour activity against 
DMBA-induced skin cancer and significant in vivo antioxidant activity as revealed in chapters 4 
and 5. Mice were injected once with the above dose and spleens were collected at 6 and 24 hours 
later.
As shown in Figure 6.1, the pentane/diethylether fraction (F2) led to the most significant (p <
0.005) increase in IFN-y levels 6 and 24 hours post treatment followed by F3 and F4 fractions (p
< 0.01 and p < 0.005). A similar induction in the IFN-y level was observed following LPS
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administration. Whereas, DCOE and FI did not induce a significant change in IFN-y levels at 6 or 
24 hours post treatment. Fractions F2, F3, F4 and LPS caused a 6.7, 4.6, 3.5 and 2.3 fold increase 
in the level of IFN-y respectively compared to DMSO group 6hr after administration. A similar 
trend was also observed 24h following treatment.
3500 ,
3000 -
2500
Ë  2000Q)
CL
0  1500
1
1000 -
500 -
DCOE FI F2
i
F3 F4 DMSO
E36hr 
■  24hr
i
LPS Control
Figure 6.1. Effect of DCOE and fractions on splenic IFN-y levels. IFN-y levels in the spleen of mice 6 h and 24 h 
following intra-peritoneal injection of200mg/kg b.w of DCOE, FI, F2, F3,and F4 or 2pg LPS. Results are expressed 
as mean ± SEM; n = 6 per group. * denotes P < 0.05, ** denotes P < 0.01, *** denotes P < 0.005 versus DMSO group 
as measured by one-way ANOVA.
6.2.2 Modulation of spleen TNF-a by DCOE and its fractions
Figure 6.2 shows that DCOE significantly modulated and increased the levels of TNF-a in the
spleen 6 and 24 hours following i.p. administration (p < 0.01). Similarly, F2 and F3 fractions
revealed a significant (p< 0.005) increase in TNF-a levels 24 h post i.p. administration.
Furthermore, i.p. administration of LPS considerably (p< 0.01) increased the production of TNF-a
at 6 and 24 hours. The induction of TNF-a by DCOE, FI, F2, F3, and F4 fractions was more
prominent at 24 hours. The level of TNF-a displayed 2.4,2.8, 6.2, 3.8,2.5 and 3.1 fold increase as
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compared to DMSO group 24 hours following DCOE, FI, F2, F3, F4 and LPS administration 
respectively.
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Figure 6.2. Effect of DCOE and fractions on splenic TNF-a levels. TNF-a levels in the spleen of mice 6 h and 24 
h following intra-peritoneal injection of200mg/Kg b.w of DCOE, FI, F2,F3,and F4 or 2pg LPS. Results are expressed 
as mean ± SEM; n = 6 per group.* denotes P < 0.05, ** denotes P < 0.01 versus DMSO group as measured by one­
way ANOVA.
6.2.3 Modulation of spleen IL-10 by DCOE and its fractions
The results showed that DCOE and its fractions significantly increased IL-10 production level 
(P < 0.05 for FI, F3 and F4, P < 0.01 for DCOE and F2) 6 hours following injection (Figure 6.3). 
On the other hand, DMSO and LPS administration did not induce any significant change in IL-10 
levels. DCOE, FI, and F4, induced a 1.3 fold increase and F2 and F3 induced a 1.4 fold increase 
in the level of IL-10 compared to DMSO group 6 hours after administration. However, no 
significant elevation of IL-10 was observed 24 hours post i.p. injection of F2, F3 and F4 fractions 
while there was a significant decrease in LPS.
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Figure 6.3. Effect of DCOE and fractions on splenic IL-10 levels. IL-10 levels in the spleen of mice 6 h and 24 h 
following intra-peritoneal injection of 200mg/kg b.w of DCOE, FI, F2,F3,and F4 or 2pg LPS. Results are expressed 
as mean ± SEM; n = 6 per group. * denotes P < 0.05 versus DMSO group as measured by one-way ANOVA.
6.2.4 Modulation of spleen IL-17 by DCOE and its fractions
The results indicated that F2, F3 and F4 fractions induced a marked increase (P < 0.05) in IL- 
17 levels compared to DMSO group 6 hours after treatment. Whereas, a non-significant (p > 0.05) 
increasing trend in the level of IL-17 was observed 24 hours post i.p. injection of F2, F3 and F4 
(Figure 6.4). The production of IL-17 displayed a 1.7, 1.6, and 1.75 fold increase compared to 
DMSO group 6 hours post i.p. injection of F2, F3 and F4 fractions respectively.
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Figure 6.4. Effect of DCOE and fractions on splenic IL-17 levels. IL-17 levels in the spleen of mice 6 h and 24 h
following intra-peritoneal injection of 200mg/Kg b.w of DCOE, FI, F2, F3,and F4 or 2(ig LPS. Results are expressed 
as mean ± SEM; n = 6 per group. * denotes P < 0.05 significant versus DMSO group as measured by one-way ANOVA.
6.2.5 Modulation of spleen VEGF by DCOE and its fractions
As shown in Figure 6.5, FI fraction demonstrated significant decrease (p < 0.05) in the level 
of VEGF at 6 hours and a marked decrease (p < 0.05) in the level of VEGF was also obtained 6 
and 24 hours post i.p. injection of F2 compared to the control. This F1/F2- induced suppression 
was not observed at 24 hours post administration of DCOE, FI, F3, and LPS. Fraction F4 on the 
other hand, increased significantly (p < 0.05) VEGF production 6 hours following i.p. injection.
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Figure 6.5. Effect of DCOE and fractions on splenic VEGF levels. VEGF production level in the spleen of mice 6 
h and 24 h following intra-peritoneal injection of 200mg/Kg b.w of DCOE, FI, F2, F3,and F4 or 2(ig LPS. Results are 
expressed as mean ± SEM; n = 6 per group. * denotes P < 0.05, significant decrease and ** denotes P < 0.05 significant 
increase versus DMSO group as measured by one-way ANOVA.
6.3 Discussion
Immunomodulation is a process by which synthetic or natural substances modify immune 
responses and phytochemicals have been shown to stimulate, suppress, or modulate both the innate 
and adaptive immune responses (Nagarathna et al., 2013). Various plant products have potent 
immunotherapeutic activities and exert their anticancer effects mainly through the activation of 
host-mediated immune mechanisms (Kim et ah, 2006). One important mechanism by which 
immunomodulatory agents exert their effect is via cytokine modulation (Santos, 2004). Generally, 
cytokines may suppress or enhance antitumour immunity depending on how they influence 
inflammation. The results of the present study showed that DCOE and its fractions exhibited in
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vivo immunonodulatory effects by inducing different patterns of cytokine release. The production 
of IFN-y in the spleens of mice was effectively enhanced after i.p. administration of DCOE and 
particularly fractions F2 and F3. IFN-y is a pro-inflammatory cytokine that is known to possess a 
wide range of biological activities including the activation of anti-microbial and anti-tumour 
activity of macrophages, NK cells, neutrophils and monocytes (Sen and Lengyel, 1992; Shalaby et 
al., 1985). Furthermore, IFN-y plays a crucial role in promoting host responses against the growth 
of primary induced tumours as well as transplanted tumours (Dighe et al., 1994; Shankaran et al., 
2001). Thus, the antitumour promoting effect of F2 in DMBA/TPA-induced mouse skin 
carcinogenesis could be partially due to the increased levels of IFN-y in the tumour 
microenvironment.
The present results also demonstrated that the F2 fraction was found to stimulate the production 
of IL-17. The role of endogenous IL-17 in tumour immunotherapy is still controversial. Although 
IL-17 is reported to enhance tumour growth (Nam et al., 2008; Numasaki et al., 2003), a number 
of studies have described antitumour effects of this cytokine (Benchetrit et al., 2002; Kryczek et 
al., 2009). These findings suggest that the reduced growth of papillomas in DMBA/TPA- induced 
mouse skin carcinogenesis following F2 treatment may partially be due to increased levels of EFN- 
y in the tumour microenvironment leading to the activation of T cytotoxic and NK cell activities as 
well as enhanced endogenous IL-17 which was found to decrease tumour growth (Kryczek et al., 
2009).
Our results also revealed that the production level of TNF-a was markedly induced following
i.p. injections of DCOE and its fractions. TNF-a is another pro-inflammatory cytokine that has
been also implicated in inflammation, immunity and cellular organization (Locksley et ah, 2001).
Previous studies indicated that the antitumour activity of TNF-a can be attributed to direct
cytotoxic effect on tumour cells (Creasey et ah, 1986) or indirectly by destroying tumour
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vasculature (Watanabe et al., 1988). Furthermore, several in vivo studies showed that TNF-a is an 
important molecule in inducing the development of CD 8+ T cell-mediated immunity and NK-cell 
killing of tumour cells (Kashii et al., 1999; Prévost-Blondel et al., 2000). Although the above 
findings may to some extent explain the chemopreventive and antitumour effects of the F2 fraction 
against DMBA/TPA- induced mouse skin carcinogenesis, other reports do not support this 
hypothesis. A number of studies indicated that TNF-a was shown to enhance tumour development, 
invasion and metastasis in animal models (Malik et al., 1989; Orosz et al., 1993; Jaiswal et al., 
2000).
The results of this chapter also revealed that the production of IL-10 was augmented 6 hours 
after the injection of DCOE and its fractions. However, decreased levels of IL-10 were observed 
24 h ours following injection. The augmentation of the proinflammatory cytokines (TNF-a, and 
IFN-y) 24h post administration of F2, F3, and F4 fractions could be partially attributed to the 
decrease in anti-inflammatory IL-10. It has been reported that IL-10 suppresses the secretion of 
proinflammatory cytokines TNF-a and IFN-y (Moore et al., 2001) in addition to its 
immunosuppressive activity (Stanilov et al., 2010).
We further investigated the effect of DCOE and its fraction on the production of VEGF and 
thus on angiogenesis. The present results clearly illustrate the inhibitory effect of FI and F2 
fractions on the production level of spleen VGEF which may lead to suppression of angiogenesis 
and tumour invasion. Previous work in our laboratory has revealed that the F2 fraction 
demonstrated important inhibition of motility and invasion in several human cancer cell lines 
including lung (A549), skin (B16F-10), breast (MDA-MB-231) and glioblastoma (SF-268) 
(unpublished data). All of the above results suggest that the F2 fraction exhibits its antitumour 
promoting effect in DMBA/TPA-induced mouse skin carcinogenesis at least partially via the 
enhancement of IFN -y, TNF- a and IL-17 production and down regulation in the level of VEGF.
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CHAPTER 7: GENERAL DISCUSSION AND CONCLUSIONS
7.1 Phytochemical analysis of DCOE and its fractions
In this project substantial progress was made towards the identification of potentially active 
components of the oil extract from Daucus carota (Linnaeus) ssp. carota, commonly known as wild 
carrot and their biological activities. While the commonly edible carrot, Daucus carota L. ssp. 
sativus, has been extensively studied, little is known about the biological activity of the wild carrot. 
In the present study, the Lebanese DCOE and its fractions was subjected to GC/MS and HPLC 
analyses to characterize their chemical constituents revealing that sesquiterpenes constituted the 
highest proportion (73.7%) followed by phenylpropanoids (12.07%). Previous studies on the 
chemical composition of the wild carrot essential oil demonstrated considerable variations 
worldwide as reported in chapter 3 (Gonny et al., 2004; Mockute and Nivinskiene, 2004; 
Staniszewska et al., 2005; Rossi et al., 2007; Maxia et al., 2009). Such variations were even obvious 
in neighboring Mediterranean countries emphasizing the importance of knowing the plant 
constituents of different origins. Phytochemical analysis of DCOE fractions showed that the 
sesquiterpenes mainly p-caryophyllene, a-humelene, a-longipinene, 10s,lla-himachala-3(12),4- 
diene, as well as a- and y-selinene, the major compounds present in the pentane fraction (FI) were 
detected in trace amounts or even lacking in oil extracts of wild carrot from different world 
locations. Furthermore, we report for the first time the presence of a new sesquiterpene 2- 
himachalen-6-ol which made up more than 60% of the pentane/diethylether fraction (F2) and 32% 
of DCOE. This compound has not been reported to occur in Daucus carota species or other 
members of the family Apiaceae, but it was first isolated from the heartwood of Juniperus species 
(Shiu et al., 1999). Other major compounds of F2 fraction are the phenylpropanoids (E)- 
methylisoeugenol and elemicin, both of which are present in high concentrations in mature umbels
of wild carrot from different origin (Gonny et al., 2004; Rossi et al., 2007; Maxia et al., 2009). The 
polar fractions F3 (diethyl ether) and F4 (chloroform/methanol), in addition to the presence of 
sesquiterpenes such as a-longipinene and P-selinene, were characterized by the presence of several 
phenolic acid and flavonoids including caffeic acid, luteolin, kaempferol, apigenin, and quercetin. 
The present data stresses the importance of reporting the plant origin and its phytochemical 
constituents since tremendous variations may exist from one location to another. In other words, 
the same plant species may have different biological activities when it comes from different 
geographical origins.
7.2 In vitro antioxidant activity of DCOE and its fractions
The in vitro antioxidant potential of DCOE and its fraction was evaluated using the DPPH, 
FRAP, and FIC assays. The DPPH assay is a widely used method to evaluate the capacity of a plant 
extract to scavenge free radicals (Huang et al., 2005). On the other hand, FRAP assay measures 
directly the capacity of antioxidants to reduce a ferric tripyridyltriazine complex (Fe3+-TPTZ) to 
the ferrous complex (Fe2+-TPTZ) (Alanôn et al., 2011).
In the present study, DCOE and its fractions exhibited important DPPH radical scavenging 
activity and FRAP reducing capacity. The DPPH IC50 values of DCOE and fractions indicated that 
the more polar diethylether (F3) and chloroform/methanol (F4) fractions possessed the highest 
scavenging activity. This may be partially attributed to the presence of the phenolic compounds 
such as, luteolin (Yin et al., 2008), kaempferol (Park et al., 2006), apigenin (Skerget et al., 2005), 
caffeic acid (Gülçin, 2006), and quercetin (Boots et al., 2008). Phenols, flavonoids and terpenes 
are among natural non-enzymatic antioxidants, which play an important role in quenching and 
neutralizing free radicals and protect against oxidative stress and tissue damage (Ajith and 
Janardhanan, 2001).The antioxidant capacity of DCOE fractions evaluated by DPPH was strongly
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correlated to the high phenolic content (r = 0.93) and flavonoid content (r = 0.93). A high positive 
correlation was also observed between FRAP antioxidant power of the fractions and phenolic 
content (r = 0.98) as well as flavonoid content (r = 0.99). This is in accordance with earlier studies 
which demonstrated a direct relationship between antioxidant capacity and total phenolic content 
in certain herbs, vegetables and fruits (Velioglu et al., 1998; Zheng and Wang, 2001; Sun et al., 
2002; Maisuthisakul et al., 2007). However, this is not always true. In some plants the phenolic 
content and antioxidant activities do not show a positive correlation (Chanda and Nagani, 2010; 
Locatelli et al., 2010). The antioxidant activity of phenolics (phenolic and flavonoid compounds) 
was associated to their chemical structures. For example, the potent radical scavenging capacity of 
quercetin (Cushnie and Lamb, 2005), present in F4 fraction, is due to the presence hydrogen- 
donating hydroxyl groups on the aromatic rings (Heijnen et al., 2002).
Another antioxidant mechanism of natural products is the chelation of transition metals. 
Transition metal ions are capable of producing free radicals from peroxides through Fenton 
reactions leading to lipid peroxidation of biological membranes (Viuda-Martos et al., 2010). The 
ferrous ion-chelating (FIC) assay relies on the complex formation between ferrozine and Fe2+ ions. 
In the presence of other chelating substances, the ferrozine complex formation is disrupted which 
results in the decrease in red color of the complex. Therefore, the chelating ability of the plant 
extract can be estimated by measuring the decrease in the absorbance at 562 nm (Dinis et al., 1994). 
According to IC50 values of the Fe2+ chelating activity, the non-polar pentane fraction (FI) and the 
pentane/diethylether fraction (F2) exhibited the highest chelating activity and thus may have an 
inhibitory effect on lipid peroxidation by stabilizing the metal ions. The chelating effect of DCOE 
fractions did not correlate with their phenolic content (r = - 0.81) or with flavonoid content (r = - 
0.82). This is consistent with previous work that described a similar relationship between the total 
phenolic content and the metal ion chelating capacity of plant extracts (Wang et al., 2009). One
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possible explanation could be due to the diversity of the polyphenols’ chemical structures with 
respect to the number and position of phenolic hydroxyl groups which could influence their Fe2+ 
chelating ability (Mladënka et al., 2011).
7.3 In vivo antioxidant and hepatoprotective activity of DCOE fractions
Carbon tetrachloride which induces hepatotoxicity in animals is a well-established 
experimental model for assessing antioxidant and hepatoprotective effects of plant extracts 
(Johnston and Kroening, 1998; Shenoy et al., 2001; Akindele et al., 2010). To further confirm the 
antioxidant properties of DCOE fractions and explore their possible hepatoprotective effects the in 
vivo CCL acute liver injury model was used. It has been shown that the accumulation of CCL in 
hepatic cells leads to the formation of highly reactive trichloromethyl free radicals (CCI3*) which 
react with proteins and membrane lipids leading to the formation of lipid peroxides (Amani et al., 
2006). This in turn produces oxidation products such as melondialdehyde (MDA) (Karakus et al.,
2011), and as a result the plasma membrane becomes severely damaged leading to the leakage and 
loss of several hepatic marker enzymes into the circulation (Botsoglou et al., 2008). In this study, 
CCL-intoxicated mice exhibited increased levels of serum hepatic markers ALT and AST 
suggesting extensive liver injury. However, pretreatment with FI or F4 fractions significantly 
attenuated the increased levels of both enzymes caused by CCL treatment and subsequently 
restored the normal values exhibited by the non-treated control group. A major component of the 
antioxidant system includes SOD, CAT, and GST which are involved in defense mechanisms 
against damaging effects of ROS. SOD catalyzes the conversion ofsuperoxide radicals 02*'to 02 
and H2O2, thus participating in the protection of cells against oxygen toxicity (McCord and 
Fridovich, 1969). CAT enzyme is a key component of the antioxidant defense system which 
metabolizes H2O2 into O2 and H2O. It was reported that a decrease in the level of CAT may lead to
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harmful effects as a result of the accumulation of free radicals (Srinivasan et ah, 2007). In our 
study, SOD and CAT activities were reduced in liver tissues of CCU treated mice. However, 
pretreatment of FI or F4 fractions significantly elevated both enzymes and hence minimized 
hepatic damage. These results are consistent with those of ALT and AST after treatment with either 
fraction.
Previous reports indicated that phenolic compounds such as quercetin, kaempferol, apigenin 
and luteolin may act as primary antioxidants or as free radical scavengers, resulting in the protection 
of antioxidative enzymes such as SOD and CAT (Benavente-Garcia et ah, 2000; Skerget et ah, 
2005; Park et ah, 2006; Boots et ah, 2008; He et ah, 2012). Therefore, the hepatoprotective effect 
of F4 fraction could be attributed to the presence of phenolic and polyphenolic (flavonoids) 
compounds mainly luteolin, kaempferol, apigenin, and quercetin. Future studies may be conducted 
to verify which of these compounds has the most potent hepatoprotective activity. Also, the 
exploration of potential synergism between different compounds is essential.
It has been reported that natural compounds are able to inhibit or enhance phase I or phase II 
metabolic enzymes (Block and Gyllenhaal, 2002). Several studies indicated that plant extracts were 
able to induce phase II detoxifying enzymes such as glutathione-S-transferase (GST) providing 
protection against toxicity and chemical carcinogenesis (Yang et ah, 2001; Dasgupta et ah, 2004). 
GST is an important enzyme that catalyzes the glutathione conjugation reaction involved in the 
detoxification of endogenous substances and xenobiotics. In this study, we observed a significant 
increase in the activity of GST in the four pretreated groups (FI, F2, F3, and F4) compared to the 
CCL-treated control. This indicates that terpenes, phenols, and flavonoids present in DCOE 
fractions may induce phase II detoxification enzyme and thereby protect cells against toxicity and 
chemically induced carcinogenesis.
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7.4 Cytotoxicity of DCOE and its fractions on various human cancer cells
The present study also investigated the in vivo and in vitro anticancer effects of DCOE and 
its fractions. These results clearly demonstrated that DCOE and its fractions exhibited growth 
inhibition effect against several human cancer cell lines in a dose-dependent manner. The cytotoxic 
activity of DCOE was less effective (higher IC50 values) than that obtained in the each of the four 
fractions (lower IC50 values) in breast cancer cells (MCF-7, MDA-MB-231) and colon cancer cells 
(HT-29, Caco-2). This difference may be due to the presence of bioactive compounds in small 
quantities in the crude extract which become more concentrated upon fractionation. Complex 
mechanisms may exist in plant extracts with various classes of phytochemicals that can exert 
synergistic or antagonistic effects (Lien et al., 1999; Okokon andNwafor, 2010). Therefore, another 
possible explanation might be linked to the presence of some natural compounds that may work 
antagonistically in the crude extract leading to lower anticancer activity such as certain terpenes 
(Cox et al., 2001; Savelev et al., 2003; Adams et al., 2006).
The present work revealed that the non-polar pentane (FI) and pentane/diethylether (F2) 
fractions were the most active against all tested cancer cell lines (lower IC50 values). However, the 
moderately polar diethylether (F3) and chloroform/methanol (F4) fractions, displaying less 
cytotoxicity, suggests that the components responsible for activity in the crude extract are mostly 
nonpolar in nature. This agrees with the literature that nonpolar fractions of several plant species 
were found to exhibit stronger cytotoxicity than moderately polar and polar fractions (Sacoman et 
al., 2008; Prachayasittikul et al., 2009)
 The anti-proliferative activity of the FI fraction mightbe attributed to the presence of major
sesquiterpenes such as /?-caryophyllene and oc-humulene. Several studies conducted on tumour cells 
showed that /?-caryophyllene exhibited potent anticancer activity over a wide range of cancer cell 
lines (Kubo et al., 1996; Loizzo et al., 2008; Silva et al., 2008; Tundis et al., 2009; Amiel et al.,
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2012). Also, oc-humulene demonstrated a strong cytotoxicity against several human cancer cell 
lines including MCF-7 breast tumour cells and HT-29 colon tumour cells (Legault et ah, 2003; 
Loizzo et ah, 2005; Tundis et ah, 2009; El Hadri et ah, 2010). The potent cytotoxic activity of the 
pentane/diethylether fraction (F2) may also be attributed to the presence of the major compound 2- 
himachalene-6-ol which constituted more than 60%. However, no reports are currently available to 
support the anticancer activity of 2-himachalene-6-oh Hence, further purification steps are required 
to isolate this compound and evaluate its potential anticancer activity. Generally, isolation and 
purification steps may involve several and successive chromatography techniques including TLC, 
column chromatography and F1PLC (Dua et ah, 2004). Different fractions eluted from column 
chromatography are further subjected to TLC and fractions with similar Æ/values are combined. 
The identity of the isolated compound can be confirmed by GC/MS and NMR techniques. The 
sesquiterpene widdrol, a structural isomer of 2-himachalen-6-ol, extracted from Juniperus 
chinensis, possessed antitumour activity against colon adenocarcinoma cells HT-29 by inhibiting 
cell division and inducing cell cycle G1 arrest (Kwon et ah, 2010a). Similarly, the sesquiterpene /?- 
selinene (Sivashanmugam and Jagannath, 2011; Elsharkawy and Alshathly, 2013), and 
phenylpropanoids represented by (E)-methylisoeugenol and elemicin identified in F2 fraction, are 
also known to demonstrate anti-proliferative activity and antitumour effects against several human 
cancer cell lines (Pisano et ah, 2007; Andrea L. Medina-Holgum, 2008; Kaminski et ah, 2010). 
Furthermore, DCOE fractions demonstrated selective cytotoxicity against the seven types of 
tumour cell lines tested. The breast cancer cells (MDA-MB-231) were the most sensitive to
treatment (lowest IC50 values), whereas the skin non-tumourigenic (HaCat) cells were most__
resistant to cytotoxicity (highest IC50 values).
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7.5 Apoptotic effects of FI and F2 fractions on breast and colon cancer cells
Current anti-neoplastic approaches target hallmark characteristics of cancer cells, including 
constitutive cell division and insensitivity to cell death-inducing factors (Hu and Kavanagh, 2003). 
Hence, many studies have been conducted to develop drugs that induce cell cycle arrest or apoptosis 
(Kim, 2005). In the present study, the inhibition of cell proliferation by FI or F2 fractions was 
mainly due to cell cycle arrest and apoptotic cell death. The hallmarks of apoptosis include 
chromatin condensation, DNA fragmentation, cell shrinkage, membrane blebbing, and formation 
of apoptotic bodies (Darzynkiewicz et al., 2001). DAPI staining of treated MDA-MB-231 and HT- 
29 cells with either fractions revealed the formation of apoptotic nuclei characterized by chromatin 
condensation and DNA fragmentation. Additionally, annexin V staining of MDA-MB-231 cells 
showed that treatment with FI or F2 fraction induced the extemalization of phosphatidylserine (PS) 
in the plasma membrane which is considered an early marker of apoptosis (Vermes et al., 1995). 
Annexin V has a high affinity to PS and thus binds to the exposed PS of the apoptotic cell surface. 
To differentiate between dead (necrotic) and apoptotic cells, propidium iodide (PI) can be added 
simultaneously with annexin V. PI is a membrane impermeable DNA stain where viable cells with 
intact plasma membrane prevent PI entry. Accordingly, flow cytometry can be applied to 
discriminate viable, early apoptotic, late apoptotic and necrotic cells according to double labeling 
for Annexin V and PI. Therefore, viable cells with intact cell membrane were both Annexin V and 
PI negative, early apoptotic cells are Annexin V positive and PI negative, late apoptotic cells are 
positive for both Annexin V and PI, while necrotic cells with damaged cell membrane are only PI 
positive (Van Engeland et al., 1998). The Annexin V/PI apoptosis assay revealed that treatment of 
MDA-MB-231 and HT-29 cells with FI or F2 fractions for 48 hours caused a significant dose 
dependent increase in late apoptotic cell population. Further examination of cell cycle distribution 
of both cell lines clearly indicated that both fractions induced cell cycle arrest at the sub-Gl
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apoptotic phase. It also showed a decrease in cycling cells (cells in S and G2/M phases), which is 
indicative of cell cycle arrest. It is well established that activation of p53 can lead to cell cycle 
arrest or apoptosis (Zhang et al., 2010) and plays a crucial role in mediating DNA damage-induced 
apoptosis (Roos and Kaina, 2006). Western blot analysis of cell lysates of both MDA-MB-231 and 
HT-29 cells showed dose dependent increases in the level of p53 protein after FI and F2 treatments. 
Therefore, the up-regulation in the p53 expression along with the previously mentioned 
observations, suggest that these fractions may induce apoptosis and sub-Gl arrest accompanied by 
p53 activation in HT-29 cells, in which p53 is a wild type. However, the MDA-MB-231 cells harbor 
a mutant and non-functional form of p53 (Hui et al., 2006). Thus the increase in p53 protein after 
FI or F2 treatment does not indicate p53-dependent apoptosis. These results suggest that cell cycle 
arrest and apoptosis in MDA-MB-231 cells are independent of p53 status. A previous report 
indicated that widdrol, the structural isomer of 2-himachalen-6-ol, induced apoptosis and cell cycle 
G1 arrest in HT-29 cells (Kwon et al., 2010a). In another study, widdrol was demonstrated to exert 
its anti-proliferative effect by inducing cell cycle G1 arrest. This induction is mediated through the 
stimulation of Chk2, p53 phosphorylation and CDK inhibitor p21 expression as well as inhibition 
of cyclin E, cyclin-dependent kinase (CDK2) and retinoblastoma protein (pRB) (Kwon et al., 
2010b).
The p53 protein has been also shown to directly or indirectly modulate apoptotic gene 
products that may induce apoptosis through either the intrinsic or the extrinsic pathway. The 
product of these genes include pro-apoptotic proteins such as Bax (Toshiyuki and Reed, 1995), 
Noxa (Oda et al., 2000) and Puma (Nakano and Vousden, 2001) which are activatedJby_p53_ 
following DNA damage. Additionally, p53 can directly binds to Bcl-2 to displace Bax and hence 
promote Bax-dependent mitochondrial apoptosis (Mihara et al., 2003). The anti-apoptotic protein, 
Bcl-2, has been shown to form a complex with Bax protein, thereby preventing its pro-apoptotic
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activity. Thus the ratio of Bcl-2: Bax plays a crucial role in determining whether cells will undergo 
apoptosis or survival. It is reported that the ratio of Bcl-2 to Bax proteins decreases during apoptosis 
(Elmore, 2007). This is in agreement with the western blot results of the present work which 
revealed that treatment of MDA-MB-231 and HT-29 cells with either FI or F2 fraction caused up- 
regulation of pro-apoptotic Bax and a decrease in anti-apoptotic protein Bcl-2 in a dose dependent 
manner. This leads to a lowered ratio of Bcl2/Bax followed by apoptotic cell death. Previous reports 
revealed that Bcl2 protein inhibited apoptosis by preventing Bax translocation to mitochondrial 
membrane and subsequent release of cytochrome c (Kroemer and Reed, 2000; Cheng et al., 2001; 
Martinou and Green, 2001).
The present results also showed that treatment of MDA-MB-231 and HT-29 cells with 
either FI or F2 fraction induced a decrease in the level of the inactive procaspase-3 in a dose 
dependent manner indicating its cleavage into the activated form. Once activated, the executioner 
caspase-3 causes the proteolytic cleavage and activation of a wide variety of downstream protein 
targets (Los et al., 1999). One important downstream substrate of caspase-3 is PARP enzyme which 
is cleaved by caspase-3 resulting in the loss of its enzymatic activity during apoptosis (Tewari et 
al., 1995). Immunoblot analysis revealed that PARP cleavage was observed after FI or F2 treatment 
in both cell lines. Taken together, these results proposed that the induction of apoptosis by either 
fractions might be via the mitochondria mediated pathway. The sesquiterpene widdrol has been 
reported to induce apoptosis in HT-29 cells through the intrinsic (mitochondrial) pathway, 
characterized by the release of cytochrome c from mitochondria leading to the activation of 
caspase-8, -9, and -3 followed by cleavage of PARP (Kwon et al., 2010a). Similarly, caryophyllene 
oxide, a sesquiterpene isolated from essential oils of medicinal plants induced apoptosis in MCF-7 
accompanied by the release of cytochrome c, activation of caspase-3, and down-regulation of Bcl2 
(Park et al., 2011). Several sesquiterpenes extracted from various medicinal plants such as 0-
elemene (Wang et al., 2005; Li et al., 2010), bisabolol (Cavalier! et al., 2004; Chen et al., 2010), 
atractylenolide III (Kang et al., 2011), p-eudesmol (Li et al., 2013), and germacrone (Lin et al.,
2013) promote apoptosis through the mitochondrial pathway involving the release of cytochrome 
c, cascade activation of caspase -3, -7, -8, -9, and PARP cleavage.
Cellular signaling pathways such as MAPK and PI3K/Akt which are involved in controlling 
cell cycle, cell proliferation and apoptosis are constitutively activated in cancer cells (Roy et al., 
2002; Vivanco and Sawyers, 2002; Kohno and Pouyssegur, 2006; Torii et ah, 2006). Therefore, it 
is of high importance to design a strategy to target both pathways using natural products. ERK1/2 
(MAPK) is a transcription factor that leads to the expression of several gene products which 
positively regulate cell survival (Lawlor and Alessi, 2001; Yang et ah, 2013). It was reported that 
constitutively activated Erk is responsible for high levels of cell growth in various cancers (Dhillon 
et ah, 2007; Yang et ah, 2012). Furthermore, activation of Erk 1/2 has also been shown to prevent 
apoptosis in response to various types of stimuli such as tumour necrosis factor and radiation (Tran 
et ah, 2001; Kitagawa et ah, 2002). On the other hand, down-regulation of Erk activity is highly 
associated with apoptosis (Salminen et ah, 2010). This is consistent with the current western blot 
results which indicated that treatment of MDA-MB-231 and HT-29 cells with either FI or F2 
fractions significantly inhibited the phosphorylation of Erk. The down regulation in the level of 
phosphorylated Erk is associated with a decrease in cell survival and proliferation and hence the 
induction of apoptosis by both fractions may be mediated through the inhibition of the MAPK/Erk 
pathway. This is in line with previous reports indicating that natural anti-cancer agents induce 
apoptosis via the suppression of the MAPK signaling pathway (Agarwal et al., 2000; Roccaro et 
al., 2008).
The PI3K/Akt pathway is another important signaling pathway in controlling cell proliferation 
and apoptosis (Lawlor and Alessi, 2001). The serine/threonine protein kinase PI3K signaling
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pathway is activated in several types of human cancer through different mechanisms (Samuels et 
al., 2004; Kang et al., 2006). It has been reported that total Akt activity is increased in various 
cancers including melanoma, colon, brain, breast and prostate cancer (Alkan and Izban, 2002; 
Gupta et al., 2002; Malik et al., 2002; Roy et al., 2002; Vivanco and Sawyers, 2002). Increased 
PI3K signaling is mainly due to mutations in genes encoding various components of this pathway 
such as PTEN, PEK3CA and Akt (Li et al., 1997; Dcenoue et al., 2005; Shop et al., 2009). The Akt 
protein, main downstream effector of PI3K, is a key mediator of cell survival (Franke et al., 1997). 
Additionally, PBK/Akt survival pathway inhibits apoptosis and promotes tumour cell survival 
through different types of stimuli such as growth factor withdrawal and loss of cell adhesion (Datta 
et al., 1999). The present data revealed that both FI and F2 fractions caused a considerable 
reduction in Akt phosphorylation in HT-29 cells reflecting an inhibition of the PI3K/Akt pathway. 
However, a combined treatment of FI or F2 fractions with wortmannin (PI3K inhibitor) to HT-29 
cells showed no significant increase in cytotoxicity, indicating that both fractions and wortmannin 
may exert their effect through the same pathway. A previous report revealed that inhibition of Akt 
and Erk phosphorylation leads to p53 activation and subsequent induction of pro-apoptotic 
signaling pathways (Fraser et al., 2003). This is in agreement with the present results where a 
significant increase in the level of p53 protein was obtained after FI or F2 treatment in HT-29 cells. 
On the contrary, treatment of MDA-MB-231 cells with either fractions did not show any significant 
decrease in the levels of phosphorylated Akt indicating that Fl/F2-induced apoptosis was not 
mediated by PI3K/Akt pathway. Furthermore, in the presence of wortmannin, treatment with either 
fractions further enhanced cytotoxicity against MDA-MB-231 cells suggesting that they may act 
on two different signaling pathways. Collectively, our data showed that the cell cycle arrest and the 
induction of apoptosis by either fraction may be mediated through the MAPK/Erk as well as the
171
PBK/Akt pathway in HT-29 cells, while it is mediated only through MAPK/Erk pathway in MDA- 
MB-231 cells.
Numerous natural products have been shown to exhibit their anticancer activity by targeting 
PBK/Akt and MAPK/Erk pathways. The sesquiterpene ^ -caryophyllene oxide, a major component 
of FI, was reported to induce apoptosis through the suppression of the PBK/Akt/mTOR pathway 
(Park et al., 2011). Several sesquiterpenes including geraniol, a-bisabolol, and p-elemene were also 
reported to exert their antitumour effect by inhibiting PBK/Akt/mTOR pathway (Seki et al., 2011; 
Kim et al., 2012; Liu et al., 2012). Other phytochemicals and food bioactives such as luteolin, 
resveratrol, curcumin, silibinin and EGCG promote apoptosis through the modulation PBK/Akt 
and MAPK/Erk pathways (Agarwal et al., 2007; Alkhalaf, 2007; Deeb et al., 2007; Kim et al., 
2007; Qin et al., 2007).
7.6 Antitumour-promoting activity of F2 fraction
The chemopreventive effect of the F2 fraction was evaluated in DMBA/TPA- induced mouse 
skin carcinogenesis. The results demonstrated that intraperitoneal injection of F2 fraction at the 
promotion stage revealed a significant reduction in papilloma incidence, papilloma yield and 
papilloma volume. These results were consistent with previous work conducted in our laboratory 
where DCOE treatment in mice induced similar inhibition (Abu Zeinab et a l, 2011). A previous 
report indicated that oil extract derived from Juniperus chinensis possessed antitumour-promoting 
activity against DMBA/TPA- induced mouse skin carcinogenesis (Ali et al., 1996). A later study 
showed that the sesquiterpene 2-himachalene-6-ol was isolated for the first time from the 
heartwood Juniperus chinensis (Shiu et al., 1999). These findings suggest that the antitumour 
promoting activity of the F2 fraction could be attributed to the presence of 2-himachalene-6-ol 
which constitute more than 60% of this fraction. The chemopreventive potential of F2 fraction and
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its active components may be attributed to different mechanisms. The in vitro anticancer activity 
of F2 fraction against several cancer cell lines, including HaCaT cells, the counterparts to the 
human invasive squamous cell carcinoma (papilloma), support the direct cytotoxic effect of F2 on 
the growth of papilloma. Another strategy, is through scavenging of ROS that are generated by 
topical application of TPA. Several studies showed that TP A increases the production of free 
radicals which in turn alter DNA structure and chromosomal proteins (Wei and Frenkel, 1991; 
Katiyar et al., 1993). This is followed by a decrease in the activity of epidermal SOD and catalase 
antioxidant enzymes (DiGiovanni, 1992). Thus the chemopreventive activity of F2 fraction may be 
due to its antioxidant and free radical scavenging capacity. Furthermore, the phase II enzyme GST 
catalyzes the glutathione conjugation reaction involved in the detoxification of carcinogens or 
xenobiotics and in turn protect cellular components against toxic compounds and chemical 
carcinogenesis (Yang et al., 2001). Since the pretreatment of the mice with DCOE fractions 
including the F2 markedly increased the level of GST, its chemopreventive action against 
DMBA/TPA induced skin tumourigenesis may be attributed to this enhanced activity of GST. 
Several studies reported that extracts obtained from different plants inhibited tumour promotion in 
two-stage DMBA/TPA induced skin carcinogenesis in mouse (Ali et al., 1996; Hora et al., 2003; 
Sancheti and Goyal, 2006; Chaudhary et al., 2007; Suh et al., 2007). Various phytochemicals 
including terpenes (diterpenes, triterpenes, and sesquiterpenes), phenols, and flavonoids 
(polyphenols) were shown to inhibit tumour promotion in two-stage mouse skin carcinogenesis 
(Taniguchi et al., 2002; Kaur et al., 2010; Mahale et al., 2011; Monga et al., 2011). Furthermore, 
these compounds demonstrated their chemopreventive effect by activating antioxidant enzymes 
such as SOD and CAT and phase II detoxifying enzymes GST as well as inhibiting lipid 
peroxidation in hepatic and skin cells which is in agreement with the in vivo antioxidant results.
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7.7 Immunomodulatory effects of DCOE and its fractions
The present investigation explored the effect of DCOE and its fraction on the production of 
several proinflammatory cytokines (IFN-y, TNF-a, and IL-17) and anti-inflammatrory cytokine 
(IL-10) as well as VEGF in the spleens of BALB/c mice. These cytokines have been linked to human 
cancers and can either promote or prevent tumour growth (Coussens and Werb, 2002; Candido and 
Hagemann, 2013). Additionally, there is a growing body of evidence that various malignancies are 
initiated from areas of infection and chronic inflammation (Kuper et al., 2000; Shacter and 
Weitzman, 2002). Our preliminary data demonstrated that DCOE and its fractions mainly the 
pentane/diethylether fraction (F2) and the diethylether fraction (F3) had immunostimulatory 
effects. Both fractions have been shown to induce and modulate in vivo proinflammatory cytokines 
production, IFN-y, TNF-a, and IL-17 more than the anti-inflammatory cytokine, IL-10. The two 
fractions F2 and F3 markedly enhanced production of Thl type cytokines (IFN-y and TNF-a) 
which are considered important factors for activating cell mediated cytotoxicity (Foulds et al., 
2006) and hence augmenting anti-tumour immunity (Baxevanis et al., 2000). IFN-y is a major 
immunoregulatory cytokine exhibiting antitumour and immunomodulatory effects (Blankenstein 
and Qin, 2003) and also known to stimulate host immune responses against growth of primary 
induced tumours as well as transplanted tumours (Dighe et al., 1994; Shankaran et al., 2001). On 
the other hand, TNF-a has a paradoxical role in cancer. While TNF-a is closely associated with 
tumour promotion and development (Malik et al., 1989; Malik et al., 1990; Orosz et al., 1993), 
numerous reports indicated that TNF-a exhibited antitumour action through direct cytotoxic effect 
on tumour cells or indirectly by destroying tumour vasculature (Creasey et al., 1986; Havell et al., 
1988; North and Havell, 1988; Watanabe et al., 1988). The results also showed that F2, F3, and F4 
fractions induced significant elevation in the level of IL-17. Similar to TNF-a, the role of IL-17 in 
tumour immunity remains relatively undefined. The pro-tumour function of IL-17 relies on its
proangiogenic activity by inducing various angiogenic factors including VEGF and TGF-p 
(Honorati et al., 2006; Jeon et al., 2007). In contrast, the antitumour function of IL-17 was highly 
dependent on presence of IFN-y and to the cytotoxic T lymphocytes (CTL) activation (Benchetrit 
et ah, 2002; Muranski et ah, 2008; Kryczek et ah, 2009). Thus IL-17 produced by Thl7 cells plays 
a dual role in cancer immunity. On one hand, IL-17 suppresses tumour growth by activating 
cytotoxic T lymphocytes (CTL) whilst on the other hand, it promotes tumour growth by inducing 
tumour angiogenesis. These findings suggest that the reduced growth of papillomas in 
DMBA/TPA- induced mouse skin carcinogenesis following F2 treatment may partially be due to 
increased levels of IFN-y in the tumour microenvironment which induced T cytotoxic and NK cell 
activities as well as enhanced endogenous IL-17 leading to decreased tumour growth (Kryczek et 
ah, 2009).
The results also demonstrated that 6 hours-post i.p. injection, DCOE and its fractions 
significantly increased IL-10 levels in the spleen cultures from the DCOE, FI, F2, F3, and F4 
treated mice. However, reduced levels of IL-10 were observed 24 hours-post i.p. injection. The 
induction of the proinflammatory cytokines (TNF-a, IFN-y) post administration of DCOE and its 
fraction could be partially attributed to the decrease in anti-inflammatory IL-10. It has been 
reported that IL-10 inhibited the secretion of the proinflammatory cytokines IFN-y, TNF-a and 
suppressed the expression of major histocompatibility complex (MHC) class II antigens (Moore et 
ah, 2001). Moreover, IL-10 mRNA and protein have been detected in various types of cancer 
including lung (Huang et ah, 1995), breast (Venetsanakos et ah, 1997), and skin squamous 
carcinoma (Kim et ah, 1995) and plays a role in tumour-induced immune suppression and tolerance 
(Stanilov et ah, 2010). Our results also illustrated the inhibitory effect of FI and F2 fractions on 
the production level of spleen VEGF which may lead to suppression of angiogenesis and tumour 
invasion. Recent work in our lab revealed that F2 fraction demonstrated significant reduction of
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motility and invasion of cancer cells which were mediated through the decrease in the expression 
of Rho GTPases such as Rac and Cdc42 proteins (data not published). These proteins play an 
important role in cell motility and cell-cell adhesion (Nobes and Hall, 1995; Braga et ah, 1997). 
Also, they have been reported to be aberrantly expressed or activated in breast, colon, lung and 
other human cancers (Fritz et ah, 1999; Fritz et ah, 2002) and implicated in cellular motility and 
invasion of cancer cells (Keely et ah, 1997; Liliental et ah, 2000).
7.8 Conclusions
The results in this thesis have indicated that the chemical composition of DCOE from wild 
carrot grown in Lebanon was significantly different from those of other origins. This variation may 
be attributed to geographical locations, genetic variability and stage of development (flowering or 
mature umbels). The nonpolar FI and F2 fractions were dominated by sesquiterpenes and 
phenylpropanoids, while the more polar F3 and F4 fractions are rich in phenolic and flavonoid 
compounds. In this study, we also reported for the first time the presence of the sesquiterpene 2- 
himachalene-6-ol in the oil extract of the wild carrot.
The current study revealed that DCOE and its fractions demonstrated significant in vitro and 
in vivo antioxidant as well as hepatoprotective effects. The in vivo antioxidant activity of DCOE 
fractions mainly FI and F4 was demonstrated by increased activity of SOD, CAT and GST 
antioxidant enzymes. The in vitro antioxidant activity of DCOE fractions mainly F3 and F4 
fractions displayed potent scavenging and reducing capacity in the DPPH and FRAP assays 
respectively. Both effects could be correlated to the presence of various phytochemicals including 
terpenes, phenols, and flavonoid compounds.
In this work, DCOE and its fractions exhibited dose dependent anti-proliferative effects 
against several human cancer cell lines including colon, breast, and skin. The pentane (FT) and
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pentane-diethylether (F2) fractions had the highest cytotoxicity with the lowest IC50 values in all 
the tested cancer cells. The anticancer activity of the nonpolar FI and F2 fractions could be 
attributed to the presence of major sesquiterpene compounds. Selective cytotoxicity was observed 
among the cancer cell lines with breast cancer cells (MDA-MB-231) the most sensitive and skin 
non-tumerigenic (HaCat) cells the least sensitive.
The inhibition of cell growth by FI or F2 fractions was mainly due to cell cycle arrest and 
apoptotic cell death as assessed by flow cytometry analysis and western blot analysis of several 
pro-apoptotic and anti-apoptotic proteins. Additionally, the induction of apoptosis was mediated 
through the inhibition of both MAPK/Erk and PDK/Akt pathways in human colon cancer cells 
(FIT-29) and only through MAPK/Erk pathway in human breast cancer cells (MDA-MB-231).
The in vivo anticancer activity of the most potent F2 fraction was also evaluated in 
DMBA/TPA- induced mouse skin carcinogenesis. The antitumour promoting effect of F2 was 
illustrated by a significant reduction in tumour incidence, tumour yield and tumour volume.
The present work also demonstrated that DCOE and its fractions mainly F2, and F3 induced 
the production of proinflammatory cytokines IFN-y, TNF- a and IL-17 6 and 24 hours as well as 
anti-inflammatory cytokine IL-10 six hours after i.p injection. In contrast, FI and F2 fractions 
reduced the production of VEGF 6 and 24 hours following i.p injection.
The F2 fraction may thus be exerting its chemoprotective effect by acting as an antioxidant 
as well as playing a role in enhancing the activities of antioxidant enzymes such as CAT, SOD, and 
GST. Other chemopreventive approaches of F2 fraction could be through the induction of apoptosis 
in tumour cells or through immunomodulation of pro-inflammatory and anti-inflammatory 
cytokines in tumour microenvironment.
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7.9 Future prospects
The present work demonstrated that DCOE and its fractions contain several active components 
with promising antioxidant, anticancer and hepatoprotective effects. Currently, our research group 
is in the process of isolating and purifying the major compound 2-himachalene-6-ol from F2, found 
to be the most prominent compound in the fraction that showed the most potent anticancer activity. 
Once isolated, purified and identified by ID and 2D NMR spectroscopy, 2-himachalene-b-ol will 
be tested for its potential anticancer and anti-inflammatory effect using in vitro and in vivo 
biological models. Additionally, chromatographic analysis will be conducted to purify other 
unidentified compounds in DCOE in order to assess their biological activities in future work.
Similarly, if  2-himachalene-b-ol demonstrated in vitro and in vivo anticancer activity, several 
toxicological assays will be conducted to establish the safety levels and the mechanism of action 
of the compound. Further studies will also be conducted to investigate the effect of the compound 
on cell motility and invasion by examining Rho GTPases activity. Finally, future investigations 
may explore potential synergistic activity of combination therapy of 2-himachalene-b-ol with 
conventional anticancer drugs.
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Appendix A: MS Spectra of FI fraction
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MS spectrum of P-Caryophyllene
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MS spectrum of Aromadendrene
A b u n d a n c e
2 2 0 0 0 0
2 0 0 0 0 0
1 8 0 0 0 0
9 3 . 1
1 6  0 0 0 0
1 4  0 0 0 0
1 2  0 0 0 0
1 0  0 0 0 0 7 9. 1
8 0 0 0 0
16 1.
1 4 7 .6 0 0 0 0
5 5. 14 0 0 0 0 1 0  6 . 1 1 8  9 . 2
2 0 4 . 2
2 0 0 0 0 1 7  5. 1
2 1 8 . 2
9 0 1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 1 5 0 1 6 0 1 7 0 1 8 0 1 9 0 2 0 0 2 1 0 2 2 06 0 7 0 8 05 0
m / z - - >
MS spectrum of p-Selinene
S c a n  2 3 7 6 ( 1 6 . 6  6 9 m in ) :  F 0 - o i l . D \ d a I a . m a
226
MS spectrum of a-Selinene
S c a n  2 4 1 3 ( 1 6 . 8 8 0  m in ): F 0 - o  i l .D \ d  a t a . m s
1 0  5 .1
4 5 0 0 0 0
7 9 . 14 0 0 0 0 0
3 5 0 0 0 0
2 0 4 . 2
1 2  1 . 1
1 6  1 . 1
3 0 0 0 0 0
1 4  7 . 1
2 5 0 0 0 0
2 0 0 0 0 0
5 5 .1
1 5  0 0 0 0 1 7  5 . 2
1 3  4 . 19 2  .11 0  0 0 0 0
5 0 0 0 0
2 1 8 . 1
9 0 1 0  0 2 1 0  2 2 05 0 6 0 7 0 8  0
m / z - - >
MS spectrum of y-Selinene
A b u n d a n c e
227
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Appendix B: MS Spectrum of F2 fraction
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Figure B.2. Gas chromatogram of F2- fraction
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Appendix C: MS Spectrum of F3 and F4 fractions
L
223.31"
_^______ i |
- ^3 ^ 7 1 4 . 3 3 ^
60343
i " ' i  »" » i " 1 1" '■ 
ZKXCD  S Q O O
Figure C.3. Gas chromatogram of F3- fraction
SOODODO
G Q O O S Q O O3Q C D
Figure C.4. Gas chromatogram of F4- fraction
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MS spectrum 1,4,7,-Cycloundecatriene, 1,5,9,9-tetramethyl-, Z,Z,Z-
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MS spectrum 2,3-Dicyano-6-ethyl-5,7-dimethyl-6H-l,4-diazepine
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Appendix D: TLC profile of DCOE fractions
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Figure 3.1. TLC profile of DCOE fractions eluted on a Si-Gel column.
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A ppendix E: Stuctural formulas of DCOE major compounds
QH CH
CH
H
H
2-himachalene-6-ol (+)-a-longipinene
a-humelene (3-caryophyllene
(E)- Methylisoeugenol
H
a-Selinene
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p-Selinene Y -Selinene
CH
CH
10s,lla-Himachala-3(12),4-diene p-Himachalene
H3CO
OCH3 OH
OH
Elemicine Luteolin
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Kaempferol
Caffeic acid
Apigenin
OH
OH
OH
Quercetin
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